Methods and compositions for desensitisation

ABSTRACT

The invention relates to a method of desensitising a patient to a polypeptide allergen the method comprising administering to the patient a peptide derived from the allergen wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated by the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule. A composition comprising a plurality of peptides derived from a polypeptide allergen wherein for at least one of the peptides in the composition restriction to a MHC Class II molecule can be demonstrated, and the composition is able to induce a late phase response in an individual possessing the given MHC Class II moleculeis also provided. The invention also relates to a method of selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to a polypeptide allergen capable of eliciting an allergic response in the patient.

[0001] The present invention relates to methods and compositions for desensitising patients who are hypersensitive to particular allergens, especially polypeptide allergens. Moreover, the invention relates to immunological vaccines which may be used to prevent and/or treat conditions involving hypersensitivity to allergens.

[0002] The ability of the immune system to elicit a response to a particular molecule depends critically upon its ability to recognise the presence of an antigen. Classically, the term antigen has been associated with the ability of a molecule to be an antibody generator via induction of B-cells. It is now known, however, that T cells also possess the ability to recognise antigens. T-cell antigen recognition requires antigen presenting cells (APCs) to present antigen fragments (peptides) on their cell surface in association with molecules of the major histocompatibility complex (MHC). T cells use their antigen specific T-cell receptors (TCRs) to recognise the antigen fragments presented by the APC. Such recognition acts as a trigger to the immune system to generate a range of responses to eradicate the antigen which has been recognised.

[0003] T lymphocytes have been implicated in the pathogenesis of a wide variety of diseases involving immune recognition of antigens derived both from the internal (host) and external environments. Autoimmune diseases such as autoimmune thyroiditis, rheumatoid arthritis and lupus erythrematosus arise from the recognition by the immune system of host, or self, antigens.

[0004] Recognition of external antigens by the immune system of an organism, such as man, can in some cases result in diseases, known as atopic conditions. An example of the latter are the allergic diseases including asthma, atopic dermatitis and allergic rhinitis. In this group of diseases, B lymphocytes generate antibodies of the IgE class (in humans) which bind externally derived antigens, which are referred to in this context as allergens, since these molecules elicit an allergic response. Production of allergen-specific IgE is dependent upon T lymphocytes which are also activated by (are specific for) the allergen. Allergen-specific IgE antibodies bind to the surface of cells such as basophils and mast cells by virtue of the expression by these cells of surface receptors for IgE. Crosslinking of surface bound IgE molecules by allergen results in degranulation of these effector cells causing release of inflammatory mediators such as histamine, 5-hydroxtryptamine and lipid mediators such as the sulphidoleukotrienes. In addition to IgE-dependent events, certain allergic diseases such as asthma are characterised by IgE-independent events. It has been demonstrated that the induction of the late phase reaction is an IgE-independent event which is dependent upon the activation of allergen-specific T lymphocytes.

[0005] Allergic IgE-mediated diseases are currently treated with agents which provide symptomatic relief or prevention. Examples of such agents are anti-histamines, β₂ agonists, and glucocorticosteroids. In addition, some IgE-mediated diseases are treated by desensitisation procedures that involve the periodic injection of allergen components or extracts. Desensitisation treatments may induce an IgG response that competes with IgE for allergen, or they may induce specific suppressor T cells that block the synthesis of IgE directed against allergen. This form of treatment is not always effective and poses the risk of provoking serious side effects, particularly general anaphylactic shock. This can be fatal unless recognised immediately and treated with adrenaline. A therapeutic treatment that would decrease or eliminate the unwanted allergic-immune response to a particular allergen, without altering the immune reactivity to other foreign antigens or triggering an allergic response itself would be of great benefit to allergic individuals.

[0006] Asthma can be provoked by inhalation of allergen in the clinical laboratory under controlled conditions. The response is characterised by an early asthmatic reaction (EAR) followed by a delayed-in-time late asthmatic reaction (LAR) (See Allergy and Allergic Diseases (1997), A. B. Kay (Ed.), Blackwell Science, pp 1113 to 1130). The EAR occurs within minutes of exposure to allergen, is maximal between 10 and 15 min and usually returns to near baseline by 1 hour. It is generally accepted that the EAR is dependent on the IgE-mediated release of mast cell-derived mediators such as histamine and leukotrienes. In contrast the LAR reaches a maximum at 6-9 hours and is believed to represent, at least in part, the inflammatory component of the asthmatic response and in this sense has served as a useful model of chronic asthma.

[0007] The late asthmatic response is typical of responses to allergic stimuli collectively known as late phase responses (LPR). LPR is seen particularly in the skin and the nose following intracutaneous or intranasal administration of allergens.

[0008] Using cat allergic individuals (rhinitic and asthmatic), Norman et al (1996) Am. J. Respir. Crit. Care Med. 154:1623-8 attempted to induce the counterpart of murine experimental T cell tolerance by subcutaneous injection of “T cell reactive peptides” (termed IPC1 and IPC2) in humans. Peptides were designed on the basis of patterns of epitope recognition of short overlapping peptides by Fel d 1 reactive T cell lines. It was found that peptides derived from chain 1 gave greater proliferative responses than chain 2, with the majority of activity being associated in the N terminal region of chain 1. IPC1 and IPC2 were considerably longer (27 amino acids each) than previously defined T-cell epitopes. This may have been partly responsible for immediate (presumed IgE-mediated) reactions in some patients following administration (Norman et al, Op. Cit.). Large peptide doses (4×750 μg) were required to achieve minimal clinical efficacy. The choice of peptides for therapy was based upon reactivity of secondary T-cell lines derived from a large number of cat-allergic individuals and did not take into account primary T-cell reactivity (ie ex vivo), which may be more sensitive, or MHC class II haplotype.

[0009] Norman et al reported a number of adverse hypersensitivity reactions including respiratory, and other allergic, symptoms. As stated, some had a rapid time of onset ie with 10 minutes whereas others were not observed until several hours after IPC1/IPC2 administration (although there was no local redness or swelling at the site of injection). These results have been interpreted as indicating the unsuitability of the peptides for immunotherapy, the production of a LPR being considered to be undesirable (Wheeler & Drachenberg (1997) Allergy 52:602-612).

[0010] WO 92/11859 describes a method of reducing the immune response to an allergen in which a non-allergen derived, non-stimulating peptide which binds to specific MHC class II molecules of APCs is used to inhibit T-cell response to particular allergens.

[0011] WO 91/06571 purports to disclose peptides derived from human T-cell reactive feline protein which can be used in the diagnosis, treatment or prevention of cat allergy.

[0012] WO 94/24281 relates to peptides and modified peptides of the major house dust mite allergens. The modified peptides have the intent of reducing the level of undesirable side effects associated with desensitising therapies.

[0013] We have observed that peptide allergens used in immunotherapy associate with particular MHC types in patients. Moreover, successful desensitisation of patients is achieved where a peptide allergen is used which is capable of giving an initial LPR in an individual to whom it is administered.

[0014] The MHC complex is a genetic locus made up of a number of genes which encode MHC molecules. MHC molecules are also known as Human Leucocyte Antigens (HLA).

[0015] Each individual inherits a number of MHC genes from each parent and the genes are referred to collectively as the individual's haplotype. This is a genetic term referring to the genes rather than the molecules they encode. Although the term “haplotype” should, strictly speaking, be used to describe the genes inherited from one parent, it is generally used to include genes from both sets of parents. Where the term is used in this patent specification it is given this general meaning unless the context suggests the stricter meaning.

[0016] A first aspect of the invention provides a method of desensitising a patient to a polypeptide allergen the method comprising administering to the patient a peptide derived from the allergen wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule.

[0017] Restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide by, for example, T cell reactivity to the peptide. By “MHC Class II molecule possessed by the patient” is meant the particular type which type, of course, may be possessed by other individuals which have the genes that encode the particular type of MHC Class II molecule.

[0018] By a “peptide derived from the allergen” we include the meaning that the peptide is chemically derived from the polypeptide allergen, for example by proteolytic cleavage and we also include the meaning that the peptide is derived in an intellectual sense from the polypeptide allergen, for example by making use of the amino acid sequence of the polypeptide allergen and synthesising peptides based on the sequence. Peptides may be synthesised using methods well known in the art, some of which are described in more detail below.

[0019] By “peptide” we include not only molecules in which amino acid residues are joined by peptide (—CO—NH—) linkages but also molecules in which the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Mézière et al (1997) J. Immunol. 159, 3230-3237, incorporated herein by reference. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Mézière et al (1997) show that, at least for MHC class II and T helper cell responses, these pseudopeptides are useful. Retro-inverse peptides, which contain NH—CO bonds instead of CO—NH peptide bonds, are much more resistant to proteolysis.

[0020] Similarly, the peptide bond may be dispensed with altogether provided that an appropriate linker moiety which retains the spacing between the Cα atoms of the amino acid residues is used; it is particularly preferred if the linker moiety has substantially the same charge distribution and substantially the same planarity as a peptide bond.

[0021] It will be appreciated that the peptide may conveniently be blocked at its N- or C-terminus so as to help reduce susceptibility to exoproteolytic digestion.

[0022] By “restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide” we mean that the peptide is able to bind to a particular MHC Class II possessed by the patient. That is not to say that a particular peptide cannot bind to another MHC Class II molecule. Peptides are generally only recognised in the context of a “self” MHC molecule, thus recognition of MHC-bound peptides by an individual's T cells is generally restricted by the MHC molecules expressed by the individual molecule.

[0023] Although binding to the given MHC Class II molecule may be demonstrated directly using suitable samples from the patient, whether or not a particular peptide can bind to a particular MHC Class II molecule (ie is restricted by a particular Class II molecule) can readily be determined in vitro using methods well known in the art, some of which are disclosed below.

[0024] Determination of the MHC Class II haplotype of the patient or the identification of particular MHC Class II genes possessed by the patient can readily be determined using any suitable method as is well known in the art, including the PCR-based methods described more fully below for example techniques based on those of Olerup & Zetterquist (1992) Tissue Antigens 29:225-235. Determination of the MHC Class II haplotype indicates which MHC molecules are expressible by an individual.

[0025] By “late phase response” we include the meaning as set forth in Allergy and Allergic Diseases (1997) A. B. Kay (Ed.), Blackwell Science, pp 1113-1130. The late phase response may be any late phase response (LPR). Preferably, the peptide is able to induce a late asthmatic response (LAR) or a late rhinitic response, or a late phase skin response or a late phase ocular response. Whether or not a particular peptide can give rise to a LPR can be determined using methods well known in the art; a particularly preferred method is that described in Cromwell O, Durham S R, Shaw R J, Mackay J and Kay A B. Provocation tests and measurements of mediators from mast cells and basophils in asthma and allergic rhinitis. In: Handbook of Experimental Immunology (4) Chapter 127, Editor: Weir D M, Blackwell Scientific Publications, 1986. Not all individuals who possess the particular MHC Class II molecule would experience a LPR following the administration of allergen or allergen-derived peptides since generation of the LPR is dependent upon prior allergic sensitisation to the allergen in question.

[0026] Thus, preferably, the peptide is able to induce a LPR in an individual who possesses the said MHC Class II molecule and who has been sensitised to the allergen in question. Whether or not an individual has been sensitised to the allergen in question may be determined by well known procedures such as skin prick testing with solutions of allergen extracts, induction of cutaneous LPRs, clinical history, allergen challenge and radio-allergosorbent test (RAST) for measurement of allergen specific IgE.

[0027] Preferably, the peptide is included in a composition containing a plurality of peptides derived from the said allergen. The peptides in the composition may or may not be multiple overlapping peptides (MOPs) derived from the polypeptide allergen. The plurality of peptides may be derived from the whole of the polypeptide allergen and therefore the peptides span the whole of the polypeptide chain or chains of the allergen.

[0028] However, they may be derived from only portions of the polypeptide allergen such that some portions of the polypeptide allergen are not represented in the plurality of peptides (for example, as is shown below, some peptides derived from an allergen may not be very soluble in aqueous solution and so may not be useful and other peptides may not show restriction to MHC Class II molecules). MOPs or any peptides derived from the allergen and present in the composition can be designed by reference to the amino acid sequence of the polypeptide allergen. Typically, the peptides are at least seven amino acid residues. Typically, the peptides would be between around 14 to 18 amino acid residues in length. It is preferred that the peptides have a reduced ability to bind IgE compared to longer peptides containing the same sequence. It is particularly preferred if the peptides are substantially incapable of binding IgE. Typically, when the MOPs overlap, the overlap is around one amino acid residue. This is particularly useful when the MOPs are used in in vitro T cell assays in order to identify MHC-binding peptides which may then be screened for their ability to induce LPR in an individual. More details of screening procedures are given below.

[0029] MHC Class II molecules are encoded by MHC Class II genes. There are at least three loci (DR, DQ and DP) that encode MHC Class II molecules, and each individual has two copies of each locus. These loci exhibit considerable genetic diversity and the preponderance of different MHC Class II genes (alleles) varies. The approximate frequencies of various MHC Class II genes (alleles) from a normal (disease free) population of people in England is described in Haworth S, Sinnott P, Davidson J & Dyer P. Caucasian England Normal In: HLA Typing 1997, Eds: Terasaki, P I and Gjertson, D W, Publishers: UCLA tissue typing laboratory, incorporated herein by reference.

[0030] For DR molecules, the most common in the Caucasian population are those that can be classified DR1, DR2, DR3, DR4, DR5, DR6, DR7, DR51, DR52 and DR53.

[0031] For DP molecules, the most common are DPB1*0201, DPB1*0301 and DPB1 *0401.

[0032] For DQ molecules, the most common are DQB1*0201, DQB1*0301, DQB1*0501, DQB1*0601 and DQB1*0602.

[0033] It is particularly preferred if the plurality of polypeptides administered to the patient includes peptides for which restriction to MHC Class II molecules can be demonstrated. It is particularly preferred if the plurality of peptides administered to the patient includes peptides for which restriction to the MHC Class II DR molecules DR2, DR3, DR4, and DR7 can be demonstrated. In a further embodiment it is preferred if the plurality of peptides further includes peptides for which restriction to any one or more of the MHC Class II DR molecules DR1, DR5 and DR6 can be demonstrated.

[0034] It is also particularly preferred if the plurality of peptides administered to the patient includes peptides for which restriction to the MHC Class II DR molecules DR51, DR52 and DR53 has been demonstrated.

[0035] It is also particularly preferred if the plurality of peptides administered to the patient includes peptides for which restriction to the MHC Class II DP molecules DPB1*0201, DPB1*0301 and DPB1*0401 can be demonstrated.

[0036] It is also particularly preferred if the plurality of peptides administered to the patient includes peptides for which restriction to the MHC Class II DQ molecules DQB1*0301 and DQB1*0601 can be demonstrated. In a further embodiment it is preferred if the plurality of peptides further includes peptides for which restriction to any one or more of the MHC Class II DQ molecules DQB1*0201, DQB1*0501 and DQB1*0602 can be demonstrated.

[0037] It is preferred if the plurality of peptides includes only a single peptide for which restriction to a particular MHC Class II molecule can be demonstrated.

[0038] Restriction to a particular Class II molecule can be demonstrated as has been described above and is described in more detail below. It will be appreciated that it may not be possible to derive a peptide for which restriction to a particular Class II molecule can be demonstrated; for example, a particular polypeptide allergen may not contain a T cell epitope which can be presented by every MHC Class II molecule. In this case, of course, such a peptide is not present in the plurality of peptides derived from the polypeptide allergen.

[0039] By “desensitising a patient to a polypeptide allergen” is meant inhibition or dampening of allergic tissue reactions induced by allergens in appropriately sensitised individuals. It will be appreciated that whether or not a patient is sensitive to a particular polypeptide allergen can be assessed using well known procedures such as skin prick testing with solutions of allergen extracts, induction of cutaneous LPRs, clinical history, allergen challenge and radio-allergosorbent test (RAST) for measurement of allergen specific IgE, and whether or not a particular patient is one who is expected to benefit from treatment may be determined by the physician based, for example, on such tests.

[0040] Administration of the peptide (such as the composition containing a plurality of peptides) may be by any suitable method, some of which are described below in more detail. Suitable amounts of the peptide may be determined empirically, but typically are in the range given below. As is described in a further aspect of the invention below, the invention also includes a method of determining an initial dose of peptide which is suitable to administer to the patient. A single administration of the peptide may be sufficient to have a beneficial effect for the patient, but it will be appreciated that it may be beneficial if the peptide is administered more than once, in which case typical administration regimes may be, for example, once or twice a week for 2-4 weeks every 6 months, or once a day for a week every four to six months.

[0041] A second aspect of the invention provides a composition comprising a plurality of peptides derived from a polypeptide allergen wherein for at least one of the peptides in the composition restriction to a MHC Class II molecule can be demonstrated and the composition is able to induce a late phase response in an individual possessing the given MHC Class II molecule. Preferably, at least one peptide is present in the composition for which restriction to each of MHC Class II DR molecules DR2, DR3, DR4 and DR7 can be demonstrated, provided of course that such peptides can be derived from the allergen.

[0042] Also preferably the composition may include peptides for which restriction to any one or more of the MHC Class II DR molecules DR1, DR5 and DR6 can be demonstrated.

[0043] Preferably, at least one peptide is present in the composition for which restriction to each of MHC Class II DR molecules DR51, DR52 and DR53 has been demonstrated.

[0044] Preferably, at least one peptide is present in the composition for which restriction to each of MHC Class II DP molecules DPB1*0201, DPB1*0301, and DPB1*0401 can be demonstrated.

[0045] Preferably, at least one peptide is present in the composition for which restriction to each of MHC Class DQ molecules DQB1*0301 and DQB 1*0601 can be demonstrated. In a further embodiment it is preferred if the plurality of peptides further includes peptides for which restriction to any one or more of the MHC Class II DQ molecules DQB1*0201, DQB1*0501 and DQB1*0602 can be demonstrated.

[0046] These preferences are all with the proviso that for any particular allergen it may not be possible to derive a peptide for which restriction to a particular Class II molecule can be demonstrated.

[0047] Although the composition (or a peptide within the composition) is able to induce a LPR in an individual possessing the given MHC Class II molecule (and as described below in more detail suitable compositions and peptides may be identified by their ability to induce a LPR), it should be appreciated that when the composition (or a peptide within the composition) is used to treat a patient it is preferable that a sufficiently low concentration of the composition or peptide is used such that no observable LPR will occur but the response will be sufficient to partially desensitise the T cells such that the next (preferably higher) dose may be given, and so on. In this way the dose is built up to give fill desensitisation but often without ever inducing a LPR in the patient (although, of course, the composition or peptide is able to do so at a higher concentration than is administered. It will be appreciated further, and as discussed in more detail below, induction of LPR in an individual is particularly useful in selecting appropriate compositions and peptides but is not essential in the clinical efficacy and treatment stages.

[0048] It will be appreciated that the composition may contain as many or as few peptides derived from the polypeptide allergen as will make it useful. Although in one embodiment of the method of desensitising the patient of the first aspect of the invention a single peptide may be administered to the patient wherein the peptide demonstrates restriction to a MHC Class II molecule possessed by the patient and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule, it is preferred if the composition of the second aspect of the invention contains sufficient number of peptides, each of which demonstrate restriction to a particular MHC Class II molecule and which are able to induce a late phase response in an individual who possesses the said MHC Class II molecule, such that for at least 75% of the population a peptide is present in the composition which is MHC Class II restricted and which is capable of inducing a late phase response in an individual with an appropriate restricted MHC Class II molecule. More preferably the composition contains sufficient peptides such that for at least 80% of the population (and still more preferably at least 85%, or yet still more preferably 90% of the population) a peptide is present in the composition which is MHC Class II restricted and which is capable of inducing a late phase response in an individual with an appropriate restricted MHC Class II molecule.

[0049] In a particularly preferred embodiment, the composition contains (as the only polypeptide allergen-derived peptide components of the composition) peptides which are MHC Class II restricted and which are capable of inducing a LPR in an individual who possesses the given MHC Class II molecule. Preferably, the composition contains as the only polypeptide allergen-derived peptide components a sufficient number of peptides, each of which demonstrate restriction to a particular MHC Class II molecule and which are able to induce a LPR in an individual who possesses the said MHC Class II molecule, such that for at least 75% of the population a peptide is present in the composition which is MHC Class II restricted and which is capable of inducing a LPR in an individual with an appropriate restricted MHC Class II molecule.

[0050] It is well known that the frequency of particular MHC Class II molecules in a population varies with ethnic groups, and that for at least some ethnic groups the frequency of particular MHC Class II molecules is known (see, for example, HLA Typing 1997, supra). For example, the frequency of particular MHC Class II molecules is different in the Caucasian population compared to the Mongoloid population or Negroid population and so on. It will readily be appreciated that the polypeptide allergen-derived peptides to be included in a composition of tie invention may be selected according to the ethnic group to which the patient belongs. For example, compositions of the invention may readily be prepared for desensitisation to a particular polypeptide allergen by reference to the MHC Class II gene frequencies in the Caucasian or Mongoloid or Negroid populations.

[0051] A third aspect of the invention provides a composition of the second aspect of the invention packaged and presented for use in medicine. In particular, the composition will be packaged and presented with an indication of who may be treated (in particular who may benefit from being treated) with the composition including, if desirable, an indication of the MHC Class II molecules to which the peptides within the composition are restricted.

[0052] It will be appreciated that the composition of the second aspect of the invention is conveniently administered to the patient according to the method of the first aspect of the invention.

[0053] A fourth aspect of the invention provides a pharmaceutical formulation comprising a composition according to the second aspect of the invention and a pharmaceutically acceptable carrier. Suitable ingredients for pharmaceutical formulations are described in more detail below.

[0054] A fifth aspect of the invention provides the use of a peptide derived from a polypeptide allergen wherein restriction to a MHC Class II molecule possessed by a patient can be demonstrated for the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule in the manufacture of a medicament for desensitising a patient to said polypeptide allergen.

[0055] A sixth aspect of the invention provides the use of a composition according to the second aspect of the invention in the manufacture of a medicament for desensitising a patient to said polypeptide allergen.

[0056] It will be appreciated that with respect to the method of the first aspect of the invention it may be desirable to determine which MHC Class II molecules the patient possesses in order to select an appropriate peptide or composition to administer to the patient. (It will be appreciated that this may be determined by determining the MHC haplotype of the individual by genetic means.) This is particularly desirable when the administration of a single peptide is contemplated. However, it will also be appreciated that when a composition is used which contains sufficient number of peptides, each of which demonstrate restriction to a particular MHC Class II molecule and which are able to induce a late phase response in an individual who possesses the said MHC Class II molecule, such that for at least 75% (or more preferably 80%, or 85% or 90%) of the population a peptide is present in the composition which is MHC Class II restricted and which is capable of inducing a late phase response in an individual with an appropriate restricted MHC Class II molecule, then it may not be necessary or desirable to type the patient to determine which MHC Class II molecules he or she possesses.

[0057] The polypeptide allergen may be any polypeptide allergen, some of which are described in more detail below.

[0058] A seventh aspect of the invention provides a method of selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to a polypeptide allergen capable of eliciting an allergic response in the patient, which patient possesses a particular MHC Class II molecule, the method comprising the steps of (1) selecting a candidate peptide derived from the polypeptide allergen, (2) determining whether the candidate peptide demonstrates restriction to the said MHC Class II molecule, and (3) determining whether the candidate peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule.

[0059] The candidate peptide may be any peptide derived from the polypeptide allergen and is, conveniently, a polypeptide in the size range described elsewhere as being a suitable size of a peptide for use in immunotherapy.

[0060] Whether or not the candidate demonstrates restriction to the said MHC Class II molecule may be determined by any suitable method such as those well known in the art, some of which are described in the Examples.

[0061] Whether or not the candidate peptide is able to induce a LPR can be determined by the methods described herein and which are well known in the art. It is particularly preferred if step (2) is carried out prior to step (3) and only candidate peptides which demonstrate restriction to the particular MHC Class II molecules are selected for testing in step (3).

[0062] It is particularly preferred that the individual in step (3) is an appropriately sensitised individual; that is to say an individual who has been sensitised previously to the allergen in question. It is those peptides which are capable of inducing a LPR and which demonstrate restriction to the particular MHC Class II molecule which are selected as an immunotherapeutic agent.

[0063] Determination of whether the candidate peptide demonstrates restriction to the said MHC Class II molecules may conveniently be done using a suitable T cell activation assay.

[0064] Thus, in one preferred embodiment the invention provides a method for selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to an allergen capable of eliciting an allergic response in the patient which patient possesses a particular MHC Class II haplotype, comprising the steps of:

[0065] a) administering a candidate peptide to an individual who possesses the same said MHC Class II molecule as the patient and determining whether the peptide induces a late phase response; and

[0066] b) selecting a peptide capable of inducing a late-phase response as an immunotherapeutic agent.

[0067] The individual to whom the candidate peptide is administered for the purpose of determining whether the peptide induces a LPR may or may not be the patient.

[0068] In an eighth aspect, the invention provides a method for testing for candidate peptides for further selection according to the preferred embodiment discussed immediately above of the invention, comprising the steps of:

[0069] a) assaying a peptide or peptides in a T-cell activation assay and selecting peptides capable of inducing activation of an individual's T-cells;

[0070] b) tissue-typing the individual to determine MHC type;

[0071] c) determining the MHC molecule(s) bound by each candidate peptide; and

[0072] d) selecting a peptide or peptides satisfying part (a) above and capable of binding to an MHC type possessed by the individual, for use as a candidate peptide in a method according to the preferred embodiment discussed immediately above.

[0073] In a ninth aspect, the invention provides a method for selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to an allergen comprising the steps of:

[0074] a) tissue-typing the patient to determine MHC Class II type; and

[0075] b) selecting, from a database of peptides which are known to bind to particular MHC molecules and induce a late phase response in an individual possessing such MHC Class II molecules, one or more peptides capable of binding to the MHC Class II molecules possessed by the individual.

[0076] Preferably, the individual is an appropriately sensitised individual who has been sensitised previously to the allergen in question.

[0077] In a tenth aspect, the invention provides a database of peptides characterised according to the seventh and eighth aspects of the invention.

[0078] TCRs are highly variable in their specificity. Variability is generated, as with antibody molecules, through gene recombination events within the cell. TCRs recognise antigen in the form of short peptides bound to molecules encoded by the genes of the Major Histocompatibility Complex (MHC). These gene products are the same molecules that give rise to “tissue types” used in transplantation and are also referred to as Human Leukocyte Antigen molecules (HLAs) which terms may be used interchangeably within this document. Individual MHC molecules possess peptide binding grooves which, due to their shape and charge are only capable of binding a limited group of peptides. The peptides bound by one MHC molecule may not necessarily be bound by other MHC molecules. As a result of this restricted peptide-MHC binding, T cell receptor recognition of a particular peptide is said to be “restricted” by the MHC molecule to which the peptide is bound. As used herein the term “allergen peptide-binding MHC” will be used to mean the MHC molecule(s) that bind the said allergen or allergen-derived peptide.

[0079] When a protein molecule such as an antigen or allergen is taken up by antigen presenting cells such as B lymphocytes, dendritic cells, monocytes and macrophages, the molecule is enzymatically degraded within the cell. The process of degradation gives rise to peptide fragments of the molecule which, if they are of the appropriate size, charge and shape, may then bind within the peptide binding groove of certain MHC molecules and be subsequently displayed upon the surface of antigen presenting cells. If the peptide/MHC complexes are present upon the antigen presenting cell surface in sufficient numbers they may then activate T cells which bear the appropriate peptide/MHC-specific T cell receptors.

[0080] Due to the polymorphic nature of the MHC, individuals in an outbred population such as man will express different combinations of MHC molecules on their cell surfaces. Since different MHC molecules can bind different peptides from the same molecule based on the size, charge and shape of the peptide, different individuals will display a different repertoire of peptides bound to their MHC molecules.

[0081] Identification of universal MHC-binding peptide epitopes in an outbred population such as man is more difficult than in inbred animals (such as certain strains of laboratory mice). On the basis of differential MHC expression between individuals and the inherent differences in peptide binding and presentation which this brings, it is unlikely that a single peptide can be identified which will be of use for desensitisation therapy in man for most diseases unless the association of a particular MHC molecule with that disease is very strong. For example, the HLA-B27 molecule has been shown to have a close relationship with ankylosing spondylitis, where approximately 90% of sufferers express HLA-B27. For some autoimmune diseases, certain disease HLA associations have been demonstrated eg HLA-DR4 and rheumatoid arthritis, but these associations are much weaker than for ankylosing spondylitis.

[0082] In allergic diseases, associations are even weaker if demonstrated at all. For this reason, it is unlikely that therapies centred around a single peptide (even an immunodominant one) or small numbers of peptides will be optimally effective as desensitisation therapies. The conclusion drawn in the art where MHC binding allergen epitopes have been identified is that even if an immunodominant epitope is identified, it would appear that it is required to react with a variety of restricted MHCs to be of therapeutic value (see Van Neerven R J J et al (1994) J Immunol 152, 4203-4210; Higgins J A et al (1994) J Allerg Clin Immunol 93, 891-899).

[0083] As set forth herein, it has now been observed that a patient may be desensitised to a particular allergen by the administration of a peptide or a composition containing a peptide that is able to bind to at least one MHC molecule of said patient and which is able to induce a LPR in an individual who possesses the same MHC Class II molecule type. According to the present invention, therefore, the concept of “universal” desensitising peptides is rejected in favour of a selective approach which takes into account tissue type. Nevertheless, it will be appreciated that using a composition containing a plurality of peptides according to the present invention may be “universal” in the sense that a single composition may be used for most of the population, but that this is still selective on the basis that the composition contains peptides which are restricted by a particular MHC Class II molecule.

[0084] It can be hypothesised that eosinophil-dependent mucosal tissue damage, including LPR, is under T-cell control. For example, by in situ hybridisation the numbers of mRNA positive cells for the Th2-type (IL-4 and IL-5) and eosinophil-active cytokines (IL-3, IL-5 and GM-CSF) were shown to be elevated in asthmatics both at baseline (Robinson et al (1992) N Engl J Med 326: 298-304) and following allergen-induced LAR (Bentley et al (1993) Am J Respir Cell Mol Biol 8:35-42). Furthermore IL-4 and IL-5 mRNA co-localised largely to CD4+ T cells (Ying et al (1997) J Immunol 158:3539-3544). A T cell component of the LAR is also suggested by the observation that cyclosporin A attenuated the LAR, but not the EAR, provoked by allergen inhalation (Sihra et al (1997) Thorax 52:447-452). Furthermore a single infusion of anti-CD4 produced significant improvement in lung function in chronic corticosteroid-dependent asthmatics. However it has been difficult to determine whether T cell activation, as an initiating event, leads directly to airway narrowing in asthmatic patients and therefore an asthmatic response.

[0085] As described herein, it has now been shown that T cells can be selectively activated, and then rendered unresponsive. Moreover the anergising or elimination of these T-cells leads to desensitisation of the patient for a particular allergen. The desensitisation manifests itself as a reduction in response to an allergen or allergen-derived peptide, or preferably an elimination of such a response, on second and further administrations of the allergen or allergen-derived peptide. The second administration may be made after a suitable period of time has elapsed to allow desensitisation to occur; this is preferably any period between one day and several weeks. An interval of around two weeks is preferred.

[0086] Based on these results, the invention provides a method for desensitising a patient to a polypeptide allergen which comprises the administration to the patient of a peptide specifically selected to induce LPR and subsequent desensitisation in the patient wherein the peptide is restricted by a particular MHC Class II molecule and capable of inducing LPR in an individual who possesses the given MHC Class II molecule to which the peptide is restricted. The peptides for desensitisation may be selected according to whether they induce LPR.

[0087] LPR is defined as set forth in Allergy and Allergic Diseases (1997) A. B. Kay (Ed.), Blackwell Science, pp 1113 to 1130, and includes asthmatic, cutaneous and nasal late phase responses as described above.

[0088] As noted above, the peptide which is administered may be included in a composition containing a plurality of peptides derived from the allergen.

[0089] Preferably, the peptides are derivatives of the allergen itself, and retain at least one common antigenic determinant of the allergen. “Common antigenic determinant” means that the derivative in question retains at least one antigenic function of the allergen. Antigenic functions include possession of an epitope or antigenic site that is capable of binding to TCRs which recognise the allergen or fragments thereof. Thus, the peptides provided by the present invention include splice variants encoded by mRNA generated by alternative splicing of a primary transcript encoding the allergen, amino acid mutants, glycosylation variants and other covalent derivatives of the allergen which retain at least an MHC-binding property of the allergen. Exemplary derivatives include molecules wherein the peptide of the invention is covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Further included are naturally occurring variants of the allergen found in a particular species. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of the allergen gene.

[0090] Derivatives of the allergen also comprise mutants thereof, which may contain amino acid deletions, additions or substitutions, subject to the requirement to maintain at least one feature characteristic of the allergen. Thus, conservative amino acid substitutions may be made to peptides according to the invention substantially without altering the nature of the allergen, as may truncations from the N or C termini. Deletions and substitutions may moreover be made to the fragments of the allergen comprised by the invention. Peptides may be produced from a DNA which has been subjected to in vitro mutagenesis resulting eg in an addition, exchange and/or deletion of one or more amino acids. Preferably, peptides are produced by peptide synthesis according to known techniques using commercially available peptide synthesisers. Mutations and/or truncations may thus be made by changing the amino acid sequence during the synthesis procedure.

[0091] Suitable variants capable of binding to TCRs may be derived empirically or selected according to known criteria. Within a single peptide there are certain residues which contribute to binding within the MHC antigen binding groove and other residues which interact with hypervariable regions of the T cell receptor (Allen et al (1987) Nature 327:713-5). Within the residues contributing to T cell receptor interaction, a hierarchy has been demonstrated which pertains to dependency of T cell activation upon substitution of a given peptide residue. Using peptides which have had one or more T cell receptor contact residues substituted with a different amino acid, several groups have demonstrated profound effects upon the process of T cell activation. Evavold & Allen (1991) Nature 252:1308-10) demonstrated the dissociation of T cell proliferation and cytokine production. In this in vitro model, a T cell clone specific for residues 64-76 of haemoglobin (in the context of I-E^(k)), was challenged with a peptide analogue in which a conservative substitution of aspartic acid for glutamic acid had been made. This substitution did not significantly interfere with the capacity of the analogue to bind to I-E^(k). Following in vitro challenge of a T cell clone with this analogue, no proliferation was detected although IL-4 secretion was maintained, as was the capacity of the clone to help B cell responses. In a subsequent study the same group demonstrated the separation of T cell-mediated cytolysis from cytokine production. In this instance, the former remained unaltered while the latter was impaired. The efficacy of altered peptide ligands in vivo was initially demonstrated in a murine model of EAE (experimental allergic encephalomyelitis) by McDevitt and colleagues (Smilek et al (1991) Proc Natl Acad Sci USA 88:9633-9637). In this model EAE is induced by immunisation with the encephalitogenic peptide Ac1-11 of MBP (myelin basic protein). Substitution at position four (lysine) with an alanine residue generated a peptide which bound well to its restricting element (Aα^(u)Aβ^(u)), but which was non-immunogenic in the susceptible PL/JxSJLF1 strain and which, furthermore prevented the onset of EAE when administered either before or after immunisation with the encephalitogenic peptide. Thus, residues can be identified in peptides which affect the ability of the peptides to induce various functions of T-cells.

[0092] Advantageously, peptides may be designed to favour T-cell proliferation and induction of desensitisation. Metzler and Wraith have demonstrated improved tolerogenic capacity of peptides in which substitutions increasing peptide-MHC affinity have been made (Metzler & Wraith (1993) Int Immunol 5:1159-65). The demonstration that an altered peptide ligand can cause long-term and profound anergy in cloned T cells (Sloan-Lancaster et al (1993) Nature 363:156-9) is particularly relevant to the applications of such peptide analogues in immunotherapy for diseases such as autoimmunity and allergy, in addition to the induction of host/donor-specific tolerance in transplantation.

[0093] Derivatives which retain common antigenic determinants are preferably fragments of the allergen. Fragments of the allergen comprise individual domains thereof, as well as smaller polypeptides derived from the domains. Preferably, smaller polypeptides derived from the allergen according to the invention define a single epitope of the allergen capable of binding a TCR. Fragments may in theory be almost any size, although smaller fragments are more likely to be restricted to a single MHC molecule and are thus preferred. Preferably, fragments will be between 5 and 50, preferably between 5 and 25, and advantageously about 17 amino acids in length. It is preferred if the peptides do not invoke an IgE response and do not lead to the release of histamine from enriched basophils or mast cell preparations from most sensitised individuals.

[0094] Candidate peptides potentially capable of inducing LPR in a patient may be preselected in order to maximise the chances of identifying a therapeutically useful peptide in in vivo tests. The steps of this aspect of the invention comprise the determination that the peptide is MHC Class II restricted, for example it is capable of causing T-cell proliferation when associated with an MHC molecule present in the patient to be treated. Thus, in a particular embodiment the selection procedure can be broken down into three steps, performed either sequentially (in any order) or together:

[0095] a) assaying a peptide or peptides in a T-cell activation assay and selecting peptides capable of inducing activation in an individual's T-cells;

[0096] b) tissue-typing the individual to determine MHC Class II type; and

[0097] c) determining the MHC Class II molecule bound by each candidate peptide.

[0098] Steps (a) and (c), in particular, may be combined in a single T-cell activation assay. Preferably, the assay involves the use of cells transfected to express a particular MHC molecule, and the binding of the peptide to this MHC assessed by its ability to induce T-cell proliferation in the presence of the transfected cells alone. Suitable transfected cells are readily available and can, in any case, be readily made by transfecting the cloned genes into suitable cell lines.

[0099] Preferably, a peptide selected according to the above procedure is tested for its ability to induce LPR in an individual. If LPR is induced, repeated administration will result in desensitisation to the allergen from which the peptide is derived.

[0100] However, once a peptide has been determined to bind a particular MHC Class II type and to be capable of inducing LPR when administered to an individual possessing that MHC Class II type, it can be used to induce desensitisation to the relevant allergen in substantially any patient possessing the required MHC Class II molecule. Therefore, peptides derived from particular allergens may be characterised according to their binding to particular MHC Class II types and their ability to induce LPR, thus providing a database from which a suitable peptide may be selected for any given patient upon tissue typing of that patient. Additionally or alternatively, a preparation containing a plurality of MHC-binding peptides capable of inducing LPR may be employed which will be effective in desensitising the majority of sensitised individuals.

[0101] Thus, in one embodiment antigen presenting cells may be isolated from a patient known to be sensitive to a particular allergen or allergens, and based on the peptide-binding MHC molecules displayed by said cells, a peptide may be selected for use in desensitising said patient by virtue of its ability to bind to at least one MHC molecule. The invention accordingly provides a method for selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to an allergen comprising the steps of:

[0102] a) tissue-typing the patient to determine MHC Class II type; and

[0103] b) selecting, from a database of peptides which are known to bind to particular MHC Class II molecules and induce a late phase response in an individual possessing such MHC Class II molecules, one or more peptides capable of binding to the MHC Class II molecules possessed by the patient.

[0104] For the avoidance of doubt, the individual referred to in part (b) above need not necessarily be the same individual as the patient undergoing treatment whom is tissue typed in part (a). In fact, once the MHC Class II restriction of a particular allergen-derived peptide is determined, and it has been determined that the peptide is capable of inducing a LPR in an individual, particularly an appropriately sensitised individual, who possesses the said MHC Class II molecule, there is no requirement to test the ability of the patient's own MHC Class II molecules.

[0105] Allergens that may be amenable to desensitisation procedures as described herein include the peptides derived or chosen from the list comprising the allergens; Fel d 1 (the feline skin and salivary gland allergen of the domestic cat Felis domesticus—the amino acid sequence of which is disclosed in WO 91/06571), Der p I, Der p II, Der fI or Der fII (the major protein allergens from the house dust mite dermatophagoides—amino acid sequences disclosed in WO 94/24281).

[0106] The invention is applicable substantially to any allergen, including allergens present in any of the following: grass, tree and weed (including ragweed) pollens; fungi and moulds; foods eg fish, shellfish, crab lobster, peanuts, nuts, wheat gluten, eggs and milk; stinging insects eg bee, wasp and hornet and the chirnomidae (non-biting midges); spiders and mites, including the house dust mite; allergens found in the dander, urine, saliva, blood or other bodily fluid of mammals such as cat, dog, cows, pigs, sheep, horse, rabbit, rat, guinea pig, mouse and gerbil; airborne particulates in general; latex; and protein detergent additives.

[0107] Where the allergen is an insect protein, the peptides may be selected from the group comprising: housefly, fruit fly, sheep blow fly, screw worm fly, grain weevil, silkworm, honeybee, non-biting midge larvae, bee moth larvae, mealworm, cockroach and larvae of Tenibrio molitor beetle. All these being insect allergens, they are of particular relevance to allergic problems arising in the workplace.

[0108] Where the allergen is the Fel d 1 allergen, useful peptides may preferably comprise a sequence as shown in any one of SEQ ID Nos. 1 to 3. Particular preferred peptides for use in the methods of the invention are those with the sequence given in SEQ ID Nos. 1 or 2 or 3. Preferred compositions of the invention include those that contain the peptides with the sequence given in SEQ ID Nos. 1, 2 and 3, and compositions containing the MHC Class II-restricted peptides of the thirteen peptides described in Example 7 and for which can be determined a LPR in an individual possessing appropriate MHC Class II molecules.

[0109] A database according to the invention includes information on the MHC Class II molecule(s) bound by peptides in the database and the ability of the peptides to induce a LPR in patients possessing such MHC Class II molecule(s). Thus, the database allows a practitioner to select peptides capable or potentially capable of eliciting a LPR and therefore desensitisation in a particular patient on the basis of that patient's tissue type.

[0110] The invention moreover provides a peptide listed in a database according to the invention, for use in therapy. Preferably, such peptides are useful in methods for desensitising patients to allergens in accordance with the methods set forth herein. Peptides to be included in the database, and peptides which may be useful either individually or as a mixture in a composition of the invention may readily be selected by the methods of the invention from polypeptide allergens whose polypeptide sequences, or reference to polypeptide sequences, are given in Example 6.

[0111] The MHC molecules expressed on APCs which bind peptides derived from a specific allergen may be identified by methods known in the art, such as T cell proliferation studies with MHC blocking antibodies, and PCR techniques, for example techniques based on those of Olerup & Zetterquist (1992) Tissue Antigens 29:225-235. Thus, antigen-presenting cells, expressing a variety of MHC molecules may be incubated with allergen and T cells and the latter observed for proliferation. Addition of antibodies to specific MHC classes may then be made in repeat incubations in order to identify the restricted MHC in respect of the allergen being tested. See Van Neerven R J J et al (1994) Immunol 82:351-356, and Yssel H et al (1992) J Immunol 148:738-745.

[0112] Alternatively, cells presenting a single MHC Class II type, for example cells such as fibroblast cells transfected with the genes encoding an MHC Class II molecule, may be incubated with individual peptides for which T-cell clones or lines are known to be specific. Culturing of such T-cell clones or lines with peptide presented by the appropriate MHC Class II molecule will lead to T-cell proliferation. T cell proliferation is not the only indicator that a particular peptide binds to a particular MHC Class II molecule on an APC. Other indicators include the secretion of measurable soluble products such as cytokines, changes in intracellular calcium levels, and other means of measuring T cell activation which are well known in the art.

[0113] Preferred fibroblasts for use in this aspect of the invention include human or murine fibroblasts, particularly L-cells.

[0114] The latter method may be used in a combinatorial approach, in which groups of peptides may be tested together and effective peptides identified by standard combinatorial techniques.

[0115] Specific epitopes of the allergen or peptide derived therefrom that bind to at least one MHC Class II molecule may then be identified by standard procedures and used in desensitisation procedures as described herein. Accordingly, the invention provides peptides when selected according to the foregoing aspects of the invention.

[0116] For example, when the allergen is a cat allergen such as the Fel d 1 protein, then the MHC molecule may include DR13 or DR1 class II MHC, and a peptide that binds to DR13 and/or DR1 or any of its sub-types that may be used in a desensitisation procedure is that shown in SEQ. ID No. 3.

[0117] The peptides identified in such a manner, and those of use in the methods of the present invention may be used in desensitisation procedures that typically involve sequential administration of said peptide. Although the first administration of the peptide may induce a measurable or observable LPR, as has been described elsewhere the peptide or composition administered to the patient may be at a concentration that does not invoke a measurable or observable LPR. Subsequent administration will lead to desensitisation of the patient. For example, if the peptide is that of SEQ. ID No. 3 (a fragment of the Fel d 1 allergen), then upon first administration of this peptide a LPR will be observed. Subsequent administration of this peptide results in a weaker reaction or no reaction, the patient having been desensitised.

[0118] The invention also relates to the use of a peptide in desensitising a patient against an allergen, the peptide being identified by its capability to bind to at least one MHC Class II molecule present in an individual and induce LPR in an individual who possesses the said MHC Class II molecule, wherein the patient also possesses the given MHC Class II molecule.

[0119] Peptides may be administered to a patient singly or in combination (for example as a composition as defined above). Thus, the database according to the invention may be used to prepare a designer vaccine which may be used to desensitise a patient to a chosen allergen, on the basis of the patient's MHC Class II type. The MHC Class II type can be correlated to the known MHC Class II binding characteristics of the peptides listed in the database, and the appropriate peptides selected and combined to form a designer vaccine. Similarly, the database may be used to design compositions (ie mixtures of peptides) which contain sufficient number of peptides, each of which demonstrate restriction to a particular MHC Class II molecule and which are able to induce a late phase response in an individual who possesses the said MHC Class II molecule, such that for at least 75% (preferably at least 80% or 85% or 90%) of the population a peptide is present in the composition which is MHC Class II restricted and which is capable of inducing a late phase response in an individual with the appropriate MHC Class II molecule.

[0120] Whilst it may be possible to design a vaccine which targets all or most of the epitopes on a particular antigen, this is unnecessary due to linked suppression of T-cells. Linked suppression is a phenomenon in which administration of a single epitope from a protein leads to the induction of a population of regulatory peptide-specific T lymphocytes which, by release of soluble factors such as TGFβ and/or IL-10, are able to suppress or modify responses of non-tolerant T cells specific for other epitopes within the same protein and in some models epitopes derived from other proteins (“bystander suppression”) (Davies et al (1996) J Immunol 156:3602-7). In transplantation models, such regulatory T cells have been demonstrated to be capable of inducing a similar phenotype in naive T cells. This has given rise to the term “infectious tolerance” (Qin et al (1993) Science 259:974-7) which may be a mechanism for effecting long-term hyporesponsiveness.

[0121] Linked suppression is thought to occur when peptide-specific regulatory T cells engage peptide/MHC complexes on the surface of the same or neighbouring APC as T cells specific for other epitopes. The latter may be responding to epitopes derived from the same molecule as the regulatory T cells or from a distinct molecule being processed by the same APC. This phenomenon allows desensitisation of patients to one or multiple allergens by the administration of a limited number of peptides.

[0122] Whilst it may be possible for the peptides or compositions according to the invention to be presented in raw form, it is preferable to present them as a pharmaceutical formulation. Thus, according to a further aspect, the present invention provides a pharmaceutical formulation comprising a peptide or composition according to the invention together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients. The carrier(s) must be ‘acceptable’ in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Typically, carriers for injection, and the final formulation, are sterile and pyrogen free.

[0123] The formulations include those suitable for oral (particularly inhaled), parenteral (including subcutaneous, transdermal, intradermal, intramuscular and intravenous and rectal) administration, although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of the present invention as herein defined or a pharmacologically acceptable salt or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.

[0124] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Formulations for inhalation may be presented in any of the ways known to be effective eg metered dose inhalers.

[0125] Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0126] Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.

[0127] Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.

[0128] The compounds of the invention may typically be administered intranasally, by inhalation, orally or via injection at a dose of from 0.0001 to 1 μg/kg per dose. Preferred are doses in the region of 10 to 150 μg per human patient, advantageously about 80 μg.

[0129] A further aspect of the invention provides a method of determining an initial dose of an immunotherapeutic peptide for desensitising a patient to a polypeptide allergen, which peptide is derived from the allergen and wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC molecule, the method comprising (1) determining the dose which is able to generate an observable late phase response in a given proportion of individuals who possess the said MHC molecule and in whom the peptide is able to induce a late phase response and (2) selecting a lower dose which is incapable of inducing an observable late phase response in substantially all individuals who possess the said MHC molecule and in whom the peptide is able to induce a late phase response.

[0130] Preferably, the individuals who possess the said MHC molecules are appropriately sensitised; that is to say that the individuals have been sensitised previously to the allergen in question.

[0131] The initial dose which is administered to the patient to be desensitised is, as is described above, one which may not itself give rise to an observable LPR.

[0132] In step (1) of the method of determining an initial dose the given proportion of individuals may be any suitable proportion of, but not all, individuals as given. Typically, the proportion is 50% of individuals as given, but it may be, for example, 30% or 40% or 60% or 70% of individuals as given. In step (2), the lower dose may be the maximum dose that is incapable of inducing an observable late phase response in substantially all individuals who possess the said MHC molecules and in whom the peptide is able to induce a LPR.

[0133] Typically, but it will be appreciated that this will vary from peptide to peptide, the lower dose is between 10-fold and 100-fold lower than the dose which induces an observable LPR in 50% of suitable individuals (a suitable individual is one who is appropriately sensitised and has the appropriate MHC Class II molecule(s) to facilitate peptide reactivity.

[0134] The LPR may be any suitable LPR as herein disclosed. Suitably, late asthmatic reactions are determined in asthmatics, late nasal reactions in rhinitics and late phase skin reactions in all allergic individuals.

[0135] It is preferred if the LPR is a late cutaneous reaction.

[0136] The methods of the invention are particularly suited for use in connection with human patients. However, it will be appreciated that animals, particularly mammals, and more particularly domestic and farm animals such as dogs and cats, may suffer from allergies due to polypeptide allergens. The methods of the invention include methods in connection with such animals. Although the specification refers to MHC and HLA Class II molecules, equivalent molecules exist in mammals other than humans as is well known in the art.

[0137] The invention is further described, for the purpose of illustration only, in the following examples, which refer to the figures.

[0138]FIG. 1. The three peptides comprising FCIP (solid circles; 80 μg) or vehicle control (open circles) are injected intradermally at time zero on two separate days. Forced expiratory volume in 1 second (FEV1) is measured at intervals as a readout of lung function over a 24 hr period. The use of rescue medication is indicated by arrows.

[0139]FIG. 2. Repeated administration of FC1P leads to a reduced lung response. Three patient volunteers who develop a late asthmatic reaction following administration of FC1P (closed circles), are challenged again with the same dose after a period of at least 2 weeks. No significant fall in FEV1 is observed following the second challenge (closed triangles). Open circles indicate the control day. Arrows indicate the use of bronchodilators.

[0140]FIG. 3. Murine L cells expressing two DR13 variants, DRB1*1301 and 1302 are incubated overnight with each of the three FC1P peptides, or a control peptide or medium alone. Cells are washed and incubated for one hour with a cytostatic agent to prevent proliferation in the subsequent assay. L cells are then incubated for 48 hours with T cells from a T cell line raised to whole cat dander (and including the Fel d 1 protein). Proliferation of the T cells is measured by their incorporation of the radiolabelled compound ³H-thymidine. T cells demonstrate a statistically significant response to the DR13 L cells and peptide FC1P3 (KALPVVLENARILNCV) but not to the other peptides/control.

[0141]FIG. 4. Human fibroblasts expressing the DR1 allele DRB1*0101 are incubated overnight with each of the three FC1P peptides, or medium alone, as described for FIG. 3. In T cell proliferation assays, T cells demonstrate a statistically significant response to the DR1 expressing cells and peptide FC1P3 (KALPVVLENARILNCV) but not to the other peptides/control.

[0142]FIG. 5. Human fibroblasts expressing the DR4 alleles DRB1*0404 and DRB1*0405 are incubated overnight with each of the three FC1P peptides, or medium alone, as described for FIG. 3. FIG. 5 a) and b): in T cell proliferation assays, DRB1*0408 responder cells demonstrate a statistically significant response to the DRB1*0405 expressing cells and peptide FC1P2 (EQVAQYKALPVVLENA) but not to DRB1*0404 expressing cells and peptide FC1P2 or to the other peptides/control.

[0143]FIG. 6. Human fibroblasts expressing the DR4 allele DRB1*0405 are incubated overnight with each of the three FC1P peptides, or medium alone, as described for FIG. 3. In T cell proliferation assays, DRB1*0405 responder cells demonstrate a statistically significant response to the DRB1*0405 expressing cells and peptide FC1P2 (EQVAQYKALPVVLENA) but not to the other peptides/control.

[0144]FIG. 7. The T cell proliferation responses observed in FIGS. 3, 4 and 6 are confirmed by [IL-5] measurement in FIGS. 7(a), 7(b) and 7(c) respectively. As expected, these results show that IL-5 production correlates with T-cell proliferation.

[0145]FIG. 8. Hypothetical protein and peptides (15mers) derived from overlapping by one residue.

[0146]FIG. 9. Multiple overlapping peptides (MOP) from die cat allergen Fel d I. The three sequences within the box were insoluble in aqueous solution and as a result were excluded from the MOP preparation for clinical use.

[0147]FIG. 10. An example of a LAR induced by the Fel d I MOP. The intradermal administration of 13 peptides which comprise MOP (solid circles; 2.5 μg, day 1) induce a fall in FEV1 of greater than 20% at 3 hours. Control day administration of 30BU cat dander extract does not induce a fall in FEV1 (open circles). A second administration of MOP (solid triangles; 2.5 μg, day 66) results in an attenuated fall in FEV1 which does not reach 20%. Arrows indicate the use of rescue medication (β₂ agonists).

[0148]FIG. 11. Changes in the cutaneous late phase response to whole allergen 6 hours after intradermal administration of whole cat dander extract before and after intradermal administration of MOP.

[0149]FIG. 12. The 3 peptides comprising FC1P (open down triangles: 80 μg, Figures (a), (b) and (c)) were administered intradermally to cat allergic asthmatic subjects inducing a fall in FEV1 of greater than 20% compared to a control day (open circles; 30BU whole cat dander extract, FIGS. 12(a), (b) and (c)). A second administration of FCIP within 6weeks (closed down triangles; 80 μg, FIG. 12(a)) demonstrated an attenuation of the response. Following administration of FC1P greater than one year after the initial dose (closed up triangles; 80 μg, FIGS. 12(a), (b) and (c)), a fall in FEV1 of similar magnitude to the initial injection was observed. Arrows indicate the use of rescue medication (β₂ agonists).

[0150] Schedule of sequences for sequence listing: SEQ ID No 1: LFLTGTPDEYVEQVAQY (FC1P1) SEQ ID No 2: EQVAQYKALPVVLENA (FC1P2) SEQ ID No 3: KALPVVLENARILKNCV (FC1P3) SEQ ID No 4: Fel d I chain 1 in FIG. 9 SEQ ID No 5: Fel d 2 chain 2 in FIG. 9

[0151] Other SEQ ID Nos. for peptides are shown on FIG. 9.

EXAMPLES Experimental Techniques

[0152] Primary Proliferation Assays

[0153] PBMCs are separated from whole blood by density gradient centrifugation according to standard methods. Cultures are established at 2×10⁵ cells per well in flat bottomed 96 well plates with 3 concentrations each individual peptide, or an optimum concentration of cat dander cat allergen extract, medium (negative control) or PPD (positive control). Cells are cultured for 8 days (cat dander) and 6 days (all others) and pulsed with 1 μCi tritiated thymidine. Cultures are harvested and counted after 8-16 hours.

[0154] T Cell Clones

[0155] PBMCs are cultured in 24 well plates with cat dander for 10-12 days, with the addition of approximately 10ng IL-2 on days 5 and 7, restimulated twice with irradiated autologous PBMCs and cat dander, and the line expanded with Phytohaemaglutinin (PHA) and IL-2. Clones are established by limiting dilution and will subsequently be frozen for use at a later stage to determine changes in cytokine secretion.

Example 1 Preparation of Allergen Peptides

[0156] The sequence of chain 1 of the cat allergen Fel d 1 is shown in FIG. 9 (SEQ. ID. No. 4); chain 2 is also shown in FIG. 9 (SEQ. ID. No. 5). Multiple overlapping peptides are designed around this sequence, as well as that of chain 2 of Fel d 1, as shown in FIG. 9.

Example 2 Observation of LAR in Patients on Peptide Administration

[0157] A single intradermal administration (80 μg of each peptide) of a mixture containing three short peptides (FIG. 9; (SEQ. ID Nos. 1, 2 or 3)) is given to 18 cat asthmatic individuals. 6 patients develop an isolated late asthmatic reaction as shown in FIG. 1 wherein a greater than 20% fall in Forced Expiratory Volume in 1 second (FEV1—a measure of lung function) is considered as a positive asthmatic effect. The results are shown in FIG. 1 where the three peptides comprising FC1P [solid circles; FC1P comprises FC1P1 (SEQ. ID. No. 1), FC1P2 (SEQ. ID. No. 2) and FC1P3 (SEQ. ID. No. 3)] or vehicle control (open circles) are injected intradermally at time zero on two separate days. FEV1 is measured at intervals as a readout of lung function over a 24 hr period. The use of rescue medication is indicated by arrows.

[0158] This result demonstrates that peptides capable of causing a LPR can be derived from a common allergen such as cat dander and tested for LAR production in cat asthmatic individuals.

[0159] Three patient volunteers who develop a late asthmatic reaction following administration of FC1P (closed circles), are challenged again with the same dose after a period of at least 2 weeks. No significant fall in FEV1 is observed following the second challenge (closed triangles). Open circles indicate the control day. Arrows indicate the use of bronchodilators. As shown in FIG. 2, none of the three develop a late asthmatic reaction to the second peptide administration indicating that the immune response to this peptide has been downregulated.

Example 3 Correlation Between Tissue Type and LAR

[0160] The 18 patients observed in Example 2 are MHC-typed using PCR, based upon the method of Olerup & Zetterquist (1992) Tissue Antigens 29:225-235. Four of the 6 reactors express HLA-DR13 (a closely related family of MHC molecules) compared to 1 out of 12 of the non-reactors. These results indicate that one of the three peptides injected is capable of binding to a DR13 family member and thus stimulating peptide-specific T cells from the reactors.

[0161] In order to demonstrate that specific T cells have been activated, L cells which have been transfected with the human genes encoding two DR13 family members are obtained from Georgetown University Medical School, USA. (DR13 is a split of DR6). Murine L cells expressing two DR13 variants, DRB1*1301 and 1302 are incubated overnight with each of the three FC1P peptides, or a control peptide, or medium alone. Cells are washed and incubated for one hour with a cytostatic agent to prevent proliferation in the subsequent assay. L cells are then incubated for 48 hours with T cells from a T cell line raised from PBMCs isolated from a reactor patient as described above and stimulated weekly with whole cat dander (and including the Fel d 1 protein). Proliferation of the T cells is measured by their incorporation of the radiolabelled compound ³H-thymidine. T cells demonstrate a statistically significant response to the DR13 L cells and peptide FC1P3 (SEQ. ID No 3) but not to the other peptides/control as shown in FIG. 3.

[0162] A further experiment is performed with human fibroblasts expressing the DR1 variant DRB1*0101. Cells are incubated overnight with each of the three FC1P peptides, or medium alone, washed, treated and incubated with T-cells as described above for the DR13 variants. T cells demonstrate a statistically significant response to the DR1 L cells and peptide FC1P3 (SEQ. ID No 3) but not to the other peptides/control as shown in FIG. 4

[0163] It is demonstrated halt FC1P3 is capable of binding to both DR1 and DR13 MHC molecules and activating T cells, thereby inducing the isolated late asthmatic reaction shown in FIG. 1. This result correlates extremely well with the tissue type data obtained from the patient population, wherein 4 out of six reactors are DR13 and two are DR1, compared with 1 out of 12 DR1 and 1 out of 12 DR13 non-reactors.

[0164] In a further series of experiments, patients reacting to FC1P are identified which express HLA-DR4 (DRB1*0405 and 0408). The same experiments are conducted as set forth above for HLA-DR13 patients, using DRB1*0404 and 0405 L-cells (0408 cells are not available). The results are shown in FIG. 5 and FIG. 6.

[0165] The results indicate that patients expressing DRB1* 0408 respond to FC1P2 presented by 0405 L cells but not 0404 L cells or to other peptides or controls. Likewise, patients expressing DRB1* 0405 respond to FC1P2 presented by 0405 L cells but not to other peptides or controls.

[0166]FIG. 7 shows the IL-5 secretion levels for DR13(a), DR1(b) and DR4(c) HLA types which correlate with T cell proliferation data as expected.

Example 4 FC1P3 Induces LAR and Desensitisation in Tissue-Typed Patients

[0167] Patients are selected on the basis of being allergic to cat dander, as in the previous examples. T-cell lines are prepared from each patient as described above, and maintained with weekly stimulation with cat dander extract. The patients are tissue-typed, and patients possessing DR1 or DR13 variants selected.

[0168] In order to predict the ability of peptide FC1P3 to desensitise the patients against cat dander, T-cell proliferation assays are performed using T-cells isolated from the patients as described and human fibroblasts or murine L-cells transfected with DR1 or DR13 alleles in the presence of FC1P3 according to Example 3. The T-cells are observed to proliferate, by the incorporation of ³H-thymidine, indicating that T-cells isolated from DR13 and DR1 possessing patients are responsive to stimulation with the FC1P3 peptide.

[0169] FC1P3 peptide is injected into patients which are DR1 and/or DR13 positive and in respect of whom a positive result has been obtained in the T-cell proliferation assay. These patients experience a LAR response, as measured by a 20% or greater fall in FEV1.

[0170] Patients who develop a late asthmatic reaction following administration of FC1P3 are challenged again with the same dose after a period of 2 weeks. As in Example 2. no significant fall or a reduced fall in FEV1 is observed following the second challenge, indicating that the immune response to this peptide has been downregulated.

Example 5 MHC Restriction Mapping of Fel d 1

[0171] In order to prepare a database of Fel d 1 derived peptides characterised according to MHC type restriction, an in vitro study of MHC class II restriction mapping is performed using a panel of L cells, T-cell lines to whole cat allergen and the overlapping peptides from chain 1 and chain 2, as described in Example 1. T cell lines with specificity for whole cat extract (which includes Fel d 1) are generated from the peripheral blood of subjects before peptide administration according to the procedures described above. Subjects are HLA-DR, DP and DQ typed, and, based on their expression, initially of DR alleles, transfected fibroblasts are selected to assay T-cell stimulation by each of the peptides.

[0172] Where the required HLA type clone is not available, MHC genes are cloned directly from the patient's cells by PCR amplification and cloning, as described above. Cloned genes are subsequently expressed in murine L-cells.

[0173] Cell lines (generous gifts from Prof. J. R. Lamb, University of Edinburgh, Prof. R. I. Lechler and Dr. G. Lombardi, ICSM, Hammersmith Hospital, Dr. C. Hurley and Dr. J. R. Richert, Georgetown University Medical Center. Washington, USA) expressing the appropriate restriction element are incubated with each individual Fel d 1 peptide as described in Example 3. Equivalent cell lines are generally available or may be readily made by transfecting appropriate genes expressing MHC Class II molecules. Following incubation in the cytostatic agent mitomycin C to prevent L cell division, cells are extensively washed and incubated with the T cell line. Proliferative responses are measured after 48 hours by addition of tritiated thymidine to all cultures for 8-16 hours. Peptides eliciting a proliferative response from the T cell line are thus restricted by the HLA allele expressed by the chosen L cell line.

[0174] Administration of peptides obtained from the database to patients possessing the HLA type in respect of which a proliferative response is seen in the above assay in the majority of cases results in a LAR, as expected, which is followed by desensitisation of the patient to cat dander on subsequent administration of the peptides.

[0175] In this way an MHC class II restriction map of the Fel d 1 molecule is constructed such that the appropriate peptides for immunotherapy may subsequently be selected on an individual patient basis, solely by virtue of that subject's HLA type.

Example 6 Identification of MHC-Restricted Peptides Capable of Inducing Late Phase Reactions in Individuals Possessing the Appropriate MHC Molecule

[0176] (1) Overlapping peptides of 15 amino acid residues (range approx. 7-20) which are offset by one residue are chemically synthesised for example using FastMoc chemistry. An example of a hypothetical protein and the overlapping peptides (in this example 15mers) which may be derived from it is given in FIG. 8.

[0177] (2) Each individual peptide is incubated with murine or human cells such as fibroblasts for example, which have been transfected with, or already express, the genes encoding a particular MHC molecule such as, for example DRA and DRB1*0101. The concentration of peptide used for the incubation stage may vary from approximately 0.01 mg/ml to 1 mg/ml or more. An example is 200 μg/ml. The incubation period may vary from approximately a few minutes to several hours. An example is 16 hours.

[0178] (3) Following incubation with peptide, the cells are washed several times (for example 3 times) in tissue culture medium (for example RPMI-1640 medium supplemented with 5% normal human AB serum, 2 mM L-glutamine, 100 microgram/ml streptomycin and 100U/ml penicillin).

[0179] (4) Cells are then incubated with mitomycin C (at approximately 50 μg/ml) or another suitable cytostatic agent to prevent cell division. Cells are washed several times (for example 5 times) in culture medium and dispensed into 96 well tissue culture plates at a concentration of approximately 3×10⁴ cells per well for example.

[0180] (5) To these cells are added approximately 1×10⁴ cells of a T lymphocyte cell line which has been cultured in the presence of, and is reactive with, the protein from which the peptides in step (1) were derived. The MHC molecules expressed by the individual from which the T lymphocyte line was raised would usually include the MHC molecule expressed on the cells in step (2). Alternatively, the MHC molecules expressed by the individual from whom the T lymphocyte line was raised may differ from those expressed on the cells in step (2). Additionally, T lymphocytes from the same cell line are cultured on their own and also with the MHC-expressing cells described in stage (2) which have either not been incubated with a peptide, or have been incubated with an irrelevant peptide such as a peptide from another protein.

[0181] 6) The cell mixture is cultured for approximately 2-3 days prior to the addition to each well of approximately 37MBq (1 μCi) of tritiated thymidine or similar for several hours (for example 6-16 hours).

[0182] 7) Cultures are then harvested onto glass fibre filters and cellular proliferation (of the T lymphocytes), as correlated with uptake of tritiated thymidine into the DNA of the cells, is measured by liquid scintillation spectroscopy or a similar technique.

[0183] Peptides capable of binding to the relevant MHC molecules and inducing T cell activation are identified by the incorporation of the tritiated thymidine into the newly synthesised DNA of the activated T cells. When the DNA is analysed by liquid scintillation spectroscopy (or other suitable techniques) the radioactive label (tritium) generated counts per minute which correlate with the degree of T cell proliferation and thus activation.

[0184] Thus, MOPs derived from a polypeptide allergen are useful principally in the selection procedure for identifying the one or more useful peptides (which show MHC Class II restriction and which are able to give rise to a LPR in an individual who possesses the appropriate MHC Class II molecules) which may be used either individually or in combination as an immunotherapeutic agent.

[0185] The following is a list of known allergen sequences and database accession numbers (NCBI Entrez accession numbers). NCBI is the National Center for Biotechnology information and is a division of the US National Institutes of Health. The NCBI web site, from which access to the database may be sought, www.ncbi.nlm.nih.gov/. The allergens may be used as described above in order to identify MHC-restricted peptides capable of inducing LPR in individuals who possess a particular MHC molecule.

[0186] Allergen sequences and database accession numbers (NCBI Entrez accession numbers): House dust mite Dermatophagoides pteronyssinus Der p 1 MKIVLAIASLLALSAVYARPSSIKTFEEYKKAFNKSYATFEDEEAAR KNFLESVKYVQSNGGAINHLSDLSLDEFKNRFLMSAEAFEHLKTQFD LNAETNACSINGNAPAEIDLRQMRTVTPIRMQGGCGSCWAFSGVAAT ESAYLAYRNQSLDLAEQELVDCASQHGCHGDTIPRGIEYIQHNGVVQ ESYYRYVAREQSCRRPNAQRFGISNYCQIYPPNVNKIREALAQTHSA IAVIIGIKDLDAFRHYDGRTIIQRDNGYQPNYHAVNIVGYSNAQGVD YYWIVRNSWDTNWGDNGYGYFAANIDLMMIEEYPYVVIL Der p 2 MMYKILCLSLLVAAVARDQVDVKDCANHEIKKVLVPGCHGSEPCIIH RGKPFQLEAVFEANQNTKTAKIEIKASIDGLEVDVPGIDPNACHYMK CPLVKGQQYDIKYTWNVPKIAPKSENVVVTVKVMGDDGVLACAIATH AKIRD Der p 3 MIIYNILIVLLLAINTLANPILPASPNATIVGGEKALAGECPYQISL QSSSHFCGGTILDEYWILTAAHCVAGQTASKLSIRYNSLKHSLGGEK ISVAKIFAHEKYDSYQIDNDIALIKLKSPMKLNQKNAKAVGLPAKGS DVKVGDQVRVSGWGYLEEGSYSLPSELRRVDIAVVSRKECNELYSKA NAEVTDNMICGGDVANGGKDSCQGDSGGPVVDVKNNQVVGIVSWGYG CARKGYPGVYTRVGNFIDWIESKRSQ Der p 4 KYXNPHFIGXRSVITXLME Der p 5 MKFIIAFFVATLAVMTVSGEDKKHDYQNEFDFLLMERIHEQIKKGEL ALFYLQEQINHFEEKPTKEMKDKIVAEMDTIIAMIDGVRGVLDRLMQ RKDLDIFEQYNLEMAKKSGDILERDLKKEEARVKKIEV Der p 6 AIGXQPAAEAEAPFQISLMK Der p 7 MMKLLLIAAAAFVAVSADPIHYDKITEEINKAVDEAVAAIEKSETFD PMKVPDHSDKFERHIGIIDLKGELDMRNIQVRGLKQMKRVGDANVKS EDGVVKAHLLVGVHDDVVSMEYDLAYKLGDLHPNTHVISDIQDFVVE LSLEVSEEGNMTLTSFEVRQFANVVNHIGGLSILDPIFAVLSDVLTA IFQDTVRAEMTKVLAPAFKKELERNNQ Der p 9 IVGGSNASPGDAVYQIAL Dermatophagoides farinae Der f 1 MKFVLAIASLLVLTVYARPASIKTFEFKKAFNKNYATVEEEEVARKN FLESLKYVEANKGAINHLSDLSLDEFKNRYLMSAEAFEQLKTQFDLN AETSACRINSVNVPSELDLRSLRTVTPIRMQGGCGSCWAFSGVAATE SAYLAYRNTSLDLSEQELVDCASQHGCHGDTIPRGIEYIQQNGVVEE RSYPYVAREQRCRRPNSQHYGISNYCQIYPPDVKQIREALTQTHTAI AVIIGIKDLRAFQHYDGRTIIQHDNGYQPNYHAVNIVGYGSTQGDDY WIVRNSWDTTWGDSGYGYFQAGNNLMMIEQYPYVVIM Der f 2 MISKILCLSLLVAAVVADQVDVKDCANNEIKKVMVDGCHGSDPCIIH RGKPFTLEALFDANQNTKTAKIEIKASLDGLEIDVPGIDTNACHFMK CPLVKGQQYDIKYTWNVPKIAPKSENVVVTVKLIGDNGVLACAIATH GKIRD Der f 3 MMILTIVVLLAANILATPILPSSPNATIVGGVKAQAGDCPYQISLQS SSHFCGGSILDEYWILTAAHCVNGQSAKKLSIRYNTLKHASGGEKIQ VAEIYQHENYDSMTIDNDVALIKLKTPMTLDQTNAKPVPLPAQGSDV KVGDKIRVSGWGYLQEGSYSLPSELQRVDIDVVSREQCDQLYSKAGA DVSENMICGGDVANGGVDSCQGDSGGPVVDVATKQIVGIVSWGYGCA RKGYPGVYTRVGNPVDWIESKRSQ Der f 4 AVGGQDADLAEAPFQISLLK Der f 7 MMKFLLIAAVAFVAVSADPIHYDKITEEINKAIDDAIAAIEQSETID PMKVPDHADKFERHVGIVDFKGELAMRNIEARGLKQMKRQGDANVKG EEGIVKAHLLIGVHDDIVSMEYDLAYKLGDLHPTTHVISDIQDFVVA LSLEISDEGNITMTSFEVRQFANVVNHIGGLSILDPIFGVLSDVLTA IFQDTVRKEMTKVLAPAFKRELEKN

[0187] Additional mite allergen sequences (NCBI entrez accession):

[0188] 1170095; 1359436; 2440053; 666007; 487661; 1545803; 84702; 84699; 625532; 404370; 1091577; 1460058; 7413; 9072; 387592. Cat Felis sequences 1082946 Fel dI chain 2 precursor-cat MRGALLVLALLVTQALGVKMAETCPIFYDVFFAVANGNELLLDLS LTKVNATEPERTAMKKIQDCYVENGLISRVLDGLVMTTISSSKDC MGEAVQNTVEDLKLNTLGR 1082945 Fel dI chain 1 short form-cat MLDAALPPCPTVAATADCEICPAVKRDVDLFLTGTPDEYVEQVAQ YKALPVVLENARILKNCVDAKMTEEDKENALSLLDKIYTSPLC 1082944 Fel dI chain 1 long form precursor-cat MKGARVLVLLWAALLLIWGGNCEICPAVKRDVDLFLTGTPDEYVE QVAQYKALPVVLENARILKNCVDAKMTEEDKENALSLLDMYTSPL C

[0189] Additional Felis sequences (NCBI entrez accession):

[0190] 539716; 539715; 423193; 423192; 423191; 423190; 1364213; 1364212; 395407; 163827; 1638923 163825; 1169665; 232086; 1169666. Latex Hevea sequences: Hev b 1 MAEDEDNQQGQGEGLKYLGFVQDAATYAVTTFSNVYLFAKDKSG PLQPGVDIIEGPVKNVAVPLYNRFSYIPNGALKFVDSTVVASVT IIDRSLPPIVKDASIQVVSAIRAAPEAARSLASSLPGQTKILAK VFYGEN Hev b 3 MAEEVEEERLKYLDFVRAAGVYAVDSFSTLYLYAKDISGPLKPG VDTIENVVKTVVTPVYYIPLEAVKFVDKTVDVSVTSLDGVVPPV IKQVSAQTYSVAQDAPRIVLDVASSVFNTGVQEGAKALYANLEP KAEQYAVITWRALNKLPLVPQVANVVVPTAVYFSEKYNDVVRGT TEQGYRVSSYLPLLPTEKITKVFGDEAS

[0191] Additional Hevea sequences (NCBI entrez accession):

[0192] 3319923; 3319921; 3087805; 1493836; 1480457; 1223884; 3452147; 3451147; 1916805; 232267; 123335; 2501578; 3319662; 3288200; 1942537; 2392631; 2392630; 1421554; 1311006; 494093; 3183706; 3172534; 283243; 1170248; 1708278; 1706547; 464775; 266892; 231586; 123337, 116359; 123062; 2213877; 542013; 2144920; 1070656; 2129914; 2129913; 2129912; 100135; 82026; 1076559; 82028; 82027; 282933; 280399; 100138; 1086972; 108697; 1086976; 1086978; 1086978; 1086976; 1086974; 1086972; 913758; 913757; 913756; 234388; 1092500; 228691; 1177405; 18839; 18837; 18835; 18833; 18831; 1209317; 1184668; 168217; 168215; 168213; 168211; 168209; 348137. Rye grass Lolium sequences: 126385 Lol p 1 MASSSSVLLVVALFAVFLGSAHGIAKVPPGPNITAEYGDKWLDAKS TWYGKPTGAGPKDNGGACGYKNVDKAPFNGMTGCGNTPIFKDGRGC GSCFEIKCTKPESCSGEAVTVTITDDNEEPIAPYHFDLSGHAFGSM AKKGEEQNVRSAGELELQFRRVKCKYPDDTKPTFHVEKASNPNYLA ILVKYVDGDGDVVAVDIKEKGKDKWIELKESWGAVWRIDTPDKLTG PFTVRYTTEGGTKSEFEDVIPEGWKADTSYSAK 126386 Lol p 2a AAPVEFTVEKGSDEKNLALSIKYNKEGDSMAEVELKEHGSNEWLAL KKNGDGVWEIKSDKPLKGPFNFRFVSEKGMRNVFDDVVPADFKVGT TYKPE 126387 Lol p 3 TKVDLTVEKGSDAKTLVLNIKYTRPGDTLAEVELRQHGSEEWEPMT KGNLWEVKSAKPLTGPMNFRFLSKGGMKNVFDEVIPTAFTVGKTYT PEYN 2498581 Lol p 5a MAVQKYTVALFLRRGPRGGPGRSYAADAGYTPAAAATPATPAATPA GGWREGDDRRAEAAGGRQRLASRQPWPPLPTPLRRTSSRSSRPPSP SPPRASSPTSAAKAPGLIPKLDTAYDVAYKAAEAHPRGQVRRLRHC PHRSLRVIAGALEVHAVKPATEEVLAAKIPTGELQIVDKIDAAFKI AATAANAAPTNDKFTVFESAFNKALNECTGGAMRPTSSSPPSRPRS SRPTPPPSPAAPEVKYAVFEAALTKAITAMTQAQKAGKPAAAAATA AATVATAAATAAAVLPPPLLVVQSLISLLIYY 2498582 Lol p 5b MAVQKHTVALFLAVALVAGPAASYAADAGYAPATPATPAAPATAAT PATPATPATPAAVPSGKATTEEQKLIEKINAGFKAAVAAAAVVPPA DKYKTFVETFGTATNKAFVEGLASGYADQSKNQLTSKLDAALKLAY EAAQGATPEAKYDAYVATLTEALRVIAGTLEVHAVKPAAEEVKVGA IPAAEVQLIDKVDAAYRTAATAANAAPANDKFTVFENTFNNAIKVS LGAAYDSYKFIPTLVAAVKQAYAAKQATAPEVKYTVSETALKKAVT AMSEAEKEATPAAAATATPTPAAATATATPAAAYATATPAAATATA TPAAATATPAAAGGYKV 455288 Lol p isoform 9 MAVQKHTVALFLAVALVAGPAASYAADAGYAPATPATPAAPATAAT PATPATPATPAAVPSGKATTEEQKLIEKINAGFKAAVAAAAVVPPA DKYKTFVETPGTATNKAFVEGLASGYADQSKNQLTSKLDAALKLAY EAAQGATPEAKYDAYVATLTEALRVIAGTLEVHAVKPAAEEVKVGA IPAAEVQLIDKVDAAYRTAATAANAAPANDKFTVFENTFNNAIKVS LGAAYDSYKFIPTLVAAVKQAYAAKQATAPEVKYTVSETALKKAVT AMSEAEKEATPAAAATATPTPAAATATATPAAAYATATPAAATATA TPAAATATPAAAGGYKV 1582249 Lol p 11 DKGPGFVVTGRVYCDPCRAGFETNVSHNVEGATVAVDCRPFDGGES KLKAEATTDKDGWYKIEIDQDHQEEICEVVLAKSPDKSCSEIEEFR DRARVPLTSNXGIKQQGIRYANPIAFFRKEPLKECGGILQAY

[0193] Additional Lolium sequences (NCBI entrez accession):

[0194] 135480; 417103; 687261; 687259; 1771355; 2388662; 631955; 542131; 542130; 542129; 100636; 626029; 542132; 320616; 320615; 320614; 100638; 100634; 82450; 626028; 100639; 283345; 542133; 1771353: 1763163; 1040877; 1040875; 250525; 551047; 515377; 510911; 939932; 439950; 2718; 168316; 168314; 485371; 2388664; 2832717; 2828273; 548867. Olive tree Olive sequences 416610 Ole e 1 EDIPQPPVSQFHIQGQVYCDTCRAGFITELSEFIPGASLRLQCKDKEN GDVTFTEVGYTRAEGLYSMLVE RDHKNEFCEITLISSGRKDCNEIPTEGWAKPSLKFKLNTVNGTTRTVN PLGFFKKEALPKCAQVYNKLGM YPPNM Parietaria Parietaria sequences: 2497750 Par j P2 MRTVSMAALVVIAAALAWTSSAEPAPAPAPGEEACGKVVQDIMPCLHF VKGEEKEPSKECCSGTKKLSEEVKTTEQKREACKCIVRATKGISGIKN ELVAEVPKKCDIKTTLPPITADFDCSKIQSTIFRGYY 1352506 Par j P5 MVRALMPCLPFVQGKEKEPSKGCCSGAKRLDGETKTGPQRVHACECIQ TAMKTYSDIDGKLVSEVPKHCGIVDSKLPPIDVNMDCKTVGVVPRQPQ LPVSLRHGPVTGPSDPAHKARLERPQIRVPPPAPEKA 1532056 Par j P8 MRTVSMAALVVIAAALAWTSSAELASAPAPGEGPCGKVVHHIMPCLKF VKGEEKEPSKSCCSGTKKLSEEVKTTEQKREACKCIVAATKGISGIKN ELVAEVPKKCGITTTLPPITADFDCSKIESTIFRGYY 1532058 Par j P9 MRTVSAPSAVALVVIVAAGLAWTSLASVAPPAPAPGSEETCGTVVRAL MPCLPFVQGKEKEPSKGCCSGAKRLDGETKTGLQRVHACECIQTAMKT YSDIDGKLVSEVPKHCGIVDSKLPPIDVNMDCKTLGVVPRQPQLPVSL RHGPVTGPSDPAHKARLERPQIRVPPPAPEKA 2497749 Par j P9 MRTVSARSSVALVVIVAAVLVWTSSASVAPAPAPGSEETCGTVVGALM PCLPFVQGKEKEPSKGCCSGAKRLDGETKTGPQRVHACECIQTAMKTY SDIDGKLVSEVPKHCGIVDSKLPPIDVNMDCKTLGVLHYKGN 1086003 Par j 1 MVRALMPCLPFVQGKEKEPSKGCCSGAKRLDGETKTGPQRVHACECIQ TAMKTYSDIDGKLVSEVPKHCGIVDSKLPPIDVNMDCKTVGVVPRQPQ LPVSLRHGPVTGPSRSRPPTKHGWRDPRLEFRPPHRKKPNPAFSTLG

[0195] Additional Parietaria sequences (NCBI entrez accession):

[0196] 543659; 1836011; 1836010; 1311513; 1311512; 1311511; 1311510; 1311509; 240971. Timothy grass Phleum sequences: Phl p 1 MASSSSVLLVVVLFAVFLGSAYGIPKVPPGPNITATYGDKWLDAKS TWYGKPTGAGPKDNGGACGYKDVDKPPFSGMTGCGNTPIFKSGRGC GSCFEIKCTKPEACSGEPVVVHITDDNEEPIAPYHFDLSGHAFGAM AKKGDEQKLRSAGELELQFRRVKCKYPEGTKVTFNVEKGSNPNYLA LLVKYVNGDGDVVAVDIKEKGKDKWIELKESWGAIWRIDTPDKLTG PFTVRYTTEGGTKTEAEDVIPEGWKADTSYESK Phl p 1 MASSSSVLLVVALFAVFLGSAHGIPKVPPGPNITATYGDKWLDAKS TWYGKPTAAGPKDNGGACGYKDVDKPPFSGMTGCGNTPIFKSGRGC GSCFEIKCTKPEACSGEPVVVHITDDNEEPIAAYHFDLSGIAFGSM AKKGDEQKLRSAGEVEIQFRRVKCKYPEGTKVTFHVEKGSNPNYLA LLVKFSGDGDVVAVDIKEKGKDKWIALKESWGAIWRIDTPEVLKGP FTVRYTTEGGTKARAKDVIPEGWKADTAYESK Phl p 2 MSMASSSSSSLLAMAVLAALFAGAWCVPKVTFTVEKGSNEKHLAVL VKYEGDTMAEVELREHGSDEWVAMTKGEGGVWTFDSEEPLQGPFNF RFLTEKGMKNVFDDVVPEKYTIGATYAPEE Phl p 5 ADLGYGGPATPAAPAEAAPAGKATTEEQKLIEKINDGFAALAAAAG VPPADKYKTFVATFGAASNKAFAEGLSAEPKGAAESSSKAALTSKL DAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKPA AEEVKVIPAGELQVIEKVDSAFKVAATAANAAPANDKFTVFEAAFN NAIKASTGGAYESYKFIPALEAAVKQAYAATVATAPEVKYTVFETA LKKAFTAMSEAQKAAKPATEATATATAAVGAATGAATAATGGYKV Phl p 5 ADLGYGGPATPAAPAEAAPAGKATTEEQKLIEKINDGFKAALAAAA GVPPADKYKTFVATFGAASNKAFAEGLSAEPKGAAESSSKAALTSK LDAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKP AAEEVKVIPAGELQVIEKVDSAFKVAATAANAAPANDKFTVFEAAF NNAIKASTGGAYESYKFIPALEAAVKQAYAATVATAPEVKYTVFET ALKKAITAMSEAQKAAKPATEATATATAAVGAATGAATAATGGYKV Phl p 5b AAAAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKL IEDINVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAAAAKAPGLV PKLDAAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAV KPVTEEPGMAKIPAGELQIIDMDAAFKVAATAAATAPADDKFTVFE AAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKYAV FEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATV AAGGYKV Phl p 5a ADLGYGPATPAAPAAGYTPATPAAPAGADAAGKATTEEQKLIEKIN AGFKAALAGAGVQPADKYRTFVATFGPASNKAFAEGLSGEPKGAAE SSSKAALTSKLDAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIA GTLEVHAVKPAAEEVKVIPAGELQVIEKVDAAFKVAATAANAAPAN DKFTVFEAAFNDEIKASTGGAYESYKFIPALEAAVKQAYAATVATA PEVKYTVFETALKKAITAMSEAQKAAKPAAAATATATAAVGAATGA ATAATGGYKV Phl p 5 MAVQKYTVALFLAVALVAGPAASYAADAGYAPATPAAAGAEAGKAT TEEQKLIEDINVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAATA KAPGLVPKLDAAYSVSYKAAVGATPEAKFDSFVASLTEALRVIAGA LEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAATAAATAPAD TVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYALATVAAAPQ VKYAVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAAS GAATVAAGGYKV Phl p 5 MAVQKYTVALFLAVALVAGPAASYAADAGYAPATPAAAGAEAGKAT TEEQKLIEDINVGFAVAAAASVPAADKFKTFEAAFTSSSKAATAKA PGLVPKLDAAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALE VHAVKPVTEDPAWPKIPAGELQIIDKIDAAFKVAATAAATAPADDK FTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQ VKYAVFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTATGAAS GAATVAAGGYKV Phl p 5 ADAGYAPATPAAAGAEAGKATTEEQKLIEDINVGFKAAVAAAASVP AADKFKTFEAAFTSSSKAATAKAPGLVPKLDAAYSVAYKAAVGATP EAKFDSFVASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQI IDKIDAAFKVAATAAATAPADDKFTVFEAAFNKAIKESTGGAYDTY KCIPSLEAAVKQAYAATVAAAPQVKYAVFEAALTKAITAMSEVQKV SQPATGAATVAAGAATTAAGAASGAATVAAGGYKV Phl p 5 SVKRSNGSAEVHRGAVPRRGPRGGPGRSYAADAGYAPATPAAAGAE AGKATTEEQKLIEDINVGFKAAVAAAASVPAADKFKTFEAAFTSSS KAATAKAPGLVPKLDAAYSVAYKAAVGATPEAKFDSFVASLTEALR VIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAATAAA TAPADDKFTVFEAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAA TVAAAPQVKYAVFEAALTKAITAMSEVQKVSQPATGAATVAAGAAT TAAGAASGAATVAAGGYKV Phl p 5 MAVHQYTVALFLAVALVAGPAGSYAADLGYGPATPAAPAAGYTPAT PAAPAGAEPAGKATEEQKLIEKINAGFKAALAAAAGVPPADKYRTF VATFGAASNKAFAEGLSGEPKGAAESSSKAALTSKLDAAYKLAYKT AEGATPEAKYDAYVATVSEALRIIAGTLEVHAVKPAAEEVKVIPAG ELQVIEKVDAAFKVAATAANAAPANDKFTVFEAAFNDAIKASTGGA YESYKFIPALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMSE AQKAAKPAAAATATATAAVGAATGAATAATGGYKV Phl p 5 ADLGYGGPATPAAPAEAAPAGKATTEEQKLIEKINDGFKAALAAAA GVPPADKYKTFVATFGAASNKAFAEGLSAEPKGAAESSSKAALTSK LDAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKP AAEEVKVIPAGELQVIEKVDSAFKVAATAANAAPANDKFTVFEAAF NNAIKASTGGAYESYKFIPALEAAVKQAYAATVATAPEVKYTVFET ALKKAFTAMSEAQKAAKPATEATATATAAVGAATGAATAATGGYKV Phl p 5b AAAAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKL IEDINVGFKAAVAAAASVPAADKFKTFEAAFTSSSKAAAAKAPGLV PKLDAAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAV KPVTEEPGMAKIPAGELQIIDKIDAAFKVAATAAATAPADDKFTVF EAAFNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKYA VFEAALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAAT VAAGGYKV Phl p 5a ADLGYGPATPAAPAAGYTPATPAAPAGADAAGKATTEEQKLIEKIN AGFKAALAGAGVQPADKYRTFVATFGPASNKAFAEGLSGEPKGAAE SSSKAALTSKLDAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIA GTLEVHAVKPAAEEVKVIPAGELQVIEKVDAAFKVAATAANAAPAN DKFTVFEAAFNDEIKASTGGAYESYKFIPALEAAVKQAYAATVATA PEVKYTVFETALKKAITAMSEAQKAAKPAAAATATATAAVGAATGA ATAATGGYKV Phl p 5 AVPRRGPRGGPGRSYAADAGYAPATPAAAGAEAGKATTEEQKLIED INVGFKAAVAAAASVPAGDKFKTFEAAFTSSSKAATAKAPGLVPKL DAAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAVKPV TEEPGMAKIPAGELQIIDKIDAAFKVAATAAATAPADDKFTVFEAA FNKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKYAVFE AALTKAITAMSEVQKVSQPATGAATVAAGAATTATGAASGAATVAA GGYKV Phl p 5b MAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKLIE DINVGFKAAVAARQRPAADKFKTFEAASPRHPRPLRQGAGLVPKLD AAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAVKPVT EEPGMAKIPAGELQIIDKIDAAFKVAATAAATAPADDKFTVFEAAF NKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAAEVKYAVFEA ALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAG GYKV Phl p 5 MAVHQYTVALFLAVALVAGPAASYAADLGYGPATPAAPAAGYTPAT PAAPAEAAPAGKATTEEQKLIEKINAGFKAALAAAAGVQPADKYRT FVATFGAASNKAFAEGLSGEPKGAAESSSKAALTSKLDAAYKLAYK TAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKPAAEEVKVIPA GELQVIEKVDAAFKVAATAANAAPANDKFTVFEAAFNDAIKASTGG AYESYKFIPALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMS EAQKAAKPAAAATATATAAVGAATGAATAATGGYKV Phl p 5 EAPAGKATTEEQKLIEKINAGFKAALARRLQPADKYRTFVATFGPA SNKAFAEGLSGEPKGAAESSSKAALTSKLDAAYKLAYKTAEGATPE AKYDAYVATLSEALRIIAGTLEVHAVKPAAEEVKVIPAAELQVIEK VDAAFKVAATAANAAPANDKFTVFEAAFNDEIKASTGGAYESYKFI PALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMSEAQKAAKP PPLPPPPQPPPLAATGAATAATGGYKV Phl p 5 MAVHQYTVALFLAVALVAGPAASYAADLGYGPATPAAPAAGYTPAT PAAPAEAAPAGKATTEEQKLIEKINAGFKAALAAAAGVQPADKYRT FVATFGAASNKAFAEGLSGEPKGAAESSSKAALTSKLDAAYKLAYK TAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKPAAEEVKVIPA GELQVIEKVDAAFKVAATAANAAPANDKFTVFEAAFNDAIKASTGG AYESYKFIPALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMS EAQKAAKPAAAATATATAAVGAATGAATAATGGYKV Phl p 5b MAVPRRGPRGGPGRSYTADAGYAPATPAAAGAAAGKATTEEQKLIE DINVGFKAAVAARQRPAADKFKTFEAASPRHPRPLRQGAGLVPKLD AAYSVAYKAAVGATPEAKFDSFVASLTEALRVIAGALEVHAVKPVT EEPGMAKIPAGELQIIDKIDAAFKVAATAAATAPADDKFTVFEAAF NKAIKESTGGAYDTYKCIPSLEAAVKQAYAATVAAAAEVKYAVFEA ALTKAITAMSEVQKVSQPATGAATVAAGAATTAAGAASGAATVAAG GYKV Phl p 5a ADLGYGPATPAAPAAGYTPATPAAPAGADAAGKATTEEQKLIEKIN AGFKAALAGAGVQPADKYRTFVATFGPASNKAFAEGLSGEPKGAAE SSSKAALTSKLDAAYKLAYKTAEGATPEAKYDAYVATLSEALRIIA GTLEVHAVKPAAEEVKVIPAGELQVIEKVDAAFKVAATAANAAPAN DKFTVFEAAFNDEIKASTGGAYESYKFIPALEAAVKQAYAATVATA PEVKYTVFETALKKAITAMSEAQKAAKPPPLPPPPQPPPLAATGAA TAATGGYKV Phl p 5 MAVHQYTVALFLAVALVAGPAASYAADLGYGPATPAAPAAGYTPAT PAAPAEAAPAGKATTEEQKLIEKINAGFKAALAAAAGVQPADKYRT FVATFGAASNKAFAEGLSGEPKGAAESSSKAALTSKLDAAYKLAYK TAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKPAAEEVKVIPA GELQVIEKVDAAFKVAATAANAAPANDKFTVFEAAFNDAIKASTGG AYESYKFIPALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMS EAQKAAKPAAAATATATAAVGAATGAATAATGGYKV Phl p 6 MAAHKFMVAMFLAVAVVLGLATSPTAEGGKATTEEQKLIEDVNASF RAAMATTANVPPADKYKTFEAAFTVSSKRNLADAVSKAPQLVPKLD EVYNAAYNAADHAAPEDKYEAFVLHFSEALRIIAGTPEVHAVKPGA Phl p 6 SKAPQLVPKLDEVYNAAYNAADHAAPEDKYEAFVLHFSEALHIIAG TPEVHAVKPGA Phl p 6 ADKYKTFEAAFTVSSKRNLADAVSKAPQLVPKLDEVYNAAYNAADH AAPEDKYEAFVLHFSEALHIIAGTPEVHAVKPGA Phl p 6 TEEQKLIEDVNASFRAAMATTANVPPADKYKTLEAAFTVSSKRNLA DAVSKAPQLVPKLDEVYNAAYNAADHAAPEDKYEAFVLHFSEALRI IAGTPEVHAVKPGA Phl p 6 MAAHKFMVAMFLAVAVVLGLATSPTAEGGKATTEEQKLIEDINASF RAAMATTANVPPADKYKTFEAAFTVSSYKRNLADAVSKAPQLVPKL DEVYNAAYNAADHAAPEDKYEAFVLHFSEALHIIAGTPEVHAVKPG A Phl p 6 MVAMFLAVAVVLGLATSPTAEGGKATTEEQKLIEDVNASFRAAMAT TANVPPADKYKTFEAAFTVSSKRNLADAVSKAPQLVPKLDEVYNAA YNAADHAAPEDKYEAFVLHFSEALRIIAGTPEVHAVKPGA Phl p 7 MADDMERIFKRFDTNGDGKISLSELTDALRTLGSTSADEVQRMMAE IDTDGDGFIDFNEFISFCNANPGLMKDVAKVF Phl p 11 MSWQTYVDEHLMCEIEGHHLASAAILGHDGTVWAQSADFPQFKPEE ITGIMKDFDEPGHLAPTGMFVAGAKYMVIQGEPGRVIRGKKGAGGI TIKKTGQALVVGIYDEPMTPGQCNMVVERLGDYLVEQGM

[0197] Additional Phleum sequences (NCBI entrez accession):

[0198] 458878; 548863; 2529314; 2529308; 2415702; 2415700; 2415698; 542168; 542167; 626037; 542169; 541814; 542171; 253337; 253336; 453976; 439960. Wasp (and related) Vespula sequences: 465054 ALLERGEN VES V 5 MEISGLVYLIIIVTIIDLPYGKANNYCKIKCLKGGVHTACKYGSLKPN CGNKVVVSYGLTKQEKQDILKEHNDFRQKIARGLETRGNPGPQPPAKN MKNLVWNDELAYVAQVWANQCQYGHDTCRDVAKYQVGQNVALTGSTAA KYDDPVKLVKMWEDEVKDYNPKKKFSGNDFLKTGHYTQMVWANTKEVG CGSIKYIQEKWHKHYLVCNYGPSGNFMNEELYQTK 1709545 ALLERGEN VES M 1 GPKCPFNSDTVSIIIETRENRNRDLYTLQTLQNHPEFKKKTITRPVVF ITHGFTSSASEKNFINLAKALVDKDNYMVISIDWQTAACTNEYPGLKY AYYPTAASNTRLVGQYIATITQKLVKDYKISMANIRLIGHSLGAHVSG FAGKRVQELKLGKYSEIIGLDPARPSFDSNHCSERLCETDAEYVQIIH TSNYLGTEKILGTVDFYMNNGKNNPGCGRFFSEVCSHTRAVIYMAECI KHECCLIGIPRSKSSQPISRCTKQECVCVGLNAKKYPSRGSFYVPVES TAPFCNNKGKII 1352699 ALLERGEN VES V 1 MEENMNLKYLLLFVYFVQVLNCCYGHGDPLSYELDRGPKCPFNSDTVS IIIETRENRNRDLYTLQTLQNHPEFKKKTITRPVVFITHGFTSSASET NFINLAKALVDKDNYMVISIDWQTAACTNEAAGLKYLYYPTAARNTRL VGQYIATITQKLVKHYKISMANIRLIGHSLGAHASGFAGKKVQELKLG KYSEIIGLDPARPSFDSNHCSERLCETDAEYVQIIHTSNYLGTEKTLG TVDFYMNNGKNQPGCGRFFSEVCSHSRAVIYMAECIKHECCLIGIPKS KSSQPISSCTKQECVCVGLNAKKYPSRGSFYVPVESTAPFCNNKGKII 1346323 ALLERGEN VES V 2 SERPKRVFNIYWNVPTFMCHQYDLYFDEVTNFNIKRNSKDDFQGDKIA IFYDPGEFPALLSLKDGKYKKRNGGVPQEGNITIHLQKFIENLDKIYP NRNFSGIGVIDFERWRPIFRQNWGNMKIHKNFSIDLVRNEHPTWNKKM IELEASKRFEKYARFFMEETLKLAKKTRKQADWGYYGYPYCFNMSPNN LVPECDVTAMHENDKMSWLFNNQNVLLPSVYVRQELTPDQRIGLVQGR VKEAVRISNNLKHSPKVLSYWWYVYQDETNTFLTETDVKKTFQEIVIN GGDGIIIWGSSSDVNSLSKCKRLQDYLLTVLGPIAINVTEAVN 549194 ALLERGEN VES V I 5KVNYCKIKCLKGGVHTACKYGTSTKPNCGKMVVKAYGLTEAEKQEIL KVHNDFRQKVAKGLETRGNPGPQPPAKNMNNLVWNDELANIAQVWASQ CNYGHDTCKDTEKYPVGQNIAKRSTTAALFDSPGKLVKMWENEVKDFN PNIEWSKNNLKKTGHYTQMVWAKTKEIGCGSVKYVKDEWYTHYLVCNY GPSGNFRNEKLYEKK

[0199] Additional vespula sequences (NCBI entrez accession):

[0200] 549193; 549192; 549191; 549190; 549189; 117414; 126761; 69576; 625255; 627189; 627188; 627187; 482382; 112561; 627186; 627185; 1923233; 897645; 897647; 745570; 225764; 162551. Tree allergen sequences (mainly birch) sequences: 114922 Bet v 1 MGVFNYETETTSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEG NGGPGTIKKISFPEGFPFKYVKDRVDEVDHTNFKYNYSVIEGGPIGD TLEKISNEIKIVATPDGGSILKISNKYHTKGDHEVKAEQVKASKEMG ETLLRAVESYLLAHSDAYN 130975 Bet v 2 MSWQTYVDEHLMCDIDGQASNSLASAIVGHDGSVWAQSSSFPQFKPQ EITGIMKDFEEPGHLAPTGLHLGGIKYMVIQGEAGAVIRGKKGSGGI TIKKTGQALVFGIYEEPVTPGQCNMVVERLGDYLIDQGL 1168696 Bet v 3 MPCSTEAMEKAGHGHASTPRKRSLSNSSFRLRSESLNTLRLRRIFDL FDKNSDGIITVDELSRALNLLGLETDLSELESTVKSFTREGNIGLQF EDFISLHQSLNDSYFAYGGEDEDDNEEDMRKSILSQEEADSFGGFKV FDEDGDGYISARELQMVLGKLGFSEGSEIDRVEKMIVSVDSNRDGRV DFFEFKDMMRSVLVRSS 809536 Bet v 4 MADDHPQDKAERERIFKRFDANGDGKISAAELGEALKTLGSITPDEV KHMMAEIDTDGDGFISFQEFTDFGRANRGLLKDVAKIF 543675 Que a I-Quercus alba = oak trees (fragment) GVFTXESQETSVIAPAXLFKALFL 543509 Car b I-Carpinus betulus = hornbeam trees (fragment) GVFNYEAETPSVIPAARLFKSYVLDGDKLIPKVAPQAIXK 543491 Aln g I-Alnus glutinosa = alder trees (fragment) GVFNYEAETPSVIPAARLFKAFILDGDKLLPKVAPEAVSSVENI 1204056 Rubisco VQCMQVWPPLGLKKFETLSYLPPLSSEQLAKEVDYLLRKNLIPCLEF ELEHGFVYREHNRSPGYYDGRYWTMWKLPMFGCNDSSQVLKELEECK KAYPSAFIRIIGFDDK

[0201] Additional tree allergen sequences (NCBI entrez accession number):

[0202] 131919; 128193; 585564; 1942360; 2554672; 2392209; 2414158; 1321728; 1321726; 1321724; 1321722; 1321720; 1321718; 1321716; 1321714; 1321712; 3015520; 2935416; 464576; 1705843; 1168701; 1168710; 1168709; 1168708; 1168707; 1168706; 1168705; 1168704; 1168703; 1168702; 1842188; 2564228; 2564226; 2564224; 2564222; 2564220; 2051993; 1813891; 1536889; 534910; 534900; 534898; 1340000; 1339998; 2149808; 66207; 2129477; 1076249; 1076247; 629480; 481805; 81443; 1361968; 1361967; 1361966; 1361965; 1361964; 1361963; 1361962; 1361961; 1361960; 1361959; 320546; 629483; 629482; 629481; 541804; 320545; 81444; 541814:; 629484; 474911; 452742; 1834387; 298737; 298736; 1584322; 1584321; 584320; 1542873; 1542871; 1542869; 1542867; 1542865; 1542863; 1542861; 1542859; 1542857; 1483232; 1483230; 1483228; 558561; 551640; 488605; 452746; 452744; 452740; 452738; 452736; 452734; 452732; 452730; 452728; 450885; 17938; 17927; 17925; 17921; 297538; 510951; 289331; 289329; 166953. Peanut Peanut sequences 1168391 Ara h 1 MRGRVSPLMLLLGILVLASVSATHAKSSPYQKKTENPCAQRCLQSC QQEPDDLKQKACESRCTKLEYDPRCVYDPRGHTGTTNQRSPPGERT RGRQPGDYDDDRRQPRREEGGRWGPAGPREREREEDWRQPREDWRR PSHQQPRKIRPEGREGEQEWGTPGSHVREETSRNNPFYFPSRRFST RYGNQNGRIRVLQRFDQRSRQFQNLQNHRIVQIEAKPNTLVLPKHA DADNILVIQQGQATVTVANGNNRKSFNLDEGHALRIPSGFISYILN RHDNQNLRVAKISMPVNTPGQFEDFFPASSRDQSSYLQGFSRNTLE AAFNAEFNEIRRVLLEENAGGEQEERGQRRWSTRSSENNEGVIVKV SKEHVEELTKHAKSVSKKGSEEEGDITNPINLREGEPDLSNNFGKL FEVKPDKKNPQLQDLDMMLTCVEIKEGALMLPHFNSKAMVIVVVNK GTGNLELVAVRKEQQQRGRREEEEDEDEEEEGSNREVRRYTARLKE GDVFIMPAAHPVAINASSELHLLGFGINAENNHRIFLAGDKDNVID QIEKQAKDLAFPGSGEQVEKLIKNQKESHFVSARPQSQSQSPSSPE KESPEKEDQEEENQGGKGPLLSILKAFN

[0203] Ragweed

[0204] Ambrosia Sequences 113478 Amb a 1 MGIKHICCYILYFTLALVTLLQPVRSAEDLQQILPSANETRSLTTCGT YNIIDGCWRGKADWAENRKALADCAQGFAKGTIGGKDGDIYTVTS ELDDDVANPKEGTLRFGAAQNRPLWIIFARDMVIRLDRELAINNDK TIDGRGAKVEHNAGFAIYNVKNIIIHNIIMHDIVVNPGGLIKSHDGPP VPRXGSDGDAIGISGGSQIWIDHCSLSKAVDGLIDAKHGSTHFTVSN CLFTQHQYLLLFWDFDERGMLCTVAFNKFTDNVDQRMPNLRHGF VQVVNNNYERWGSYALGGSAGPTILSQGNRFLASDIKKEVVGRYG ESAMSESINWNWRSYMDVFENGAIFVPSGVDPVLTPEQNAGMIPAE PGEAVLRLTSSAGVLSCQPGAPC 113479 Amb a 2 MGIKHCCYILYFTLALVTLVQAGRLGEEVDILPSPNDTRRSLQGCE AHNIIDKCWRCKPDWAENRQALGNCAQGFGKATHGGKWGDIYM VTSDQDDDVVNPKEGTLRFGATQDRPLWIIFQRDMIIYLQQEMVVT SDKTIDGRGAKVELVYGGITLMNVKNVIIHNIDIHDVRVLPGGRIKS NGGPAIPRHQSDGDAIHVTGSSDIWIDHCTLSKSFDGLVDVNWGST GVTISNCKFTHHEKAVLLGASDTHFQDLKMHVTLAYNIFTNTVHE RMPRCRFGFFQIVNNFYDRWDKYAIGGSSNPTILSQGNKFVAPDFIY KKNVCLRTGAQEPEWMTWNWRTQNDVLENGAIFVASGSDPVLTA EQNAGMMQAEPGDMVPQLTMNAGVLTCSPGAPC 113477 Amb a 1.3 MGIKQCCYILYFTLALVALLQPVRSAEGVGEILPSVNETRSLQACEA LNIIDKCWRGKADWENNRQALADCAQGFAKGTYGGKWGDVYTV TSNLDDDVANPKEGTLRFAAAQNRPLWIIFKNDMVINLNQELVVN SDKTIDGRGVKVEIINGGLTLMNVKNIIIHNINIHDVKVLPGGMIKSN DGPPILRQASDGDTINVAGSSQIWIDHCSLSKSFDGLVDVTLGSTHV TISNCKFTQQSKAILLGADDTHVQDKGMLATVAFNMFTDNVDQR MPRCRFGFFQVVNNNYDRWGTYAIGGSSAPTILCQGNRFLAPDDQI KKNVLARTGTGAAESMAWNWRSDKDLLENGAIFVTSGSDPVLTPV QSAGMIPAEPGEAAIKLTSSAGVFSCHPGAPC 113476 Amb a 1.2 MGIKHCCYILYFTLALVTLLQPVRSAEDVEEFLPSANETRRSLKACE AHNIIDKCWRCKADWANNRQALADCAQGFAKGTYGGKHGDVYT VISDKDDDVANPKEGTLRFAAAQNRPLWIIFKRNMVIHLNQELVV NSDKTIDGRGVKVNIVNAGLTLMNVKNIIIHNINIHDIKVCPGGMIKS NDGPPILRQQSDGDAINVAGSSQIWIDHCSLSKASDGLLDITLGSSHV TVSNCKFTQHQFVLLLGADDTHYQDKGMLATVAFNMFTDHVDQR MPRCRFGFFQVVNNNYDRWGTYAIGGSSAPTILSQGNRFFAPDDIIK KNVLARTGTGNAESMSWNWRTDRDLLENGATFLPSGSDPVLTPEQ KAGMIPAEPGEAVLRLTSSAGVLSCHQGAPC 113475 Amb a 1.1 MGIKHCCYILYFTLALVTLLQPVRSAEDLQEILPVNETRRLTTSGAY NIIDGCWRGKADWAENRKALADCAQGFGKGTVGGKDGDIYTVTS ELDDDVANPKEGTLRFGAAQNRPLWIIFERDMVIRLDKEMVVNSD KTIDGRGAKVEIINAGFTLNGVKNVIIHNINMHDVKVNPGGLIKSND GPAAPRAGSDGDAISISGSSQIWIDHCSLSKSVDGLVDAKLGTTRLT VSNSLFTQHQFVLLFGAGDENIEDRGMLATVAFNTFTDNVDQRMP RCRHGFFQVVNNNYDKWGSYAIGGSASPTILSQGNRFCAPDERSKK NVLGRHGEAAAESMKWNWRTNKDVLENGAIFVASGVDPVLTPEQ SAGMIPAEPGESALSLTSSAGVLSCQPGAPC

[0205] Cedar Sequences 493634 Cry j IB precursor MDSPCLVALLVFSFVIGSCFSDNPIDSCWRGDSNWAQNRMKLADC AVGFGSSTMGGKGGDLYTVTNSDDDPVNPPGLRYGATRDRPLWI IFSGNMNIKLKMPMYIAGYKTFDGRGAQVYIGNGGPCVFIKRVSNV IIHGLYLYGCSTSVLGNVLINESFGVEPVHPQDGDALTLRTATNIWI DHNSFSNSSDGLVDVTLTSTGVTISNNLFFNHHKVMSLGHDDAYSD DKSMKVTVAFNQFGPNCGQRMPRARYGLVHVANNNYDPWTIYAI GGSSNPTILSEGNSFTAPNESYKKQVTIRIGCKTSSSCSNWVWQSTQ DVFYNGAYFVSSGKYEGGNIYTKKEAFNVENGNATPHLTQNAGVL TCSLSKRC 493632 Cry j IA precursor MDSPCLVALLVLSFVIGSCFSDNPIDSCWRGDSNWAQNRMKLADC AVGFGSSTMGGKGGDLYTVTNSDDDPVNPAPGTLRYGATRDRPL WIIFSGNMNIKLKMPMYIAGYKTFDGRGAQVYIGNGGPCVFIKRVS NVIIHGLHLYGCSTSVLGNVLINESFGVEPVHPQDGDALTLRTATNI WIDHNSFSNSSDGLVDVTLSSTGVTISNNLFFNHHKVMLLGHDDAY SDDKSMKVTVAFNQFGPNCGQRMPRARYGLVHVANNNYDPWTIY AIGGSSNPTILSEGNSFTAPNESYKKQVTIRIGCKTSSSCSNWVWQST QDVFYNGAYFVSSGKYEGGNIYTKKEAFNVENGNATPQLTKNAGV LTCSLSKRC 1076242 Cry j II precursor-Japanese cedar MAMKLIAPMAFLAMQLIIMAAAEDQSAQIMLDSVVEKYLRSNRSL RKVEHSRHDAINIFNVEKYGAVGDGKHDCTEAFSTAWQAACKNPS AMLLVPGSKKFVVNNLFFNGPCQPHFTFKVDGIIAAYQNPASWKN NRIWLQFAKLTGFTLMGKGVIDGQGKQWWAGQCKWVNGREICND RDRPTAIKFDFSTGLIIQGLKLMNSPEFHLVFGNCEGVKIIGISTAPR DSPNTDGIDIFASKNFHLQKNTIGTGDDCVAIGTGSSNIVIEDLICGP GHGISIGSLGRENSRAEVSYVHVNGAKYIDTQNGLPIKTWQGGSGM ASHIIYENVEMINSENPILINQFYCTSASACQNQRSAVQIQDVTYKNI RGTSATAAAIQLKCSDSMPCKDIKLSDISLKLTSGKIASCLNDNANG YFSGHVIPACKNLSPSAKRKESKSHKHPKTVMVENMRAYDKGNRT RILLGSRPPNCTNKCHGCSPCKAKLVIVHRIMPQEYYPQRWICSCHG KIYHP 1076241 Cry j II protein-Japanese cedar MAMKFIAPMAFVAMQLIIMAAAEDQSAQIMLDSDIEQYLRSNRSLR KVEHSRHDAINIFNVEKYGAVGDGKHDCTEAFSTAWQAACKKPSA MLLVPGNKKFVVNNLFFNGPCQPHFTFKVDGIIAAYQNPASWKNN RIWLQFAKLTGFTLMGKGVIDGQGKQWWAGQCKWVNGREICNDR DRPTAIKPDFSTGLIIQGLKLMNSPEFHLVFGNCEGVKIIGISITAPRD SPNTDGIDIFASKNFHLQKNTIGTGDDCVAIGTGSSMVIEDLICGPG HGISIGSLGRENSRAEVSYVHVNGAKFIDTQNGLRIKTWQGGSGMA SHIIYENVEMINSENPILINQFYCTSASACQNQRSAVQIQDVTYKNIR GTSATAAAIQLKCSDSMPCKDIKLSDISLKLTSGKIASCLNDNANGY FSGHVIPACKNLSPSAKRKESKSHKHPKTVMVKNMGAYDKGNRTRI LLGSRPPNCTNKCHGCSPCKAKLVIVHRIMPQEYYPQRWMCSRHG KIYHP 541803 Cry j I precursor-Japanese cedar MDSPCLVALLVLSFVIGSCFSDNPIDSCWRGDSNWAQNRMKLADC AVGFGSSTMGGKGGDLYTVTNSDDDPVNPPGTLRYGATRDRPLWI IFSGNMNIKLKMPMYIAGYKTFDGRGAQVYIGNGGPCVFIKRVSNV IIHGLHLYGCSTSVLGNVLINESFGVEPVHPQDGDALTLRTATNIWI DHNSFSNSSDGLVDVTLSSTGVTISNNLFFNHHKVMLLGHDDAYSD DKSMKVTVAFNQFGPNCGQRMPRARYGLVHVANNNYDPWTIYAI GGSSNPTILSEGNSFTAPNESYKKQVTIRIGCKTSSSCSNWVWQSTQ DVFYNGAYFVSSGKYEGGNIYTKKEAFNVENGNATPQLTKNAGVL TCSLSKRC 541802 Cry j I precursor-Japanese cedar MDSPCLVALLVFSFVIGSCFSDNPIDSCWRGDSNWAQNRMKLADC AVGFGSSTMGGKGGDLYTVTNSDDDPVNPAPGTLRYGATRDRPL WIIFSGNMNIKLKMPMYIAGYKTFDGRGAQVYIGNGGPCVFIKRVS NVIIHGLYLYGCSTSVLGNVLINESFGVEPVHPQDGDALTLRTATNI WIDHNSFSNSSDGLVDVTLTSTGVTISNNLFFNHHKVMSLGHDDAY SDDKSMKVTVAFNQFGPNCGQRMPRARYGLVHVANNNYDPWTIY AIGGSSNPTILSEGNSFTAPNESYKKQVTIRIGCKTSSSCSNWVWQST QDVFYNGAYFVSSGKYEGGNIYTKKEAFNVENGNATPHLTQNAGV LTCSLSKRC

[0206] Dog

[0207] Canis Sequences: Can f 1 MKTLLLTIGFSLIATLQAQDTPALGKDTVAVSGKWYLKAMTADQE VPEKPDSVTPMILKAQKGGNLEAKITMLTNGQCQNITVVLHKTSEP GKYTAYEGQRVVFIQPSPVRDHYILYCEGELHGRQIRMAKLLGRDP EQSQEALEDFREFSRAKGLNQEILELAQSETCSPGGQ Serum albumin fragment EAYKSEIAHRYNDLGEEHFRGLVL Serum albumin fragment LSSAKERFKCASLQKFGDRAFKAWSVARLSQRFPKADFAEISKVVT DLTKVHKECCHGDLLECADDRADLAKYMCENQDSISTKLKECCDK PVLEKSQCLAEVERDELPGDLPSLAADFVEDKEVCKNYQEAKDVF LGTFLYEYSRRHPEYSVSLLLRIAKEYEATLEKCCATDDPPTCYAK VLDEFKPLVDEPQNLVKTNCELFEKLGEYGFQNALLVRYTKKAPQ VSTPTLVVEVSRKLGKVGTKCCKKPESERMSCADDFLS Can f 2 MQLLLLTVGLALICGLQAQEGNHEEPQGGLEELSGRWHSVALASN KSDLIKPWGHFRVFIHSMSAKDGNLHGDILIPQDGQCEKVSLTAFKT ATSNKFDLEYWGHNDLYLAEVDPKSYLILYMINQYNDDTSLVAHL MVRDLSRQQDFLPAFESVCEDIGLHKDQIVVLSDDDRCQGSRD

[0208] Additional dog allergen protein (NCBI entrez accession):

[0209] 1731859

[0210] Horse

[0211] Equus Sequences: 1575778 Equ c1 MKLLLLCLGLILVCAQQEENSDVAIRNFDISKISGEWYSIFLASDVK EKIEENGSMRVFVDVIRALDNSSLYAEYQTKVNGECTEFPMVFDKT EEDGVYSLNYDGYNVFRISEFENDEHIILYLVNFDKDRPFQLFEFYA REPDVSPEIKEEFVKIVQKRGIVKENIIDLTKIDRCFQLRGNGVAQA 3121755 Equ c 2 SQXPQSETDYSQLSGEWNTIYGAASNIXK Euroglyphus (mite) Euroglyphus sequences: Eur m 1 (variant) TYACSINSVSLPSELDLRSLRTVTPIRMQGGCGSCWAFSGVASTESA YLAYRNMSLDLAEQELVDCASQNGCHGDTIPRGIEYIQQNGVVQE HYYPYVAREQSCHRPNAQRYGLKNYCQISPPDSNKIRQALTQTHTA VAVIIGIKDLNAFRHYDGRTIMQHDNGYQPNYHAVNIVGYGNTQG VDYWIVRNSWDTTWGDNGYGYFAANINL Eur m 1 (variant) TYACSINSVSLPSELDLRSLRTVTPIRMQGGCGSCWAFSGVASTESA YLAYRNMSLDLAEQELVDCASQNGCHGDTIPRGIEYIQQNGVVQE HYYPYVAREQSCHRPNAQRYGLKNYCQISPPDSNKIRQALTQTHTA VAVIIGIKDLNAFRHYDGRTIMQHDNGYQPNYHAVNIVGYGNTQG VDYWIVRNSWDTTWGDNGYGYFAANINL Eur m 1 (variant) ETNACSINGNAPAEIDLRQMRTVTPIRMQGGCGSCWAFSGVAATES AYLAYRNQSLDLAEQELVDCASQHGCHGDTIPRGIEYIQHNGVVQE SYYRYVAREQSCRRPNAQRFGISNYCQIYPPNANKIREALAQTHSAI AVHGTKDLDAFRHYDGRTIIQRDNGYQPNYHAVNIVGYSNAQGVD YWIVRNSWDTNWGDNGYGYFAANIDL Eur m 1 (variant) ETSACRINSVNVPSELDLRSLRTVTPIRMQGGCGSCWAFSGVAATES AYLAYRNTSLDLSEQELVDCASQHGCHGDTIPRGIEYIQQNGVVEE RSYPYVAREQQCRRPNSQHYGISNYCQIYPPDVKQIREALTQTHTAI AVIIGIKDLRAFQHYDGRTIIQHDNGYQPNYHAVNIVGYGSTQGVD YWIVRNSWDTTWGDSGYGYFQAGNNL Poa (grass) sequences 113562 POLLEN ALLERGEN POA P 9 MAVQKYTVALFLVALVVGPAASYAADLSYGAPATPAAPAAGYTP AAPAGAAPKATTDEQKMIEKINVGFKAAVAAAGGVPAANKYKTFV ATFGAASNKAFAEALSTEPKGAAVDSSKAALTSKLDDAAYKLAYKS AEGATPEAKYDDYVATLSEALRIIAGTLEVHGVKPAAEEVKATPAG ELQVIDKVDAAFKVAATAANAAPANDKFTVFEAAFNDAIKASGG AYQSYKFIPALEAAVKQSYAATVATAPAVKYTVFETALKKAITAMS QAQKAAKPAAAATGTATAAVGAATGAATAAAGGYKV 113561 POA P 9 MAVHQYTVALFLAVALVAGPAASYAADVGYGAPATLATPATPAA PAAGYTPAAPAGAAPKATTDEQKLIEKINAGFKAAVAAAAGVPAV DKYKTFVATFGTASNKAFAEALSTEPKGAAAASSNAVLTSKLDAA YKLAYKSAEGATPEAKYDAYVATLSEALRIIAGTLEVHAVKPAGEE VKAIPAGELQVIDKVDAAFKVAATAANAAPANDKYTVFEAAFNDA IKASTGGAYQSYKFIPALEAAVKQSYAATVATAPAVKYTVFETALK KAITAMSQAQKAAKPAAAVTATATGAVGAATGAVGAATGAATAA AGGYKTGAATPTAGGYKV 113560 POA P 9 MDKANGAYKTALKAASAVAPAEKFPVFQATFDKNLKEGLSGPDA VGFAKKLDAFIQTSYLSTKAAEPKEKFDLFVLSLTEVLRFMAGAVK APPASKFPAKPAPKVAAYTPAAPAGAAPKATTDEQKLIEKINVGFK AAVAAAAGVPAASKYKTFVATFGAASNKAFAEALSTEPKGAAVAS SKAVLTSKLDAAYKLAYKSAEGATPEAKYDAYVATLSEALRIIAGT LEVHGVKPAAEEVKAIPAGELQVIDKVDAAFKVAATAANAAPAND KFTVFEAAFNDAIKASTGGAYQSYKFIPALEAAVKQSYAATVATAP AVKYTVFETALKKAITAMSQAQKAAKPAAAVTGTATSAVGAATGA ATAAAGGYKV

[0212] Cockroach Sequences 2833325 Cr p1 MKTALVFAAVVAFVAARFPDHKDYKQLADKQFLAKQRDVLRLFH RVHQHNILNDQVEVGIPMTSKQTSATTVPPSGEAVHGVLQEGHARP RGEPFSVNYEKHREQAIMLYDLLYFANDYDTFYKTACWARDRVN EGMFMYSFSIAVFHRDDMQGVMLPPPYEVYPYLFVDHDVIHMAQ KYWMKNAGSGEHHSHVIPVNFTLRTQDHLLAYFTSDVNLNAFNTY YRYYYPSWYNTTLYGHNIDRRGEQFYYTYKQIYARYFLERLSNDLP DVYPFYYSKPVKSAYNPNLRYHNGEEMPVRPSNMYVTNFDLYYIA DIKNYEKRVEDAIDFGYAPDEHMKPHSLYHDVHGMEYLADMIEG NMDSPNFYFYGSIYHMYHSMIGHIVDPYHKMGLAPSLEHPETVLR DPVFYQLWKRVDHLFQKYKNRLPRYTHDELAFEGVKVENVDVGK LYTYFEQYDMSLDMAVYVNNVDQISNVDVQLAVRLNHKPFTYNIE VSSDKAQDVYVAVFLGPKYDYLGREYDLNDRRHYFVEMDRFPYH VGAGKTVIERNSHDSNIIAPERDSYRTFYKKVQEAYEGKSQYYVDK GHNYCGYPENLLIPKGKKGGQAYTFYVIVTPYVKQDEHDFEPYNY KAFSYCGVGSERKYPDNKPLGYPFDRKIYSNDFYTPNMYFKDVIIF HKKYDEVGVQGH 2231297 Cr p2 INEIHSIIGLPPFVPPSRRHARRGVGINGLIDDVIAILPVDELKALFQE KLETSPDFKALYDAIRSPEFQSIISTLNAMQRSEHHQNLRDKGVDVD HFIQLIRALFGLSRAARNLQDDLNDFLHSLEPISPRHRHGLPRQRRR SARVSAYLHADDFHKIITTIEALPEFANFYNFLKEHGLDVVDYINEI HSIIGLPPFVPPSRARRGVGINGLIDDVIAILPVDELKALFQEKLET SPDFKALYDAIRSPEFQSIISTLNAMPEYQELLQNLRDKGVDVDHFI RVDQGTLRTLSSGQRNLQDDLNDFLALIPTDQILAIAMDYLANDAE VQELVAYLQSDDFHKAITTIEALPEFANFYNFLKEHGLDVVDYINEI HSIIGLPPFVPPSQRHARRGVGINGLIDDVIAILPVDELKALFQEKLET SPDFKALYDAIDLRSSRA 1703445 Bla g 2 MIGLKLVTVLFAVATITHAAELQRVPLYKLVHVFINTQYAGITMGN QNFLTVFDSTSCNVVVASQECVGGACVCPNLQKYEKLKPKYISDG NVQVKFFDTGSAVGRGIEDSLTISNLTTSQQDIVLADELSQEVCILSA DVVVGIAAPGCPNALKGKTVLENFVEENLIAPVFSIHHARFQDGEH FGEIIFGGSDWKYVDGEFTYVPLVGDDSWKFRLDGVKIGDTTVAPA GTQAHDTSKAIIVGPKAYVNPINEAIGCVVEKTTTRRICKLDCSKIPS LPDVTFVINGRNFNISSQYYIQQNGNLCYSGFQPCPHSDHFFIGDFF VDHYYSEFNWENKTMGFGRSVE SV 1705483 Bla g 4 AVLALCATDTLANEDCFRHESLVPNLDYERFRGSWIIAAGTSEALT QYKCWIDRFSYDDALVSKYTDSQGKNRTTIRGRTKFEGNKFTIDYN DKGKAFSAPYSVLATDYENYAIVEGCPAAANCHVIYVQIRFSVRRF HPKLGDKEMIQHYTLDQVNQHKKAIEEDLKHFNLKYEDLHSTCH 2326190 Bla g 5 YKLTYCPVKALGEPIRFLLSYGEKDFEDYRFQEGDWPNLKPSMPFG KTPVLEIDGKQTHQSVAISRYLGKQFGLSGKDDWENLEIDMIVDTIS DFRAAIANYHYDADENSKQKKWDPLKKETIPYYTKKFDEVVKANG GYLAAGKLTWADFYFVAILDYLNHMAKEDLVANQPNLKALREKV LGLPAIKAWVAKRPPTDL

[0213] Additional cockroach sequences (NCBI Entrez accession numbers):

[0214] 2580504; 1580797; 1580794; 1362590; 544619; 544618; 1531589; 1580792; 1166573; 1176397; 2897849.

[0215] Allergen (General) Sequences:

[0216] NCBI Accession Numbers

[0217] 2739154; 3719257; 3703107; 3687326; 3643813; 3087805; 1864024; 1493836; 1480457; 2598976; 2598974; 1575778; 763532; 746485; 163827; 163823; 3080761; 163825; 3608493; 3581965; 2253610; 2231297; 2897849; 3409499; 3409498; 3409497; 3409496; 3409495; 3409494; 3409493; 3409492; 3409491; 3409490; 3409489; 3409488; 3409487; 3409486; 3409485; 3409484; 3409483; 3409482; 3409481; 3409480; 3409479; 3409478; 3409477; 3409476; 3409475; 3409474; 3409473; 3409472; 3409471; 3409470; 3409469; 3409468; 3409467; 3409466; 3409465; 3409464; 3409463; 3409462; 3409461; 3409460; 3409459; 3409458; 3409457; 3409456; 3318885; 3396070; 3367732; 1916805; 3337403; 2851457; 2851456; 1351295; 549187; 136467; 1173367; 2499810; 2498582; 2498581; 1346478; 1171009; 126608; 114091; 2506771; 1706660; 1169665; 1169531; 232086; 416898; 114922; 2497701; 1703232; 1703233; 1703233; 1703232; 3287877; 3122132; 3182907; 3121758; 3121756; 3121755; 3121746; 3121745; 3319925; 3319923; 3319921; 3319651; 3318789; 3318779; 3309647; 3309047; 3309045; 3309043; 3309041; 3309039; 3288200; 3288068; 2924494; 3256212; 3256210; 3243234; 3210053; 3210052; 3210051; 3210050; 3210049; 3210048; 3210047; 3210046; 3210045; 3210044; 3210043; 3210042; 3210041; 3210040; 3210039; 3210038; 3210037; 3210036; 3210035; 3210034; 3210033; 3210032; 3210031; 3210030; 3210029; 3210028; 3210027; 3210026; 3210025; 3210024; 3210023; 3210022; 3210021; 3210020; 3210019; 3210018; 3210017; 3210016; 3210015; 3210014; 3210013; 3210012; 3210011; 3210010; 3210009; 3210008; 3210007; 3210006; 3210005; 3210004; 3210003; 3210002; 3210001; 3210000; 3209999; 3201547; 2781152; 2392605; 2392604; 2781014; 1942360; 2554672; 2392209; 3114481; 3114480; 2981657; 3183706; 3152922; 3135503 3135501; 3135499; 3135497; 2414158; 1321733; 1321731; 1321728; 1321726; 1321724; 1321722; 1321720; 1321718; 1321716; 1321714; 1321712; 3095075; 3062795; 3062793; 3062791; 2266625; 2266623; 2182106; 3044216; 2154736; 3021324; 3004467; 3005841; 3005839; 3004485; 3004473; 3004471; 3004469; 3004465; 2440053; 1805730; 2970629; 2959898; 2935527; 2935416; 809536; 730091; 585279; 584968; 2498195; 2833325; 2498604; 2498317; 2498299; 2493414; 2498586; 2498585; 2498576; 2497749; 2493446; 2493445; 1513216; 729944; 2498099; 548449; 465054; 465053; 465052; 548671; 548670; 548660; 548658; 548657; 2832430; 232084; 2500822; 2498118; 2498119; 2498119; 2498118; 1708296; 1708793; 416607; 416608; 416608; 416607; 2499791; 2498580; 2498579; 2498578; 2498577; 2497750; 1705483; 1703445; 1709542; 1709545; 1710589; 1352699; 1346568; 1346323; 1346322; 2507248; |1352240; 1352239; 1352237; 1352229; 1351935; 1350779; 1346806; 1346804; 1346803; 1170095; 1168701; 1352506; 1171011; 1171008; 1171005; 1171004; 1171002; 1171001; 1168710; 1168709; 1168708; 1168707; 1168706; 1168705; 1168704; 1168703; 1168702; 1168696; 1168391; 1168390; 1168348; 1173075; 1173074; 1173071; 1169290; 1168970; 1168402; 729764; 729320; 729979; 729970; 729315; 730050; 730049; 730048; 549194; 549193; 549192; 549191; 549190; 549189; 549188; 549185; 549184; 549183; 549182; 549181; 549180; 549179; 464471; 585290; 416731; 1169666; 113478; 113479; 113477; 113476; 113475; 130975; 119656; 113562; 113561; 113560; 416610; 126387; 126386; 126385; 132270; 416611; 416612; 416612; 416611; 730035; 127205; 1352238; 125887; 549186; 137395; 730036; 133174; 114090; 131112; 126949; 129293; 124757; 129501; 416636; 2801531; 2796177; 2796175; 2677826; 2735118; 2735116; 2735114; 2735112; 2735110; 2735108; 2735106; 2735104; 2735102; 2735100; 2735098; 2735096; 2707295; 2154730; 2154728; 1684720; 2580504; 2465137; 2465135; 2465133; 2465131; 2465129; 2465127; 2564228; 2564226; 2564224; 2564222; 2564220; 2051993; 1313972; 1313970; 1313968; 1313966; 2443824; 2488684; 2488683; 2488682; 2488681; 2488680; 2488679; 2488678; 2326190; 2464905; 2415702; 2415700; 2415698; 2398759; 2398757; 2353266; 2338288; 1167836; 414703; 2276458; 1684718 2293571; 1580797; 1580794; 2245508; 2245060; 1261972; 2190552; 1881574 511953; 1532058; 1532056; 1532054; 1359436; 666007; 487661; 217308; 1731859; 217306; 217304; 1545803; 1514943; 577696; 516728; 506858; 493634; 493632; 2154734; 2154732; 543659; 1086046: 1086045; 2147643; 2147642; 1086003; 1086002; 1086001; 543675; 543623; 543509; 543491; 1364099; 2147108; 2147107; 1364001; 1085628; 631913; 631912; 631911; 2147092; 477301; 543482; 345521; 542131; 542130; 542129; 100636; 2146809; 480443; 2114497; 2144915; 72355; 71728; 319828; 1082946; 1082945; 1082944; 539716; 539715; 423193; 423192; 423191; 423190; 1079187; 627190; 627189; 627188; 627187; 482382; 1362656; 627186; 627185; 627182; 482381; 85299; 85298; 2133756; 2133755; 1079186; 627181; 321044; 321043; 112559; 112558; 1362590; 2133564; 1085122; 1078971; 627144; 627143; 627142; 627141; 280576; 102835; 102834; 102833; 102832; 84703; 84702; 84700; 84699; 84698; 84696; 477888; 477505; 102575; 102572; 478272; 2130094; 629813; 629812; 542172; 542168; 542167; 481432; 320620; 280414; 626029; 542132; 320615; 320614; 100638; 100637; 100635; 82449; 320611; 320610; 280409; 320607; 320606; 539051; 539050; 539049; 539048; 322803; 280407; 100501; 100498; 100497; 100496; 1362137; 1362136; 1362135; 1362134; 1362133; 1362132; 1362131; 1362130; 1362129; 1362128; 100478; 2129891; 1076531; 1362049; 1076486; 2129817; 2129816; 2129815; 2129814; 2129813; 2129812; 2129805; 2129804; 2129802; 2129801; 2129800; 2129799; 479902; 479901; 2129477; 1076247; 629480; 1076242; 1076241; 541803; 541802; 280372; 280371; 1361968; 1361967; 1361966; 1361965; 1361964; 1361963; 1361962; 1361961; 1361960; 1361959; 320546; 2119763; 543622; 541804; 478825; 478824; 478823; 421788; 320545; 81444; 626037; 626028; 539056; 483123; 481398; 481397; 100733; 100732; 100639; 625532; 1083651; 322674; 322673; 81719; 81718; 2118430; 2118429; 2118428; 2118427; 419801; 419800; 419799; 419798; 282991; 100691; 322995; 322994; 101824; 626077; 414553 398830; 1311457; 1916292; 1911819; 1911818; 1911659; 1911582; 467629; 467627; 467619; 467617; 915347; 1871507; 1322185; 1322183; 897645; 897647; 1850544; 1850542; 1850540; 288917; 452742; 1842045; 1839305; 1836011; 1836010; 1829900; 1829899; 1829898; 1829897; 1829896; 1829895; 1829894; 1825459; 1808987 159653; 1773369; 1769849; 1769847; 608690; 1040877; 1040875; 1438761; 1311513; 1311512; 1311511; 1311510; 1311509; 1311689; 1246120; 1246119; 1246118; 1246117; 1246116; 1478293; 1478292; 1311642; 1174278; 1174276; 1086972; 1086974; 1086976; 1086978; 1086978; 1086976; 1086974; 1086972; 999009; 999356; 999355; 994866; 994865; 913758; 913757; 913756; 913285; 913283; 926885; 807138; 632782; 601807; 546852; 633938; 544619; 544618; 453094; 451275; 451274; 407610; 407609; 404371; 409328; 299551; 299550; 264742; 261407; 255657; 250902; 250525; 1613674; 1613673; 1613672; 1613671; 1613670; 1613304; 1613303; 1613302; 1613240; 1613239; 1613238; 1612181; 1612180; 1612179; 1612178; 1612177; 1612176; 1612175; 1612174; 1612173; 1612172; 1612171; 1612170; 1612169; 1612168; 1612167; 1612166; 1612165; 1612164; 1612163; 1612162; 1612161; 1612160; 1612159; 1612158; 1612157; 1612156; 1612155; 1612154; 1612153; 1612152; 1612151; 1612150; 1612149; 1612148; 1612147; 1612146; 1612145; 1612144; 1612143; 1612142; 1612141; 1612140; 1612139; 1093120; 447712; 447711; 447710; 1587177; 158542; 1582223; 1582222; 1531589; 1580792; 886215; 1545897; 1545895; 1545893; 1545891; 1545889; 1545887; 1545885; 1545883; 1545881; 1545879; 1545877; 1545875; 166486; 1498496; 1460058; 972513; 1009442; 1009440; 1009438; 1009436; 1009434; 7413; 1421808; 551228; 452606; 32905; 1377859; 1364213; 1364212; 395407; 22690; 22688; 22686; 22684; 488605; 17680; 1052817; 1008445; 1008443; 992612; 706811; 886683; 747852; 939932; 19003; 1247377; 1247375; 1247373; 862307; 312284; 999462; 999460; 999458; 587450; 763064; 886209; 1176397; 1173557; 902012; 997915; 997914; 997913; 997912; 997911; 997910; 99790; 997908; 997907; 997906; 997905; 997904; 997903; 997902; 997901; 997900; 997899; 997898; 997897; 997896; 997895; 997894; 997893; 997892; 910984; 910983; 910982; 910981; 511604; 169631; 169629; 169627; 168316; 168314; 607633; 555616; 293902; 485371; 455288; 166447; 166445; 166443; 166435; 162551; 160780; 552080; 156719; 156715; 515957; 515956; 515955; 515954; 515953; 459163; 166953; 386678; 169865.

Example 7 Desensitisation Using Multiple Overlapping Peptides (MOP) from Fel d I

[0218] We have obtained data with multiple overlapping peptides (MOP) which are derived from the sequence of Fel d I and include the three FC1P peptides. Originally, 16 peptides spanning both chain 1 and chain 2 of the Fel d I molecule were designed in order to increase the percentage of individuals reacting to the peptide injection. By using peptides covering the entire molecule, we believed that we would cover more MHC-peptide pairings and thus get more reactors. Of the 16 peptides, the first three of chain 2 displayed poor solubility in aqueous solution and were excluded from the in vivo preparation termed MOP. The sequences of the MOP peptides and how they relate to the parent molecule are given in FIG. 9.

[0219] We have carried-out a dose ranging study with this preparation to determine an appropriate dose to be used in a planned clinical trial in which four injections of increasing dose will be given over a two week period. For the dose ranging study, three doses have been tested: 1 μg (of each of the 13 peptides in a mixture), 2.5 μg and 5 μg.

[0220] Four cat asthmatic individuals received the 1 μg dose. One of them developed a LAR which was similar to those induced with FC1P. Five individuals received 2.5 μg and again one developed a LAR. At 5 μg, eight individuals were tested and four developed a LAR. This demonstrates the dose response effect that we expected and, more importantly, shows that the MOP preparation produces a similar effect to the FC1P preparation. An example of a LAR induced by MOP can be seen in FIG. 10.

[0221] Rather than move to a higher dose which may give a higher percentage of LAR reactors, we have decided to use the 5 μg dose as the starting dose for the trial. From the number of peptides in the MOP preparation and the observed dose response, it might be expected that some of the non-LAR reactors at 5 μg might develop a LAR at a higher dose, ie have the appropriate MHC molecules to recognise the peptides but experienced a “sub-clinical” reaction. For this reason, we decided to investigate the cutaneous late phase reaction to whole allergen extract as an alternative clinical outcome. Basically, if whole allergen extract is injected intradermally (in our case into the forearm) in an atopic allergic individual, an immediate wheal and flare reaction will result (classical IgE mediated early allergic reaction) in about 15 minutes. This reaction is then followed by a delayed in-time phase reaction in the skin. Like the lung reaction, this peaks at 6-9 hours and believed to be driven at least in part by T cells.

[0222] Previously, immunotherapy studies using conventional whole allergen extract have demonstrated that the size of this late phase skin reaction decreases after several months of treatment.

[0223] We have measured these skin reactions before any peptide injection (ie at baseline) and we have measured them again in six patients (to date) who have had either one or two injections only of MOP. All six have reduced reactions as shown in FIG. 11. These results are statistically significant with a p value of 0.036.

[0224] A further interesting observation was that some of these individuals did not develop a lung reaction (LAR) to the MOP injection but clearly their T cells were activated by one or more of the peptides giving them a measurable reduction in reactivity to skin challenge with whole allergen extract (the latter being perhaps even more significant since the whole dander extract contains multiple proteins (including Fel d I) to which the patient may be sensitised).

[0225] As mentioned above, some (three) of the MOP injected individuals who developed lung reactions have received a second injection. As found with FC1P, these individuals did not develop reactions (an example can be seen in FIG. 10). Importantly, these two individuals received the second injection several weeks (in one case about 4 months) after the first one. This suggests that hyporesponsiveness induced after the first injection could last four months or more.

[0226] We also have other longitudinal data regarding the length of duration of the hyporesponsiveness from some of the FC1P patients. In this case, three patients who had received FC1P more than one year ago and experienced LAR's were rechallenged with the same dose. All three reacted with almost exactly the same magnitude as the initial reaction (FIG. 12a, b & c). Of these three, one (FIG. 12a) had received a second injection of FC1P a few weeks after the first and had displayed no LAR. Thus, peptides can induce a LAR which is followed by hyporesponsiveness which seems to last for four months (possibly more) but less than one year.

[0227] Finally, we now have three FC1P patients who have had one injection followed by a LAR which on reinjection was not seen (ie hyporesponsiveness). We also have the same finding in two MOP patients. We have had the areas under these curves analysed statistically. We have compared a control day (either saline injection or injection or whole cat extract, the latter does not induce a lung reaction only a skin reaction at the dose used), with the lung measurements (FEV1) after the first FC1P or MOP injection and after the second FC1P/MOP injection.

[0228] We have compared the mean values from spirometry by area under the curve analysis:

[0229] 1. Control day vs peptide day 1 (we expect to see a significant difference i.e. there has actually been a significant reaction)

[0230] 2. Control day vs peptide day 2 (do not expect a significant reaction since lung responses are back to normal)

[0231] 3. Peptide day 1 vs peptide day 2 (expect a significant difference).

[0232] The results (p values) are:

[0233] 1. p=0.0205

[0234] 2. p=0.0930

[0235] 3. p=0.0119

[0236] A p value of less than or equal to 0.05 is considered statistically significant.

[0237] Thus, there is a significant response to the peptides following the first injection (1) which is significantly different to the second injection (3) as the FEVI values appear to return to baseline. The difference between the control day and the second injection is not statistically significant (2).

1 124 1 17 PRT Felis catus 1 Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln 1 5 10 15 Tyr 2 16 PRT Felis catus 2 Glu Gln Val Ala Gln Tyr Lys Ala Leu Pro Val Val Leu Glu Asn Ala 1 5 10 15 3 17 PRT Felis catus 3 Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys Asn Cys 1 5 10 15 Val 4 70 PRT Felis catus 4 Glu Ile Cys Pro Ala Val Lys Asp Arg Val Asp Leu Phe Leu Thr Gly 1 5 10 15 Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala Leu Pro 20 25 30 Val Val Leu Glu Asn Ala Arg Ile Leu Lys Asn Cys Val Asp Ala Lys 35 40 45 Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys Ile 50 55 60 Tyr Thr Ser Pro Leu Cys 65 70 5 92 PRT Felis catus 5 Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe Ala 1 5 10 15 Val Ala Asn Gly Asn Glu Leu Leu Leu Lys Leu Ser Leu Thr Lys Val 20 25 30 Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Gln Asp Cys 35 40 45 Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val Met 50 55 60 Thr Thr Ile Ser Ser Ser Lys Asp Cys Met Gly Glu Ala Val Gln Asn 65 70 75 80 Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg 85 90 6 17 PRT Felis catus 6 Glu Ile Cys Pro Ala Val Lys Arg Asp Val Asp Leu Phe Leu Thr Gly 1 5 10 15 Thr 7 17 PRT Felis catus 7 Arg Ile Leu Lys Asn Cys Val Asp Ala Lys Met Thr Glu Glu Asp Lys 1 5 10 15 Glu 8 16 PRT Felis catus 8 Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys 1 5 10 15 9 16 PRT Felis catus 9 Lys Glu Asn Ala Leu Ser Val Leu Asp Lys Ile Tyr Thr Ser Pro Leu 1 5 10 15 10 16 PRT Felis catus 10 Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe Ala 1 5 10 15 11 17 PRT Felis catus 11 Cys Pro Ile Phe Tyr Asp Val Phe Phe Ala Val Ala Asn Gly Asn Glu 1 5 10 15 Leu 12 16 PRT Felis catus 12 Gly Asn Glu Leu Leu Leu Lys Leu Ser Leu Thr Lys Val Asn Ala Thr 1 5 10 15 13 16 PRT Felis catus 13 Leu Thr Lys Val Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys 1 5 10 15 14 16 PRT Felis catus 14 Thr Ala Met Lys Lys Ile Gln Asp Cys Tyr Val Glu Asn Gly Leu Ile 1 5 10 15 15 16 PRT Felis catus 15 Cys Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val 1 5 10 15 16 16 PRT Felis catus 16 Ser Arg Val Leu Asp Gly Leu Val Met Thr Thr Ile Ser Ser Ser Lys 1 5 10 15 17 16 PRT Felis catus 17 Ile Ser Ser Ser Lys Asp Cys Met Gly Glu Ala Val Gln Asn Thr Val 1 5 10 15 18 16 PRT Felis catus 18 Ala Val Gln Asn Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg 1 5 10 15 19 320 PRT Dermatophagoides pteronyssinus 19 Met Lys Ile Val Leu Ala Ile Ala Ser Leu Leu Ala Leu Ser Ala Val 1 5 10 15 Tyr Ala Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala 20 25 30 Phe Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 35 40 45 Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile 50 55 60 Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu 65 70 75 80 Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn 85 90 95 Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile 100 105 110 Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly 115 120 125 Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala 130 135 140 Tyr Leu Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu 145 150 155 160 Val Asp Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg 165 170 175 Gly Ile Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr 180 185 190 Arg Tyr Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg 195 200 205 Phe Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys 210 215 220 Ile Arg Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile 225 230 235 240 Gly Ile Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile 245 250 255 Ile Gln Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile 260 265 270 Val Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 275 280 285 Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala 290 295 300 Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu 305 310 315 320 20 146 PRT Dermatophagoides pteronyssinus 20 Met Met Tyr Lys Ile Leu Cys Leu Ser Leu Leu Val Ala Ala Val Ala 1 5 10 15 Arg Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys 20 25 30 Val Leu Val Pro Gly Cys His Gly Ser Glu Pro Cys Ile Ile His Arg 35 40 45 Gly Lys Pro Phe Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr 50 55 60 Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu Val 65 70 75 80 Asp Val Pro Gly Ile Asp Pro Asn Ala Cys His Tyr Met Lys Cys Pro 85 90 95 Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn Val Pro 100 105 110 Lys Ile Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Val Met 115 120 125 Gly Asp Asp Gly Val Leu Ala Cys Ala Ile Ala Thr His Ala Lys Ile 130 135 140 Arg Asp 145 21 261 PRT Dermatophagoides pteronyssinus 21 Met Ile Ile Tyr Asn Ile Leu Ile Val Leu Leu Leu Ala Ile Asn Thr 1 5 10 15 Leu Ala Asn Pro Ile Leu Pro Ala Ser Pro Asn Ala Thr Ile Val Gly 20 25 30 Gly Glu Lys Ala Leu Ala Gly Glu Cys Pro Tyr Gln Ile Ser Leu Gln 35 40 45 Ser Ser Ser His Phe Cys Gly Gly Thr Ile Leu Asp Glu Tyr Trp Ile 50 55 60 Leu Thr Ala Ala His Cys Val Ala Gly Gln Thr Ala Ser Lys Leu Ser 65 70 75 80 Ile Arg Tyr Asn Ser Leu Lys His Ser Leu Gly Gly Glu Lys Ile Ser 85 90 95 Val Ala Lys Ile Phe Ala His Glu Lys Tyr Asp Ser Tyr Gln Ile Asp 100 105 110 Asn Asp Ile Ala Leu Ile Lys Leu Lys Ser Pro Met Lys Leu Asn Gln 115 120 125 Lys Asn Ala Lys Ala Val Gly Leu Pro Ala Lys Gly Ser Asp Val Lys 130 135 140 Val Gly Asp Gln Val Arg Val Ser Gly Trp Gly Tyr Leu Glu Glu Gly 145 150 155 160 Ser Tyr Ser Leu Pro Ser Glu Leu Arg Arg Val Asp Ile Ala Val Val 165 170 175 Ser Arg Lys Glu Cys Asn Glu Leu Tyr Ser Lys Ala Asn Ala Glu Val 180 185 190 Thr Asp Asn Met Ile Cys Gly Gly Asp Val Ala Asn Gly Gly Lys Asp 195 200 205 Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Asp Val Lys Asn Asn 210 215 220 Gln Val Val Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Arg Lys Gly 225 230 235 240 Tyr Pro Gly Val Tyr Thr Arg Val Gly Asn Phe Ile Asp Trp Ile Glu 245 250 255 Ser Lys Arg Ser Gln 260 22 19 PRT Dermatophagoides pteronyssinus misc_feature X is an unknown amino acid 22 Lys Tyr Xaa Asn Pro His Phe Ile Gly Xaa Arg Ser Val Ile Thr Xaa 1 5 10 15 Leu Met Glu 23 132 PRT Dermatophagoides pteronyssinus 23 Met Lys Phe Ile Ile Ala Phe Phe Val Ala Thr Leu Ala Val Met Thr 1 5 10 15 Val Ser Gly Glu Asp Lys Lys His Asp Tyr Gln Asn Glu Phe Asp Phe 20 25 30 Leu Leu Met Glu Arg Ile His Glu Gln Ile Lys Lys Gly Glu Leu Ala 35 40 45 Leu Phe Tyr Leu Gln Glu Gln Ile Asn His Phe Glu Glu Lys Pro Thr 50 55 60 Lys Glu Met Lys Asp Lys Ile Val Ala Glu Met Asp Thr Ile Ile Ala 65 70 75 80 Met Ile Asp Gly Val Arg Gly Val Leu Asp Arg Leu Met Gln Arg Lys 85 90 95 Asp Leu Asp Ile Phe Glu Gln Tyr Asn Leu Glu Met Ala Lys Lys Ser 100 105 110 Gly Asp Ile Leu Glu Arg Asp Leu Lys Lys Glu Glu Ala Arg Val Lys 115 120 125 Lys Ile Glu Val 130 24 20 PRT Dermatophagoides pteronyssinus misc_feature X ia unknown amino acid 24 Ala Ile Gly Xaa Gln Pro Ala Ala Glu Ala Glu Ala Pro Phe Gln Ile 1 5 10 15 Ser Leu Met Lys 20 25 215 PRT Dermatophagoides pteronyssinus 25 Met Met Lys Leu Leu Leu Ile Ala Ala Ala Ala Phe Val Ala Val Ser 1 5 10 15 Ala Asp Pro Ile His Tyr Asp Lys Ile Thr Glu Glu Ile Asn Lys Ala 20 25 30 Val Asp Glu Ala Val Ala Ala Ile Glu Lys Ser Glu Thr Phe Asp Pro 35 40 45 Met Lys Val Pro Asp His Ser Asp Lys Phe Glu Arg His Ile Gly Ile 50 55 60 Ile Asp Leu Lys Gly Glu Leu Asp Met Arg Asn Ile Gln Val Arg Gly 65 70 75 80 Leu Lys Gln Met Lys Arg Val Gly Asp Ala Asn Val Lys Ser Glu Asp 85 90 95 Gly Val Val Lys Ala His Leu Leu Val Gly Val His Asp Asp Val Val 100 105 110 Ser Met Glu Tyr Asp Leu Ala Tyr Lys Leu Gly Asp Leu His Pro Asn 115 120 125 Thr His Val Ile Ser Asp Ile Gln Asp Phe Val Val Glu Leu Ser Leu 130 135 140 Glu Val Ser Glu Glu Gly Asn Met Thr Leu Thr Ser Phe Glu Val Arg 145 150 155 160 Gln Phe Ala Asn Val Val Asn His Ile Gly Gly Leu Ser Ile Leu Asp 165 170 175 Pro Ile Phe Ala Val Leu Ser Asp Val Leu Thr Ala Ile Phe Gln Asp 180 185 190 Thr Val Arg Ala Glu Met Thr Lys Val Leu Ala Pro Ala Phe Lys Lys 195 200 205 Glu Leu Glu Arg Asn Asn Gln 210 215 26 18 PRT Dermatophagoides pteronyssinus 26 Ile Val Gly Gly Ser Asn Ala Ser Pro Gly Asp Ala Val Tyr Gln Ile 1 5 10 15 Ala Leu 27 319 PRT Dermatophagoides farinae 27 Met Lys Phe Val Leu Ala Ile Ala Ser Leu Leu Val Leu Thr Val Tyr 1 5 10 15 Ala Arg Pro Ala Ser Ile Lys Thr Phe Glu Phe Lys Lys Ala Phe Asn 20 25 30 Lys Asn Tyr Ala Thr Val Glu Glu Glu Glu Val Ala Arg Lys Asn Phe 35 40 45 Leu Glu Ser Leu Lys Tyr Val Glu Ala Asn Lys Gly Ala Ile Asn His 50 55 60 Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Tyr Leu Met Ser 65 70 75 80 Ala Glu Ala Phe Glu Gln Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu 85 90 95 Thr Ser Ala Cys Arg Ile Asn Ser Val Asn Val Pro Ser Glu Leu Asp 100 105 110 Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys 115 120 125 Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr 130 135 140 Leu Ala Tyr Arg Asn Thr Ser Leu Asp Leu Ser Glu Gln Glu Leu Val 145 150 155 160 Asp Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly 165 170 175 Ile Glu Tyr Ile Gln Gln Asn Gly Val Val Glu Glu Arg Ser Tyr Pro 180 185 190 Tyr Val Ala Arg Glu Gln Arg Cys Arg Arg Pro Asn Ser Gln His Tyr 195 200 205 Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asp Val Lys Gln Ile 210 215 220 Arg Glu Ala Leu Thr Gln Thr His Thr Ala Ile Ala Val Ile Ile Gly 225 230 235 240 Ile Lys Asp Leu Arg Ala Phe Gln His Tyr Asp Gly Arg Thr Ile Ile 245 250 255 Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 260 265 270 Gly Tyr Gly Ser Thr Gln Gly Asp Asp Tyr Trp Ile Val Arg Asn Ser 275 280 285 Trp Asp Thr Thr Trp Gly Asp Ser Gly Tyr Gly Tyr Phe Gln Ala Gly 290 295 300 Asn Asn Leu Met Met Ile Glu Gln Tyr Pro Tyr Val Val Ile Met 305 310 315 28 146 PRT Dermatophagoides farinae 28 Met Ile Ser Lys Ile Leu Cys Leu Ser Leu Leu Val Ala Ala Val Val 1 5 10 15 Ala Asp Gln Val Asp Val Lys Asp Cys Ala Asn Asn Glu Ile Lys Lys 20 25 30 Val Met Val Asp Gly Cys His Gly Ser Asp Pro Cys Ile Ile His Arg 35 40 45 Gly Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gln Asn Thr 50 55 60 Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Leu Asp Gly Leu Glu Ile 65 70 75 80 Asp Val Pro Gly Ile Asp Thr Asn Ala Cys His Phe Met Lys Cys Pro 85 90 95 Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn Val Pro 100 105 110 Lys Ile Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Ile 115 120 125 Gly Asp Asn Gly Val Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile 130 135 140 Arg Asp 145 29 259 PRT Dermatophagoides farinae 29 Met Met Ile Leu Thr Ile Val Val Leu Leu Ala Ala Asn Ile Leu Ala 1 5 10 15 Thr Pro Ile Leu Pro Ser Ser Pro Asn Ala Thr Ile Val Gly Gly Val 20 25 30 Lys Ala Gln Ala Gly Asp Cys Pro Tyr Gln Ile Ser Leu Gln Ser Ser 35 40 45 Ser His Phe Cys Gly Gly Ser Ile Leu Asp Glu Tyr Trp Ile Leu Thr 50 55 60 Ala Ala His Cys Val Asn Gly Gln Ser Ala Lys Lys Leu Ser Ile Arg 65 70 75 80 Tyr Asn Thr Leu Lys His Ala Ser Gly Gly Glu Lys Ile Gln Val Ala 85 90 95 Glu Ile Tyr Gln His Glu Asn Tyr Asp Ser Met Thr Ile Asp Asn Asp 100 105 110 Val Ala Leu Ile Lys Leu Lys Thr Pro Met Thr Leu Asp Gln Thr Asn 115 120 125 Ala Lys Pro Val Pro Leu Pro Ala Gln Gly Ser Asp Val Lys Val Gly 130 135 140 Asp Lys Ile Arg Val Ser Gly Trp Gly Tyr Leu Gln Glu Gly Ser Tyr 145 150 155 160 Ser Leu Pro Ser Glu Leu Gln Arg Val Asp Ile Asp Val Val Ser Arg 165 170 175 Glu Gln Cys Asp Gln Leu Tyr Ser Lys Ala Gly Ala Asp Val Ser Glu 180 185 190 Asn Met Ile Cys Gly Gly Asp Val Ala Asn Gly Gly Val Asp Ser Cys 195 200 205 Gln Gly Asp Ser Gly Gly Pro Val Val Asp Val Ala Thr Lys Gln Ile 210 215 220 Val Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Arg Lys Gly Tyr Pro 225 230 235 240 Gly Val Tyr Thr Arg Val Gly Asn Phe Val Asp Trp Ile Glu Ser Lys 245 250 255 Arg Ser Gln 30 20 PRT Dermatophagoides farinae 30 Ala Val Gly Gly Gln Asp Ala Asp Leu Ala Glu Ala Pro Phe Gln Ile 1 5 10 15 Ser Leu Leu Lys 20 31 213 PRT Dermatophagoides farinae 31 Met Met Lys Phe Leu Leu Ile Ala Ala Val Ala Phe Val Ala Val Ser 1 5 10 15 Ala Asp Pro Ile His Tyr Asp Lys Ile Thr Glu Glu Ile Asn Lys Ala 20 25 30 Ile Asp Asp Ala Ile Ala Ala Ile Glu Gln Ser Glu Thr Ile Asp Pro 35 40 45 Met Lys Val Pro Asp His Ala Asp Lys Phe Glu Arg His Val Gly Ile 50 55 60 Val Asp Phe Lys Gly Glu Leu Ala Met Arg Asn Ile Glu Ala Arg Gly 65 70 75 80 Leu Lys Gln Met Lys Arg Gln Gly Asp Ala Asn Val Lys Gly Glu Glu 85 90 95 Gly Ile Val Lys Ala His Leu Leu Ile Gly Val His Asp Asp Ile Val 100 105 110 Ser Met Glu Tyr Asp Leu Ala Tyr Lys Leu Gly Asp Leu His Pro Thr 115 120 125 Thr His Val Ile Ser Asp Ile Gln Asp Phe Val Val Ala Leu Ser Leu 130 135 140 Glu Ile Ser Asp Glu Gly Asn Ile Thr Met Thr Ser Phe Glu Val Arg 145 150 155 160 Gln Phe Ala Asn Val Val Asn His Ile Gly Gly Leu Ser Ile Leu Asp 165 170 175 Pro Ile Phe Gly Val Leu Ser Asp Val Leu Thr Ala Ile Phe Gln Asp 180 185 190 Thr Val Arg Lys Glu Met Thr Lys Val Leu Ala Pro Ala Phe Lys Arg 195 200 205 Glu Leu Glu Lys Asn 210 32 109 PRT Felis catus 32 Met Arg Gly Ala Leu Leu Val Leu Ala Leu Leu Val Thr Gln Ala Leu 1 5 10 15 Gly Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe 20 25 30 Ala Val Ala Asn Gly Asn Glu Leu Leu Leu Asp Leu Ser Leu Thr Lys 35 40 45 Val Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Gln Asp 50 55 60 Cys Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val 65 70 75 80 Met Thr Thr Ile Ser Ser Ser Lys Asp Cys Met Gly Glu Ala Val Gln 85 90 95 Asn Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg 100 105 33 88 PRT Felis catus 33 Met Leu Asp Ala Ala Leu Pro Pro Cys Pro Thr Val Ala Ala Thr Ala 1 5 10 15 Asp Cys Glu Ile Cys Pro Ala Val Lys Arg Asp Val Asp Leu Phe Leu 20 25 30 Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala 35 40 45 Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys Asn Cys Val Asp 50 55 60 Ala Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp 65 70 75 80 Lys Ile Tyr Thr Ser Pro Leu Cys 85 34 92 PRT Felis catus 34 Met Lys Gly Ala Arg Val Leu Val Leu Leu Trp Ala Ala Leu Leu Leu 1 5 10 15 Ile Trp Gly Gly Asn Cys Glu Ile Cys Pro Ala Val Lys Arg Asp Val 20 25 30 Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Gln Val Ala 35 40 45 Gln Tyr Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys 50 55 60 Asn Cys Val Asp Ala Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu 65 70 75 80 Ser Leu Leu Asp Lys Ile Tyr Thr Ser Pro Leu Cys 85 90 35 138 PRT Hevea brasiliensis 35 Met Ala Glu Asp Glu Asp Asn Gln Gln Gly Gln Gly Glu Gly Leu Lys 1 5 10 15 Tyr Leu Gly Phe Val Gln Asp Ala Ala Thr Tyr Ala Val Thr Thr Phe 20 25 30 Ser Asn Val Tyr Leu Phe Ala Lys Asp Lys Ser Gly Pro Leu Gln Pro 35 40 45 Gly Val Asp Ile Ile Glu Gly Pro Val Lys Asn Val Ala Val Pro Leu 50 55 60 Tyr Asn Arg Phe Ser Tyr Ile Pro Asn Gly Ala Leu Lys Phe Val Asp 65 70 75 80 Ser Thr Val Val Ala Ser Val Thr Ile Ile Asp Arg Ser Leu Pro Pro 85 90 95 Ile Val Lys Asp Ala Ser Ile Gln Val Val Ser Ala Ile Arg Ala Ala 100 105 110 Pro Glu Ala Ala Arg Ser Leu Ala Ser Ser Leu Pro Gly Gln Thr Lys 115 120 125 Ile Leu Ala Lys Val Phe Tyr Gly Glu Asn 130 135 36 204 PRT Hevea brasiliensis 36 Met Ala Glu Glu Val Glu Glu Glu Arg Leu Lys Tyr Leu Asp Phe Val 1 5 10 15 Arg Ala Ala Gly Val Tyr Ala Val Asp Ser Phe Ser Thr Leu Tyr Leu 20 25 30 Tyr Ala Lys Asp Ile Ser Gly Pro Leu Lys Pro Gly Val Asp Thr Ile 35 40 45 Glu Asn Val Val Lys Thr Val Val Thr Pro Val Tyr Tyr Ile Pro Leu 50 55 60 Glu Ala Val Lys Phe Val Asp Lys Thr Val Asp Val Ser Val Thr Ser 65 70 75 80 Leu Asp Gly Val Val Pro Pro Val Ile Lys Gln Val Ser Ala Gln Thr 85 90 95 Tyr Ser Val Ala Gln Asp Ala Pro Arg Ile Val Leu Asp Val Ala Ser 100 105 110 Ser Val Phe Asn Thr Gly Val Gln Glu Gly Ala Lys Ala Leu Tyr Ala 115 120 125 Asn Leu Glu Pro Lys Ala Glu Gln Tyr Ala Val Ile Thr Trp Arg Ala 130 135 140 Leu Asn Lys Leu Pro Leu Val Pro Gln Val Ala Asn Val Val Val Pro 145 150 155 160 Thr Ala Val Tyr Phe Ser Glu Lys Tyr Asn Asp Val Val Arg Gly Thr 165 170 175 Thr Glu Gln Gly Tyr Arg Val Ser Ser Tyr Leu Pro Leu Leu Pro Thr 180 185 190 Glu Lys Ile Thr Lys Val Phe Gly Asp Glu Ala Ser 195 200 37 263 PRT Lolium perenne 37 Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Ala Leu Phe Ala Val 1 5 10 15 Phe Leu Gly Ser Ala His Gly Ile Ala Lys Val Pro Pro Gly Pro Asn 20 25 30 Ile Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp 35 40 45 Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys 50 55 60 Gly Tyr Lys Asn Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly Cys 65 70 75 80 Gly Asn Thr Pro Ile Phe Lys Asp Gly Arg Gly Cys Gly Ser Cys Phe 85 90 95 Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly Glu Ala Val Thr 100 105 110 Val Thr Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Pro Tyr His Phe 115 120 125 Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala Lys Lys Gly Glu Glu 130 135 140 Gln Asn Val Arg Ser Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val 145 150 155 160 Lys Cys Lys Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys 165 170 175 Ala Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr Val Asp Gly 180 185 190 Asp Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys 195 200 205 Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr 210 215 220 Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu Gly 225 230 235 240 Gly Thr Lys Ser Glu Phe Glu Asp Val Ile Pro Glu Gly Trp Lys Ala 245 250 255 Asp Thr Ser Tyr Ser Ala Lys 260 38 97 PRT Lolium perenne 38 Ala Ala Pro Val Glu Phe Thr Val Glu Lys Gly Ser Asp Glu Lys Asn 1 5 10 15 Leu Ala Leu Ser Ile Lys Tyr Asn Lys Glu Gly Asp Ser Met Ala Glu 20 25 30 Val Glu Leu Lys Glu His Gly Ser Asn Glu Trp Leu Ala Leu Lys Lys 35 40 45 Asn Gly Asp Gly Val Trp Glu Ile Lys Ser Asp Lys Pro Leu Lys Gly 50 55 60 Pro Phe Asn Phe Arg Phe Val Ser Glu Lys Gly Met Arg Asn Val Phe 65 70 75 80 Asp Asp Val Val Pro Ala Asp Phe Lys Val Gly Thr Thr Tyr Lys Pro 85 90 95 Glu 39 97 PRT Lolium perenne 39 Thr Lys Val Asp Leu Thr Val Glu Lys Gly Ser Asp Ala Lys Thr Leu 1 5 10 15 Val Leu Asn Ile Lys Tyr Thr Arg Pro Gly Asp Thr Leu Ala Glu Val 20 25 30 Glu Leu Arg Gln His Gly Ser Glu Glu Trp Glu Pro Met Thr Lys Lys 35 40 45 Gly Asn Leu Trp Glu Val Lys Ser Ala Lys Pro Leu Thr Gly Pro Met 50 55 60 Asn Phe Arg Phe Leu Ser Lys Gly Gly Met Lys Asn Val Phe Asp Glu 65 70 75 80 Val Ile Pro Thr Ala Phe Thr Val Gly Lys Thr Tyr Thr Pro Glu Tyr 85 90 95 Asn 40 308 PRT Lolium perenne 40 Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Arg Arg Gly Pro 1 5 10 15 Arg Gly Gly Pro Gly Arg Ser Tyr Ala Ala Asp Ala Gly Tyr Thr Pro 20 25 30 Ala Ala Ala Ala Thr Pro Ala Thr Pro Ala Ala Thr Pro Ala Gly Gly 35 40 45 Trp Arg Glu Gly Asp Asp Arg Arg Ala Glu Ala Ala Gly Gly Arg Gln 50 55 60 Arg Leu Ala Ser Arg Gln Pro Trp Pro Pro Leu Pro Thr Pro Leu Arg 65 70 75 80 Arg Thr Ser Ser Arg Ser Ser Arg Pro Pro Ser Pro Ser Pro Pro Arg 85 90 95 Ala Ser Ser Pro Thr Ser Ala Ala Lys Ala Pro Gly Leu Ile Pro Lys 100 105 110 Leu Asp Thr Ala Tyr Asp Val Ala Tyr Lys Ala Ala Glu Ala His Pro 115 120 125 Arg Gly Gln Val Arg Arg Leu Arg His Cys Pro His Arg Ser Leu Arg 130 135 140 Val Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Ala Thr Glu 145 150 155 160 Glu Val Leu Ala Ala Lys Ile Pro Thr Gly Glu Leu Gln Ile Val Asp 165 170 175 Lys Ile Asp Ala Ala Phe Lys Ile Ala Ala Thr Ala Ala Asn Ala Ala 180 185 190 Pro Thr Asn Asp Lys Phe Thr Val Phe Glu Ser Ala Phe Asn Lys Ala 195 200 205 Leu Asn Glu Cys Thr Gly Gly Ala Met Arg Pro Thr Ser Ser Ser Pro 210 215 220 Pro Ser Arg Pro Arg Ser Ser Arg Pro Thr Pro Pro Pro Ser Pro Ala 225 230 235 240 Ala Pro Glu Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala 245 250 255 Ile Thr Ala Met Thr Gln Ala Gln Lys Ala Gly Lys Pro Ala Ala Ala 260 265 270 Ala Ala Thr Ala Ala Ala Thr Val Ala Thr Ala Ala Ala Thr Ala Ala 275 280 285 Ala Val Leu Pro Pro Pro Leu Leu Val Val Gln Ser Leu Ile Ser Leu 290 295 300 Leu Ile Tyr Tyr 305 41 339 PRT Lolium perenne 41 Met Ala Val Gln Lys His Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro 20 25 30 Ala Thr Pro Ala Thr Pro Ala Ala Pro Ala Thr Ala Ala Thr Pro Ala 35 40 45 Thr Pro Ala Thr Pro Ala Thr Pro Ala Ala Val Pro Ser Gly Lys Ala 50 55 60 Thr Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys 65 70 75 80 Ala Ala Val Ala Ala Ala Ala Val Val Pro Pro Ala Asp Lys Tyr Lys 85 90 95 Thr Phe Val Glu Thr Phe Gly Thr Ala Thr Asn Lys Ala Phe Val Glu 100 105 110 Gly Leu Ala Ser Gly Tyr Ala Asp Gln Ser Lys Asn Gln Leu Thr Ser 115 120 125 Lys Leu Asp Ala Ala Leu Lys Leu Ala Tyr Glu Ala Ala Gln Gly Ala 130 135 140 Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Thr Glu Ala 145 150 155 160 Leu Arg Val Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala 165 170 175 Ala Glu Glu Val Lys Val Gly Ala Ile Pro Ala Ala Glu Val Gln Leu 180 185 190 Ile Asp Lys Val Asp Ala Ala Tyr Arg Thr Ala Ala Thr Ala Ala Asn 195 200 205 Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Asn Thr Phe Asn 210 215 220 Asn Ala Ile Lys Val Ser Leu Gly Ala Ala Tyr Asp Ser Tyr Lys Phe 225 230 235 240 Ile Pro Thr Leu Val Ala Ala Val Lys Gln Ala Tyr Ala Ala Lys Gln 245 250 255 Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Ser Glu Thr Ala Leu Lys 260 265 270 Lys Ala Val Thr Ala Met Ser Glu Ala Glu Lys Glu Ala Thr Pro Ala 275 280 285 Ala Ala Ala Thr Ala Thr Pro Thr Pro Ala Ala Ala Thr Ala Thr Ala 290 295 300 Thr Pro Ala Ala Ala Tyr Ala Thr Ala Thr Pro Ala Ala Ala Thr Ala 305 310 315 320 Thr Ala Thr Pro Ala Ala Ala Thr Ala Thr Pro Ala Ala Ala Gly Gly 325 330 335 Tyr Lys Val 42 339 PRT Lolium perenne 42 Met Ala Val Gln Lys His Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro 20 25 30 Ala Thr Pro Ala Thr Pro Ala Ala Pro Ala Thr Ala Ala Thr Pro Ala 35 40 45 Thr Pro Ala Thr Pro Ala Thr Pro Ala Ala Val Pro Ser Gly Lys Ala 50 55 60 Thr Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys 65 70 75 80 Ala Ala Val Ala Ala Ala Ala Val Val Pro Pro Ala Asp Lys Tyr Lys 85 90 95 Thr Phe Val Glu Thr Phe Gly Thr Ala Thr Asn Lys Ala Phe Val Glu 100 105 110 Gly Leu Ala Ser Gly Tyr Ala Asp Gln Ser Lys Asn Gln Leu Thr Ser 115 120 125 Lys Leu Asp Ala Ala Leu Lys Leu Ala Tyr Glu Ala Ala Gln Gly Ala 130 135 140 Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Thr Glu Ala 145 150 155 160 Leu Arg Val Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala 165 170 175 Ala Glu Glu Val Lys Val Gly Ala Ile Pro Ala Ala Glu Val Gln Leu 180 185 190 Ile Asp Lys Val Asp Ala Ala Tyr Arg Thr Ala Ala Thr Ala Ala Asn 195 200 205 Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Asn Thr Phe Asn 210 215 220 Asn Ala Ile Lys Val Ser Leu Gly Ala Ala Tyr Asp Ser Tyr Lys Phe 225 230 235 240 Ile Pro Thr Leu Val Ala Ala Val Lys Gln Ala Tyr Ala Ala Lys Gln 245 250 255 Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Ser Glu Thr Ala Leu Lys 260 265 270 Lys Ala Val Thr Ala Met Ser Glu Ala Glu Lys Glu Ala Thr Pro Ala 275 280 285 Ala Ala Ala Thr Ala Thr Pro Thr Pro Ala Ala Ala Thr Ala Thr Ala 290 295 300 Thr Pro Ala Ala Ala Tyr Ala Thr Ala Thr Pro Ala Ala Ala Thr Ala 305 310 315 320 Thr Ala Thr Pro Ala Ala Ala Thr Ala Thr Pro Ala Ala Ala Gly Gly 325 330 335 Tyr Lys Val 43 134 PRT Lolium perenne misc_feature X is unknown amino acid 43 Asp Lys Gly Pro Gly Phe Val Val Thr Gly Arg Val Tyr Cys Asp Pro 1 5 10 15 Cys Arg Ala Gly Phe Glu Thr Asn Val Ser His Asn Val Glu Gly Ala 20 25 30 Thr Val Ala Val Asp Cys Arg Pro Phe Asp Gly Gly Glu Ser Lys Leu 35 40 45 Lys Ala Glu Ala Thr Thr Asp Lys Asp Gly Trp Tyr Lys Ile Glu Ile 50 55 60 Asp Gln Asp His Gln Glu Glu Ile Cys Glu Val Val Leu Ala Lys Ser 65 70 75 80 Pro Asp Lys Ser Cys Ser Glu Ile Glu Glu Phe Arg Asp Arg Ala Arg 85 90 95 Val Pro Leu Thr Ser Asn Xaa Gly Ile Lys Gln Gln Gly Ile Arg Tyr 100 105 110 Ala Asn Pro Ile Ala Phe Phe Arg Lys Glu Pro Leu Lys Glu Cys Gly 115 120 125 Gly Ile Leu Gln Ala Tyr 130 44 145 PRT Olea europaea 44 Glu Asp Ile Pro Gln Pro Pro Val Ser Gln Phe His Ile Gln Gly Gln 1 5 10 15 Val Tyr Cys Asp Thr Cys Arg Ala Gly Phe Ile Thr Glu Leu Ser Glu 20 25 30 Phe Ile Pro Gly Ala Ser Leu Arg Leu Gln Cys Lys Asp Lys Glu Asn 35 40 45 Gly Asp Val Thr Phe Thr Glu Val Gly Tyr Thr Arg Ala Glu Gly Leu 50 55 60 Tyr Ser Met Leu Val Glu Arg Asp His Lys Asn Glu Phe Cys Glu Ile 65 70 75 80 Thr Leu Ile Ser Ser Gly Arg Lys Asp Cys Asn Glu Ile Pro Thr Glu 85 90 95 Gly Trp Ala Lys Pro Ser Leu Lys Phe Lys Leu Asn Thr Val Asn Gly 100 105 110 Thr Thr Arg Thr Val Asn Pro Leu Gly Phe Phe Lys Lys Glu Ala Leu 115 120 125 Pro Lys Cys Ala Gln Val Tyr Asn Lys Leu Gly Met Tyr Pro Pro Asn 130 135 140 Met 145 45 133 PRT Parietaria judaica 45 Met Arg Thr Val Ser Met Ala Ala Leu Val Val Ile Ala Ala Ala Leu 1 5 10 15 Ala Trp Thr Ser Ser Ala Glu Pro Ala Pro Ala Pro Ala Pro Gly Glu 20 25 30 Glu Ala Cys Gly Lys Val Val Gln Asp Ile Met Pro Cys Leu His Phe 35 40 45 Val Lys Gly Glu Glu Lys Glu Pro Ser Lys Glu Cys Cys Ser Gly Thr 50 55 60 Lys Lys Leu Ser Glu Glu Val Lys Thr Thr Glu Gln Lys Arg Glu Ala 65 70 75 80 Cys Lys Cys Ile Val Arg Ala Thr Lys Gly Ile Ser Gly Ile Lys Asn 85 90 95 Glu Leu Val Ala Glu Val Pro Lys Lys Cys Asp Ile Lys Thr Thr Leu 100 105 110 Pro Pro Ile Thr Ala Asp Phe Asp Cys Ser Lys Ile Gln Ser Thr Ile 115 120 125 Phe Arg Gly Tyr Tyr 130 46 133 PRT Parietaria judaica 46 Met Val Arg Ala Leu Met Pro Cys Leu Pro Phe Val Gln Gly Lys Glu 1 5 10 15 Lys Glu Pro Ser Lys Gly Cys Cys Ser Gly Ala Lys Arg Leu Asp Gly 20 25 30 Glu Thr Lys Thr Gly Pro Gln Arg Val His Ala Cys Glu Cys Ile Gln 35 40 45 Thr Ala Met Lys Thr Tyr Ser Asp Ile Asp Gly Lys Leu Val Ser Glu 50 55 60 Val Pro Lys His Cys Gly Ile Val Asp Ser Lys Leu Pro Pro Ile Asp 65 70 75 80 Val Asn Met Asp Cys Lys Thr Val Gly Val Val Pro Arg Gln Pro Gln 85 90 95 Leu Pro Val Ser Leu Arg His Gly Pro Val Thr Gly Pro Ser Asp Pro 100 105 110 Ala His Lys Ala Arg Leu Glu Arg Pro Gln Ile Arg Val Pro Pro Pro 115 120 125 Ala Pro Glu Lys Ala 130 47 133 PRT Parietaria judaica 47 Met Arg Thr Val Ser Met Ala Ala Leu Val Val Ile Ala Ala Ala Leu 1 5 10 15 Ala Trp Thr Ser Ser Ala Glu Leu Ala Ser Ala Pro Ala Pro Gly Glu 20 25 30 Gly Pro Cys Gly Lys Val Val His His Ile Met Pro Cys Leu Lys Phe 35 40 45 Val Lys Gly Glu Glu Lys Glu Pro Ser Lys Ser Cys Cys Ser Gly Thr 50 55 60 Lys Lys Leu Ser Glu Glu Val Lys Thr Thr Glu Gln Lys Arg Glu Ala 65 70 75 80 Cys Lys Cys Ile Val Ala Ala Thr Lys Gly Ile Ser Gly Ile Lys Asn 85 90 95 Glu Leu Val Ala Glu Val Pro Lys Lys Cys Gly Ile Thr Thr Thr Leu 100 105 110 Pro Pro Ile Thr Ala Asp Phe Asp Cys Ser Lys Ile Glu Ser Thr Ile 115 120 125 Phe Arg Gly Tyr Tyr 130 48 176 PRT Parietaria judaica 48 Met Arg Thr Val Ser Ala Pro Ser Ala Val Ala Leu Val Val Ile Val 1 5 10 15 Ala Ala Gly Leu Ala Trp Thr Ser Leu Ala Ser Val Ala Pro Pro Ala 20 25 30 Pro Ala Pro Gly Ser Glu Glu Thr Cys Gly Thr Val Val Arg Ala Leu 35 40 45 Met Pro Cys Leu Pro Phe Val Gln Gly Lys Glu Lys Glu Pro Ser Lys 50 55 60 Gly Cys Cys Ser Gly Ala Lys Arg Leu Asp Gly Glu Thr Lys Thr Gly 65 70 75 80 Leu Gln Arg Val His Ala Cys Glu Cys Ile Gln Thr Ala Met Lys Thr 85 90 95 Tyr Ser Asp Ile Asp Gly Lys Leu Val Ser Glu Val Pro Lys His Cys 100 105 110 Gly Ile Val Asp Ser Lys Leu Pro Pro Ile Asp Val Asn Met Asp Cys 115 120 125 Lys Thr Leu Gly Val Val Pro Arg Gln Pro Gln Leu Pro Val Ser Leu 130 135 140 Arg His Gly Pro Val Thr Gly Pro Ser Asp Pro Ala His Lys Ala Arg 145 150 155 160 Leu Glu Arg Pro Gln Ile Arg Val Pro Pro Pro Ala Pro Glu Lys Ala 165 170 175 49 138 PRT Parietaria judaica 49 Met Arg Thr Val Ser Ala Arg Ser Ser Val Ala Leu Val Val Ile Val 1 5 10 15 Ala Ala Val Leu Val Trp Thr Ser Ser Ala Ser Val Ala Pro Ala Pro 20 25 30 Ala Pro Gly Ser Glu Glu Thr Cys Gly Thr Val Val Gly Ala Leu Met 35 40 45 Pro Cys Leu Pro Phe Val Gln Gly Lys Glu Lys Glu Pro Ser Lys Gly 50 55 60 Cys Cys Ser Gly Ala Lys Arg Leu Asp Gly Glu Thr Lys Thr Gly Pro 65 70 75 80 Gln Arg Val His Ala Cys Glu Cys Ile Gln Thr Ala Met Lys Thr Tyr 85 90 95 Ser Asp Ile Asp Gly Lys Leu Val Ser Glu Val Pro Lys His Cys Gly 100 105 110 Ile Val Asp Ser Lys Leu Pro Pro Ile Asp Val Asn Met Asp Cys Lys 115 120 125 Thr Leu Gly Val Leu His Tyr Lys Gly Asn 130 135 50 143 PRT Parietaria judaica 50 Met Val Arg Ala Leu Met Pro Cys Leu Pro Phe Val Gln Gly Lys Glu 1 5 10 15 Lys Glu Pro Ser Lys Gly Cys Cys Ser Gly Ala Lys Arg Leu Asp Gly 20 25 30 Glu Thr Lys Thr Gly Pro Gln Arg Val His Ala Cys Glu Cys Ile Gln 35 40 45 Thr Ala Met Lys Thr Tyr Ser Asp Ile Asp Gly Lys Leu Val Ser Glu 50 55 60 Val Pro Lys His Cys Gly Ile Val Asp Ser Lys Leu Pro Pro Ile Asp 65 70 75 80 Val Asn Met Asp Cys Lys Thr Val Gly Val Val Pro Arg Gln Pro Gln 85 90 95 Leu Pro Val Ser Leu Arg His Gly Pro Val Thr Gly Pro Ser Arg Ser 100 105 110 Arg Pro Pro Thr Lys His Gly Trp Arg Asp Pro Arg Leu Glu Phe Arg 115 120 125 Pro Pro His Arg Lys Lys Pro Asn Pro Ala Phe Ser Thr Leu Gly 130 135 140 51 263 PRT Phleum pratense 51 Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Val Leu Phe Ala Val 1 5 10 15 Phe Leu Gly Ser Ala Tyr Gly Ile Pro Lys Val Pro Pro Gly Pro Asn 20 25 30 Ile Thr Ala Thr Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp 35 40 45 Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys 50 55 60 Gly Tyr Lys Asp Val Asp Lys Pro Pro Phe Ser Gly Met Thr Gly Cys 65 70 75 80 Gly Asn Thr Pro Ile Phe Lys Ser Gly Arg Gly Cys Gly Ser Cys Phe 85 90 95 Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser Gly Glu Pro Val Val 100 105 110 Val His Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Pro Tyr His Phe 115 120 125 Asp Leu Ser Gly His Ala Phe Gly Ala Met Ala Lys Lys Gly Asp Glu 130 135 140 Gln Lys Leu Arg Ser Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg Val 145 150 155 160 Lys Cys Lys Tyr Pro Glu Gly Thr Lys Val Thr Phe His Val Glu Lys 165 170 175 Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr Val Asn Gly 180 185 190 Asp Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys 195 200 205 Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Ile Trp Arg Ile Asp Thr 210 215 220 Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu Gly 225 230 235 240 Gly Thr Lys Thr Glu Ala Glu Asp Val Ile Pro Glu Gly Trp Lys Ala 245 250 255 Asp Thr Ser Tyr Glu Ser Lys 260 52 262 PRT Phleum pratense 52 Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Ala Leu Phe Ala Val 1 5 10 15 Phe Leu Gly Ser Ala His Gly Ile Pro Lys Val Pro Pro Gly Pro Asn 20 25 30 Ile Thr Ala Thr Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp 35 40 45 Tyr Gly Lys Pro Thr Ala Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys 50 55 60 Gly Tyr Lys Asp Val Asp Lys Pro Pro Phe Ser Gly Met Thr Gly Cys 65 70 75 80 Gly Asn Thr Pro Ile Phe Lys Ser Gly Arg Gly Cys Gly Ser Cys Phe 85 90 95 Glu Ile Lys Cys Thr Lys Pro Glu Ala Cys Ser Gly Glu Pro Val Val 100 105 110 Val His Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Ala Tyr His Phe 115 120 125 Asp Leu Ser Gly Ile Ala Phe Gly Ser Met Ala Lys Lys Gly Asp Glu 130 135 140 Gln Lys Leu Arg Ser Ala Gly Glu Val Glu Ile Gln Phe Arg Arg Val 145 150 155 160 Lys Cys Lys Tyr Pro Glu Gly Thr Lys Val Thr Phe His Val Glu Lys 165 170 175 Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu Val Lys Phe Ser Gly Asp 180 185 190 Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp 195 200 205 Ile Ala Leu Lys Glu Ser Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro 210 215 220 Glu Val Leu Lys Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly 225 230 235 240 Thr Lys Ala Arg Ala Lys Asp Val Ile Pro Glu Gly Trp Lys Ala Asp 245 250 255 Thr Ala Tyr Glu Ser Lys 260 53 122 PRT Phleum pratense 53 Met Ser Met Ala Ser Ser Ser Ser Ser Ser Leu Leu Ala Met Ala Val 1 5 10 15 Leu Ala Ala Leu Phe Ala Gly Ala Trp Cys Val Pro Lys Val Thr Phe 20 25 30 Thr Val Glu Lys Gly Ser Asn Glu Lys His Leu Ala Val Leu Val Lys 35 40 45 Tyr Glu Gly Asp Thr Met Ala Glu Val Glu Leu Arg Glu His Gly Ser 50 55 60 Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly Gly Val Trp Thr Phe 65 70 75 80 Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe Asn Phe Arg Phe Leu Thr 85 90 95 Glu Lys Gly Met Lys Asn Val Phe Asp Asp Val Val Pro Glu Lys Tyr 100 105 110 Thr Ile Gly Ala Thr Tyr Ala Pro Glu Glu 115 120 54 276 PRT Phleum pratense 54 Ala Asp Leu Gly Tyr Gly Gly Pro Ala Thr Pro Ala Ala Pro Ala Glu 1 5 10 15 Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 20 25 30 Lys Ile Asn Asp Gly Phe Lys Ala Ala Leu Ala Ala Ala Ala Gly Val 35 40 45 Pro Pro Ala Asp Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala 50 55 60 Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Ala Glu Pro Lys Gly Ala 65 70 75 80 Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala 85 90 95 Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys 100 105 110 Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala 115 120 125 Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu Val Lys 130 135 140 Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys Val Asp Ser Ala 145 150 155 160 Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys 165 170 175 Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile Lys Ala Ser Thr 180 185 190 Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala 195 200 205 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys 210 215 220 Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Phe Thr Ala Met Ser 225 230 235 240 Glu Ala Gln Lys Ala Ala Lys Pro Ala Thr Glu Ala Thr Ala Thr Ala 245 250 255 Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly 260 265 270 Gly Tyr Lys Val 275 55 276 PRT Phleum pratense 55 Ala Asp Leu Gly Tyr Gly Gly Pro Ala Thr Pro Ala Ala Pro Ala Glu 1 5 10 15 Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 20 25 30 Lys Ile Asn Asp Gly Phe Lys Ala Ala Leu Ala Ala Ala Ala Gly Val 35 40 45 Pro Pro Ala Asp Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala 50 55 60 Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Ala Glu Pro Lys Gly Ala 65 70 75 80 Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala 85 90 95 Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys 100 105 110 Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala 115 120 125 Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu Val Lys 130 135 140 Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys Val Asp Ser Ala 145 150 155 160 Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys 165 170 175 Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile Lys Ala Ser Thr 180 185 190 Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala 195 200 205 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys 210 215 220 Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser 225 230 235 240 Glu Ala Gln Lys Ala Ala Lys Pro Ala Thr Glu Ala Thr Ala Thr Ala 245 250 255 Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly 260 265 270 Gly Tyr Lys Val 275 56 284 PRT Phleum pratense 56 Ala Ala Ala Ala Val Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg 1 5 10 15 Ser Tyr Thr Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala 20 25 30 Gly Ala Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 35 40 45 Asp Ile Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val 50 55 60 Pro Ala Ala Asp Lys Phe Lys Thr Phe Glu Ala Ala Phe Thr Ser Ser 65 70 75 80 Ser Lys Ala Ala Ala Ala Lys Ala Pro Gly Leu Val Pro Lys Leu Asp 85 90 95 Ala Ala Tyr Ser Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu 100 105 110 Ala Lys Phe Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val 115 120 125 Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu 130 135 140 Pro Gly Met Ala Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys 145 150 155 160 Ile Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro 165 170 175 Ala Asp Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile 180 185 190 Lys Glu Ser Thr Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser 195 200 205 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala 210 215 220 Pro Gln Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile 225 230 235 240 Thr Ala Met Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala 245 250 255 Ala Thr Val Ala Ala Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser 260 265 270 Gly Ala Ala Thr Val Ala Ala Gly Gly Tyr Lys Val 275 280 57 286 PRT Phleum pratense 57 Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Thr Pro Ala Ala Pro Ala Gly Ala Asp Ala Ala Gly 20 25 30 Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly 35 40 45 Phe Lys Ala Ala Leu Ala Gly Ala Gly Val Gln Pro Ala Asp Lys Tyr 50 55 60 Arg Thr Phe Val Ala Thr Phe Gly Pro Ala Ser Asn Lys Ala Phe Ala 65 70 75 80 Glu Gly Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys 85 90 95 Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys 100 105 110 Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala 115 120 125 Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His 130 135 140 Ala Val Lys Pro Ala Ala Glu Glu Val Lys Val Ile Pro Ala Gly Glu 145 150 155 160 Leu Gln Val Ile Glu Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr 165 170 175 Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala 180 185 190 Ala Phe Asn Asp Glu Ile Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser 195 200 205 Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala 210 215 220 Ala Thr Val Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Phe Glu Thr 225 230 235 240 Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Glu Ala Gln Lys Ala Ala 245 250 255 Lys Pro Ala Ala Ala Ala Thr Ala Thr Ala Thr Ala Ala Val Gly Ala 260 265 270 Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys Val 275 280 285 58 287 PRT Phleum pratense 58 Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro 20 25 30 Ala Thr Pro Ala Ala Ala Gly Ala Glu Ala Gly Lys Ala Thr Thr Glu 35 40 45 Glu Gln Lys Leu Ile Glu Asp Ile Asn Val Gly Phe Lys Ala Ala Val 50 55 60 Ala Ala Ala Ala Ser Val Pro Ala Ala Asp Lys Phe Lys Thr Phe Glu 65 70 75 80 Ala Ala Phe Thr Ser Ser Ser Lys Ala Ala Thr Ala Lys Ala Pro Gly 85 90 95 Leu Val Pro Lys Leu Asp Ala Ala Tyr Ser Val Ser Tyr Lys Ala Ala 100 105 110 Val Gly Ala Thr Pro Glu Ala Lys Phe Asp Ser Phe Val Ala Ser Leu 115 120 125 Thr Glu Ala Leu Arg Val Ile Ala Gly Ala Leu Glu Val His Ala Val 130 135 140 Lys Pro Val Thr Glu Glu Pro Gly Met Ala Lys Ile Pro Ala Gly Glu 145 150 155 160 Leu Gln Ile Ile Asp Lys Ile Asp Ala Ala Phe Lys Val Ala Ala Thr 165 170 175 Ala Ala Ala Thr Ala Pro Ala Asp Thr Val Phe Glu Ala Ala Phe Asn 180 185 190 Lys Ala Ile Lys Glu Ser Thr Gly Gly Ala Tyr Asp Thr Tyr Lys Cys 195 200 205 Ile Pro Ser Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val 210 215 220 Ala Ala Ala Pro Gln Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr 225 230 235 240 Lys Ala Ile Thr Ala Met Ser Glu Val Gln Lys Val Ser Gln Pro Ala 245 250 255 Thr Gly Ala Ala Thr Val Ala Ala Gly Ala Ala Thr Thr Ala Ala Gly 260 265 270 Ala Ala Ser Gly Ala Ala Thr Val Ala Ala Gly Gly Tyr Lys Val 275 280 285 59 290 PRT Phleum pratense 59 Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Ala Gly Tyr Ala Pro 20 25 30 Ala Thr Pro Ala Ala Ala Gly Ala Glu Ala Gly Lys Ala Thr Thr Glu 35 40 45 Glu Gln Lys Leu Ile Glu Asp Ile Asn Val Gly Phe Lys Ala Ala Val 50 55 60 Ala Ala Ala Ala Ser Val Pro Ala Ala Asp Lys Phe Lys Thr Phe Glu 65 70 75 80 Ala Ala Phe Thr Ser Ser Ser Lys Ala Ala Thr Ala Lys Ala Pro Gly 85 90 95 Leu Val Pro Lys Leu Asp Ala Ala Tyr Ser Val Ala Tyr Lys Ala Ala 100 105 110 Val Gly Ala Thr Pro Glu Ala Lys Phe Asp Ser Phe Val Ala Ser Leu 115 120 125 Thr Glu Ala Leu Arg Val Ile Ala Gly Ala Leu Glu Val His Ala Val 130 135 140 Lys Pro Val Thr Glu Asp Pro Ala Trp Pro Lys Ile Pro Ala Gly Glu 145 150 155 160 Leu Gln Ile Ile Asp Lys Ile Asp Ala Ala Phe Lys Val Ala Ala Thr 165 170 175 Ala Ala Ala Thr Ala Pro Ala Asp Asp Lys Phe Thr Val Phe Glu Ala 180 185 190 Ala Phe Asn Lys Ala Ile Lys Glu Ser Thr Gly Gly Ala Tyr Asp Thr 195 200 205 Tyr Lys Cys Ile Pro Ser Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala 210 215 220 Ala Thr Val Ala Ala Ala Pro Gln Val Lys Tyr Ala Val Phe Glu Ala 225 230 235 240 Ala Leu Thr Lys Ala Ile Thr Ala Met Ser Glu Val Gln Lys Val Ser 245 250 255 Gln Pro Ala Thr Gly Ala Ala Thr Val Ala Ala Gly Ala Ala Thr Thr 260 265 270 Ala Thr Gly Ala Ala Ser Gly Ala Ala Thr Val Ala Ala Gly Gly Tyr 275 280 285 Lys Val 290 60 265 PRT Phleum pratense 60 Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala Gly Ala Glu 1 5 10 15 Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile Asn 20 25 30 Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala Ala 35 40 45 Asp Lys Phe Lys Thr Phe Glu Ala Ala Phe Thr Ser Ser Ser Lys Ala 50 55 60 Ala Thr Ala Lys Ala Pro Gly Leu Val Pro Lys Leu Asp Ala Ala Tyr 65 70 75 80 Ser Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu Ala Lys Phe 85 90 95 Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val Ile Ala Gly 100 105 110 Ala Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu Pro Gly Met 115 120 125 Ala Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys Ile Asp Ala 130 135 140 Ala Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro Ala Asp Asp 145 150 155 160 Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile Lys Glu Ser 165 170 175 Thr Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser Leu Glu Ala 180 185 190 Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Gln Val 195 200 205 Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met 210 215 220 Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala Thr Val 225 230 235 240 Ala Ala Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser Gly Ala Ala 245 250 255 Thr Val Ala Ala Gly Gly Tyr Lys Val 260 265 61 295 PRT Phleum pratense 61 Ser Val Lys Arg Ser Asn Gly Ser Ala Glu Val His Arg Gly Ala Val 1 5 10 15 Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg Ser Tyr Ala Ala Asp 20 25 30 Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala Gly Ala Glu Ala Gly 35 40 45 Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile Asn Val Gly 50 55 60 Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala Ala Asp Lys 65 70 75 80 Phe Lys Thr Phe Glu Ala Ala Phe Thr Ser Ser Ser Lys Ala Ala Thr 85 90 95 Ala Lys Ala Pro Gly Leu Val Pro Lys Leu Asp Ala Ala Tyr Ser Val 100 105 110 Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu Ala Lys Phe Asp Ser 115 120 125 Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala Leu 130 135 140 Glu Val His Ala Val Lys Pro Val Thr Glu Glu Pro Gly Met Ala Lys 145 150 155 160 Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys Ile Asp Ala Ala Phe 165 170 175 Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro Ala Asp Asp Lys Phe 180 185 190 Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile Lys Glu Ser Thr Gly 195 200 205 Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser Leu Glu Ala Ala Val 210 215 220 Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Gln Val Lys Tyr 225 230 235 240 Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Ser Glu 245 250 255 Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala Thr Val Ala Ala 260 265 270 Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser Gly Ala Ala Thr Val 275 280 285 Ala Ala Gly Gly Tyr Lys Val 290 295 62 312 PRT Phleum pratense 62 Met Ala Val His Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Gly Ser Tyr Ala Ala Asp Leu Gly Tyr Gly Pro 20 25 30 Ala Thr Pro Ala Ala Pro Ala Ala Gly Tyr Thr Pro Ala Thr Pro Ala 35 40 45 Ala Pro Ala Gly Ala Glu Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln 50 55 60 Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Leu Ala Ala 65 70 75 80 Ala Ala Gly Val Pro Pro Ala Asp Lys Tyr Arg Thr Phe Val Ala Thr 85 90 95 Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Gly Glu 100 105 110 Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys 115 120 125 Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr 130 135 140 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Val Ser Glu Ala Leu 145 150 155 160 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 165 170 175 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 180 185 190 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro 195 200 205 Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile 210 215 220 Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala 225 230 235 240 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala 245 250 255 Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile 260 265 270 Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala 275 280 285 Thr Ala Thr Ala Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr 290 295 300 Ala Ala Thr Gly Gly Tyr Lys Val 305 310 63 276 PRT Phleum pratense 63 Ala Asp Leu Gly Tyr Gly Gly Pro Ala Thr Pro Ala Ala Pro Ala Glu 1 5 10 15 Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 20 25 30 Lys Ile Asn Asp Gly Phe Lys Ala Ala Leu Ala Ala Ala Ala Gly Val 35 40 45 Pro Pro Ala Asp Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala 50 55 60 Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Ala Glu Pro Lys Gly Ala 65 70 75 80 Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala 85 90 95 Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys 100 105 110 Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala 115 120 125 Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu Val Lys 130 135 140 Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys Val Asp Ser Ala 145 150 155 160 Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys 165 170 175 Phe Thr Val Phe Glu Ala Ala Phe Asn Asn Ala Ile Lys Ala Ser Thr 180 185 190 Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala 195 200 205 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys 210 215 220 Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Phe Thr Ala Met Ser 225 230 235 240 Glu Ala Gln Lys Ala Ala Lys Pro Ala Thr Glu Ala Thr Ala Thr Ala 245 250 255 Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly 260 265 270 Gly Tyr Lys Val 275 64 284 PRT Phleum pratense 64 Ala Ala Ala Ala Val Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg 1 5 10 15 Ser Tyr Thr Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala 20 25 30 Gly Ala Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 35 40 45 Asp Ile Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val 50 55 60 Pro Ala Ala Asp Lys Phe Lys Thr Phe Glu Ala Ala Phe Thr Ser Ser 65 70 75 80 Ser Lys Ala Ala Ala Ala Lys Ala Pro Gly Leu Val Pro Lys Leu Asp 85 90 95 Ala Ala Tyr Ser Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu 100 105 110 Ala Lys Phe Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val 115 120 125 Ile Ala Gly Ala Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu 130 135 140 Pro Gly Met Ala Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys 145 150 155 160 Ile Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro 165 170 175 Ala Asp Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile 180 185 190 Lys Glu Ser Thr Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser 195 200 205 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala 210 215 220 Pro Gln Val Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile 225 230 235 240 Thr Ala Met Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala 245 250 255 Ala Thr Val Ala Ala Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser 260 265 270 Gly Ala Ala Thr Val Ala Ala Gly Gly Tyr Lys Val 275 280 65 286 PRT Phleum pratense 65 Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Thr Pro Ala Ala Pro Ala Gly Ala Asp Ala Ala Gly 20 25 30 Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly 35 40 45 Phe Lys Ala Ala Leu Ala Gly Ala Gly Val Gln Pro Ala Asp Lys Tyr 50 55 60 Arg Thr Phe Val Ala Thr Phe Gly Pro Ala Ser Asn Lys Ala Phe Ala 65 70 75 80 Glu Gly Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys 85 90 95 Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys 100 105 110 Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala 115 120 125 Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His 130 135 140 Ala Val Lys Pro Ala Ala Glu Glu Val Lys Val Ile Pro Ala Gly Glu 145 150 155 160 Leu Gln Val Ile Glu Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr 165 170 175 Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala 180 185 190 Ala Phe Asn Asp Glu Ile Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser 195 200 205 Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala 210 215 220 Ala Thr Val Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Phe Glu Thr 225 230 235 240 Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Glu Ala Gln Lys Ala Ala 245 250 255 Lys Pro Ala Ala Ala Ala Thr Ala Thr Ala Thr Ala Ala Val Gly Ala 260 265 270 Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys Val 275 280 285 66 281 PRT Phleum pratense 66 Ala Val Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg Ser Tyr Ala 1 5 10 15 Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala Gly Ala Glu 20 25 30 Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile Asn 35 40 45 Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Ser Val Pro Ala Gly 50 55 60 Asp Lys Phe Lys Thr Phe Glu Ala Ala Phe Thr Ser Ser Ser Lys Ala 65 70 75 80 Ala Thr Ala Lys Ala Pro Gly Leu Val Pro Lys Leu Asp Ala Ala Tyr 85 90 95 Ser Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu Ala Lys Phe 100 105 110 Asp Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val Ile Ala Gly 115 120 125 Ala Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu Pro Gly Met 130 135 140 Ala Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys Ile Asp Ala 145 150 155 160 Ala Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro Ala Asp Asp 165 170 175 Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile Lys Glu Ser 180 185 190 Thr Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser Leu Glu Ala 195 200 205 Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Pro Gln Val 210 215 220 Lys Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met 225 230 235 240 Ser Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala Thr Val 245 250 255 Ala Ala Gly Ala Ala Thr Thr Ala Thr Gly Ala Ala Ser Gly Ala Ala 260 265 270 Thr Val Ala Ala Gly Gly Tyr Lys Val 275 280 67 280 PRT Phleum pratense 67 Met Ala Val Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg Ser Tyr 1 5 10 15 Thr Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala Gly Ala 20 25 30 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 35 40 45 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Arg Gln Arg Pro Ala Ala 50 55 60 Asp Lys Phe Lys Thr Phe Glu Ala Ala Ser Pro Arg His Pro Arg Pro 65 70 75 80 Leu Arg Gln Gly Ala Gly Leu Val Pro Lys Leu Asp Ala Ala Tyr Ser 85 90 95 Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu Ala Lys Phe Asp 100 105 110 Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala 115 120 125 Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu Pro Gly Met Ala 130 135 140 Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys Ile Asp Ala Ala 145 150 155 160 Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro Ala Asp Asp Lys 165 170 175 Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile Lys Glu Ser Thr 180 185 190 Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser Leu Glu Ala Ala 195 200 205 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Ala Glu Val Lys 210 215 220 Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Ser 225 230 235 240 Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala Thr Val Ala 245 250 255 Ala Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser Gly Ala Ala Thr 260 265 270 Val Ala Ala Gly Gly Tyr Lys Val 275 280 68 312 PRT Phleum pratense 68 Met Ala Val His Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Leu Gly Tyr Gly Pro 20 25 30 Ala Thr Pro Ala Ala Pro Ala Ala Gly Tyr Thr Pro Ala Thr Pro Ala 35 40 45 Ala Pro Ala Glu Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln 50 55 60 Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Leu Ala Ala 65 70 75 80 Ala Ala Gly Val Gln Pro Ala Asp Lys Tyr Arg Thr Phe Val Ala Thr 85 90 95 Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Gly Glu 100 105 110 Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys 115 120 125 Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr 130 135 140 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu 145 150 155 160 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 165 170 175 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 180 185 190 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro 195 200 205 Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile 210 215 220 Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala 225 230 235 240 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala 245 250 255 Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile 260 265 270 Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala 275 280 285 Thr Ala Thr Ala Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr 290 295 300 Ala Ala Thr Gly Gly Tyr Lys Val 305 310 69 257 PRT Phleum pratense 69 Glu Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu 1 5 10 15 Lys Ile Asn Ala Gly Phe Lys Ala Ala Leu Ala Arg Arg Leu Gln Pro 20 25 30 Ala Asp Lys Tyr Arg Thr Phe Val Ala Thr Phe Gly Pro Ala Ser Asn 35 40 45 Lys Ala Phe Ala Glu Gly Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu 50 55 60 Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys 65 70 75 80 Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp 85 90 95 Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr 100 105 110 Leu Glu Val His Ala Val Lys Pro Ala Ala Glu Glu Val Lys Val Ile 115 120 125 Pro Ala Ala Glu Leu Gln Val Ile Glu Lys Val Asp Ala Ala Phe Lys 130 135 140 Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr 145 150 155 160 Val Phe Glu Ala Ala Phe Asn Asp Glu Ile Lys Ala Ser Thr Gly Gly 165 170 175 Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val Lys 180 185 190 Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala Pro Glu Val Lys Tyr Thr 195 200 205 Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Glu Ala 210 215 220 Gln Lys Ala Ala Lys Pro Pro Pro Leu Pro Pro Pro Pro Gln Pro Pro 225 230 235 240 Pro Leu Ala Ala Thr Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys 245 250 255 Val 70 312 PRT Phleum pratense 70 Met Ala Val His Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Leu Gly Tyr Gly Pro 20 25 30 Ala Thr Pro Ala Ala Pro Ala Ala Gly Tyr Thr Pro Ala Thr Pro Ala 35 40 45 Ala Pro Ala Glu Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln 50 55 60 Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Leu Ala Ala 65 70 75 80 Ala Ala Gly Val Gln Pro Ala Asp Lys Tyr Arg Thr Phe Val Ala Thr 85 90 95 Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Gly Glu 100 105 110 Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys 115 120 125 Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr 130 135 140 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu 145 150 155 160 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 165 170 175 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 180 185 190 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro 195 200 205 Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile 210 215 220 Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala 225 230 235 240 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala 245 250 255 Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile 260 265 270 Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala 275 280 285 Thr Ala Thr Ala Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr 290 295 300 Ala Ala Thr Gly Gly Tyr Lys Val 305 310 71 280 PRT Phleum pratense 71 Met Ala Val Pro Arg Arg Gly Pro Arg Gly Gly Pro Gly Arg Ser Tyr 1 5 10 15 Thr Ala Asp Ala Gly Tyr Ala Pro Ala Thr Pro Ala Ala Ala Gly Ala 20 25 30 Ala Ala Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile 35 40 45 Asn Val Gly Phe Lys Ala Ala Val Ala Ala Arg Gln Arg Pro Ala Ala 50 55 60 Asp Lys Phe Lys Thr Phe Glu Ala Ala Ser Pro Arg His Pro Arg Pro 65 70 75 80 Leu Arg Gln Gly Ala Gly Leu Val Pro Lys Leu Asp Ala Ala Tyr Ser 85 90 95 Val Ala Tyr Lys Ala Ala Val Gly Ala Thr Pro Glu Ala Lys Phe Asp 100 105 110 Ser Phe Val Ala Ser Leu Thr Glu Ala Leu Arg Val Ile Ala Gly Ala 115 120 125 Leu Glu Val His Ala Val Lys Pro Val Thr Glu Glu Pro Gly Met Ala 130 135 140 Lys Ile Pro Ala Gly Glu Leu Gln Ile Ile Asp Lys Ile Asp Ala Ala 145 150 155 160 Phe Lys Val Ala Ala Thr Ala Ala Ala Thr Ala Pro Ala Asp Asp Lys 165 170 175 Phe Thr Val Phe Glu Ala Ala Phe Asn Lys Ala Ile Lys Glu Ser Thr 180 185 190 Gly Gly Ala Tyr Asp Thr Tyr Lys Cys Ile Pro Ser Leu Glu Ala Ala 195 200 205 Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Ala Ala Ala Glu Val Lys 210 215 220 Tyr Ala Val Phe Glu Ala Ala Leu Thr Lys Ala Ile Thr Ala Met Ser 225 230 235 240 Glu Val Gln Lys Val Ser Gln Pro Ala Thr Gly Ala Ala Thr Val Ala 245 250 255 Ala Gly Ala Ala Thr Thr Ala Ala Gly Ala Ala Ser Gly Ala Ala Thr 260 265 270 Val Ala Ala Gly Gly Tyr Lys Val 275 280 72 285 PRT Phleum pratense 72 Ala Asp Leu Gly Tyr Gly Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 1 5 10 15 Tyr Thr Pro Ala Thr Pro Ala Ala Pro Ala Gly Ala Asp Ala Ala Gly 20 25 30 Lys Ala Thr Thr Glu Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly 35 40 45 Phe Lys Ala Ala Leu Ala Gly Ala Gly Val Gln Pro Ala Asp Lys Tyr 50 55 60 Arg Thr Phe Val Ala Thr Phe Gly Pro Ala Ser Asn Lys Ala Phe Ala 65 70 75 80 Glu Gly Leu Ser Gly Glu Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys 85 90 95 Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys 100 105 110 Thr Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala 115 120 125 Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His 130 135 140 Ala Val Lys Pro Ala Ala Glu Glu Val Lys Val Ile Pro Ala Gly Glu 145 150 155 160 Leu Gln Val Ile Glu Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr 165 170 175 Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala 180 185 190 Ala Phe Asn Asp Glu Ile Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser 195 200 205 Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala 210 215 220 Ala Thr Val Ala Thr Ala Pro Glu Val Lys Tyr Thr Val Phe Glu Thr 225 230 235 240 Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Glu Ala Gln Lys Ala Ala 245 250 255 Lys Pro Pro Pro Leu Pro Pro Pro Pro Gln Pro Pro Pro Leu Ala Ala 260 265 270 Thr Gly Ala Ala Thr Ala Ala Thr Gly Gly Tyr Lys Val 275 280 285 73 312 PRT Phleum pratense 73 Met Ala Val His Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Leu Gly Tyr Gly Pro 20 25 30 Ala Thr Pro Ala Ala Pro Ala Ala Gly Tyr Thr Pro Ala Thr Pro Ala 35 40 45 Ala Pro Ala Glu Ala Ala Pro Ala Gly Lys Ala Thr Thr Glu Glu Gln 50 55 60 Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Leu Ala Ala 65 70 75 80 Ala Ala Gly Val Gln Pro Ala Asp Lys Tyr Arg Thr Phe Val Ala Thr 85 90 95 Phe Gly Ala Ala Ser Asn Lys Ala Phe Ala Glu Gly Leu Ser Gly Glu 100 105 110 Pro Lys Gly Ala Ala Glu Ser Ser Ser Lys Ala Ala Leu Thr Ser Lys 115 120 125 Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Thr Ala Glu Gly Ala Thr 130 135 140 Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu 145 150 155 160 Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro Ala Ala 165 170 175 Glu Glu Val Lys Val Ile Pro Ala Gly Glu Leu Gln Val Ile Glu Lys 180 185 190 Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro 195 200 205 Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile 210 215 220 Lys Ala Ser Thr Gly Gly Ala Tyr Glu Ser Tyr Lys Phe Ile Pro Ala 225 230 235 240 Leu Glu Ala Ala Val Lys Gln Ala Tyr Ala Ala Thr Val Ala Thr Ala 245 250 255 Pro Glu Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile 260 265 270 Thr Ala Met Ser Glu Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala 275 280 285 Thr Ala Thr Ala Thr Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr 290 295 300 Ala Ala Thr Gly Gly Tyr Lys Val 305 310 74 138 PRT Phleum pratense 74 Met Ala Ala His Lys Phe Met Val Ala Met Phe Leu Ala Val Ala Val 1 5 10 15 Val Leu Gly Leu Ala Thr Ser Pro Thr Ala Glu Gly Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Asp Val Asn Ala Ser Phe Arg Ala 35 40 45 Ala Met Ala Thr Thr Ala Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr 50 55 60 Phe Glu Ala Ala Phe Thr Val Ser Ser Lys Arg Asn Leu Ala Asp Ala 65 70 75 80 Val Ser Lys Ala Pro Gln Leu Val Pro Lys Leu Asp Glu Val Tyr Asn 85 90 95 Ala Ala Tyr Asn Ala Ala Asp His Ala Ala Pro Glu Asp Lys Tyr Glu 100 105 110 Ala Phe Val Leu His Phe Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr 115 120 125 Pro Glu Val His Ala Val Lys Pro Gly Ala 130 135 75 57 PRT Phleum pratense 75 Ser Lys Ala Pro Gln Leu Val Pro Lys Leu Asp Glu Val Tyr Asn Ala 1 5 10 15 Ala Tyr Asn Ala Ala Asp His Ala Ala Pro Glu Asp Lys Tyr Glu Ala 20 25 30 Phe Val Leu His Phe Ser Glu Ala Leu His Ile Ile Ala Gly Thr Pro 35 40 45 Glu Val His Ala Val Lys Pro Gly Ala 50 55 76 80 PRT Phleum pratense 76 Ala Asp Lys Tyr Lys Thr Phe Glu Ala Ala Phe Thr Val Ser Ser Lys 1 5 10 15 Arg Asn Leu Ala Asp Ala Val Ser Lys Ala Pro Gln Leu Val Pro Lys 20 25 30 Leu Asp Glu Val Tyr Asn Ala Ala Tyr Asn Ala Ala Asp His Ala Ala 35 40 45 Pro Glu Asp Lys Tyr Glu Ala Phe Val Leu His Phe Ser Glu Ala Leu 50 55 60 His Ile Ile Ala Gly Thr Pro Glu Val His Ala Val Lys Pro Gly Ala 65 70 75 80 77 106 PRT Phleum pratense 77 Thr Glu Glu Gln Lys Leu Ile Glu Asp Val Asn Ala Ser Phe Arg Ala 1 5 10 15 Ala Met Ala Thr Thr Ala Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr 20 25 30 Leu Glu Ala Ala Phe Thr Val Ser Ser Lys Arg Asn Leu Ala Asp Ala 35 40 45 Val Ser Lys Ala Pro Gln Leu Val Pro Lys Leu Asp Glu Val Tyr Asn 50 55 60 Ala Ala Tyr Asn Ala Ala Asp His Ala Ala Pro Glu Asp Lys Tyr Glu 65 70 75 80 Ala Phe Val Leu His Phe Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr 85 90 95 Pro Glu Val His Ala Val Lys Pro Gly Ala 100 105 78 138 PRT Phleum pratense 78 Met Ala Ala His Lys Phe Met Val Ala Met Phe Leu Ala Val Ala Val 1 5 10 15 Val Leu Gly Leu Ala Thr Ser Pro Thr Ala Glu Gly Gly Lys Ala Thr 20 25 30 Thr Glu Glu Gln Lys Leu Ile Glu Asp Ile Asn Ala Ser Phe Arg Ala 35 40 45 Ala Met Ala Thr Thr Ala Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr 50 55 60 Phe Glu Ala Ala Phe Thr Val Ser Ser Lys Arg Asn Leu Ala Asp Ala 65 70 75 80 Val Ser Lys Ala Pro Gln Leu Val Pro Lys Leu Asp Glu Val Tyr Asn 85 90 95 Ala Ala Tyr Asn Ala Ala Asp His Ala Ala Pro Glu Asp Lys Tyr Glu 100 105 110 Ala Phe Val Leu His Phe Ser Glu Ala Leu His Ile Ile Ala Gly Thr 115 120 125 Pro Glu Val His Ala Val Lys Pro Gly Ala 130 135 79 132 PRT Phleum pratense 79 Met Val Ala Met Phe Leu Ala Val Ala Val Val Leu Gly Leu Ala Thr 1 5 10 15 Ser Pro Thr Ala Glu Gly Gly Lys Ala Thr Thr Glu Glu Gln Lys Leu 20 25 30 Ile Glu Asp Val Asn Ala Ser Phe Arg Ala Ala Met Ala Thr Thr Ala 35 40 45 Asn Val Pro Pro Ala Asp Lys Tyr Lys Thr Phe Glu Ala Ala Phe Thr 50 55 60 Val Ser Ser Lys Arg Asn Leu Ala Asp Ala Val Ser Lys Ala Pro Gln 65 70 75 80 Leu Val Pro Lys Leu Asp Glu Val Tyr Asn Ala Ala Tyr Asn Ala Ala 85 90 95 Asp His Ala Ala Pro Glu Asp Lys Tyr Glu Ala Phe Val Leu His Phe 100 105 110 Ser Glu Ala Leu Arg Ile Ile Ala Gly Thr Pro Glu Val His Ala Val 115 120 125 Lys Pro Gly Ala 130 80 78 PRT Phleum pratense 80 Met Ala Asp Asp Met Glu Arg Ile Phe Lys Arg Phe Asp Thr Asn Gly 1 5 10 15 Asp Gly Lys Ile Ser Leu Ser Glu Leu Thr Asp Ala Leu Arg Thr Leu 20 25 30 Gly Ser Thr Ser Ala Asp Glu Val Gln Arg Met Met Ala Glu Ile Asp 35 40 45 Thr Asp Gly Asp Gly Phe Ile Asp Phe Asn Glu Phe Ile Ser Phe Cys 50 55 60 Asn Ala Asn Pro Gly Leu Met Lys Asp Val Ala Lys Val Phe 65 70 75 81 131 PRT Phleum pratense 81 Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Glu Ile Glu 1 5 10 15 Gly His His Leu Ala Ser Ala Ala Ile Leu Gly His Asp Gly Thr Val 20 25 30 Trp Ala Gln Ser Ala Asp Phe Pro Gln Phe Lys Pro Glu Glu Ile Thr 35 40 45 Gly Ile Met Lys Asp Phe Asp Glu Pro Gly His Leu Ala Pro Thr Gly 50 55 60 Met Phe Val Ala Gly Ala Lys Tyr Met Val Ile Gln Gly Glu Pro Gly 65 70 75 80 Arg Val Ile Arg Gly Lys Lys Gly Ala Gly Gly Ile Thr Ile Lys Lys 85 90 95 Thr Gly Gln Ala Leu Val Val Gly Ile Tyr Asp Glu Pro Met Thr Pro 100 105 110 Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu Val Glu 115 120 125 Gln Gly Met 130 82 227 PRT Vespula vulgaris 82 Met Glu Ile Ser Gly Leu Val Tyr Leu Ile Ile Ile Val Thr Ile Ile 1 5 10 15 Asp Leu Pro Tyr Gly Lys Ala Asn Asn Tyr Cys Lys Ile Lys Cys Leu 20 25 30 Lys Gly Gly Val His Thr Ala Cys Lys Tyr Gly Ser Leu Lys Pro Asn 35 40 45 Cys Gly Asn Lys Val Val Val Ser Tyr Gly Leu Thr Lys Gln Glu Lys 50 55 60 Gln Asp Ile Leu Lys Glu His Asn Asp Phe Arg Gln Lys Ile Ala Arg 65 70 75 80 Gly Leu Glu Thr Arg Gly Asn Pro Gly Pro Gln Pro Pro Ala Lys Asn 85 90 95 Met Lys Asn Leu Val Trp Asn Asp Glu Leu Ala Tyr Val Ala Gln Val 100 105 110 Trp Ala Asn Gln Cys Gln Tyr Gly His Asp Thr Cys Arg Asp Val Ala 115 120 125 Lys Tyr Gln Val Gly Gln Asn Val Ala Leu Thr Gly Ser Thr Ala Ala 130 135 140 Lys Tyr Asp Asp Pro Val Lys Leu Val Lys Met Trp Glu Asp Glu Val 145 150 155 160 Lys Asp Tyr Asn Pro Lys Lys Lys Phe Ser Gly Asn Asp Phe Leu Lys 165 170 175 Thr Gly His Tyr Thr Gln Met Val Trp Ala Asn Thr Lys Glu Val Gly 180 185 190 Cys Gly Ser Ile Lys Tyr Ile Gln Glu Lys Trp His Lys His Tyr Leu 195 200 205 Val Cys Asn Tyr Gly Pro Ser Gly Asn Phe Met Asn Glu Glu Leu Tyr 210 215 220 Gln Thr Lys 225 83 300 PRT Vespula maculifrons 83 Gly Pro Lys Cys Pro Phe Asn Ser Asp Thr Val Ser Ile Ile Ile Glu 1 5 10 15 Thr Arg Glu Asn Arg Asn Arg Asp Leu Tyr Thr Leu Gln Thr Leu Gln 20 25 30 Asn His Pro Glu Phe Lys Lys Lys Thr Ile Thr Arg Pro Val Val Phe 35 40 45 Ile Thr His Gly Phe Thr Ser Ser Ala Ser Glu Lys Asn Phe Ile Asn 50 55 60 Leu Ala Lys Ala Leu Val Asp Lys Asp Asn Tyr Met Val Ile Ser Ile 65 70 75 80 Asp Trp Gln Thr Ala Ala Cys Thr Asn Glu Tyr Pro Gly Leu Lys Tyr 85 90 95 Ala Tyr Tyr Pro Thr Ala Ala Ser Asn Thr Arg Leu Val Gly Gln Tyr 100 105 110 Ile Ala Thr Ile Thr Gln Lys Leu Val Lys Asp Tyr Lys Ile Ser Met 115 120 125 Ala Asn Ile Arg Leu Ile Gly His Ser Leu Gly Ala His Val Ser Gly 130 135 140 Phe Ala Gly Lys Arg Val Gln Glu Leu Lys Leu Gly Lys Tyr Ser Glu 145 150 155 160 Ile Ile Gly Leu Asp Pro Ala Arg Pro Ser Phe Asp Ser Asn His Cys 165 170 175 Ser Glu Arg Leu Cys Glu Thr Asp Ala Glu Tyr Val Gln Ile Ile His 180 185 190 Thr Ser Asn Tyr Leu Gly Thr Glu Lys Ile Leu Gly Thr Val Asp Phe 195 200 205 Tyr Met Asn Asn Gly Lys Asn Asn Pro Gly Cys Gly Arg Phe Phe Ser 210 215 220 Glu Val Cys Ser His Thr Arg Ala Val Ile Tyr Met Ala Glu Cys Ile 225 230 235 240 Lys His Glu Cys Cys Leu Ile Gly Ile Pro Arg Ser Lys Ser Ser Gln 245 250 255 Pro Ile Ser Arg Cys Thr Lys Gln Glu Cys Val Cys Val Gly Leu Asn 260 265 270 Ala Lys Lys Tyr Pro Ser Arg Gly Ser Phe Tyr Val Pro Val Glu Ser 275 280 285 Thr Ala Pro Phe Cys Asn Asn Lys Gly Lys Ile Ile 290 295 300 84 336 PRT Vespula vulgaris 84 Met Glu Glu Asn Met Asn Leu Lys Tyr Leu Leu Leu Phe Val Tyr Phe 1 5 10 15 Val Gln Val Leu Asn Cys Cys Tyr Gly His Gly Asp Pro Leu Ser Tyr 20 25 30 Glu Leu Asp Arg Gly Pro Lys Cys Pro Phe Asn Ser Asp Thr Val Ser 35 40 45 Ile Ile Ile Glu Thr Arg Glu Asn Arg Asn Arg Asp Leu Tyr Thr Leu 50 55 60 Gln Thr Leu Gln Asn His Pro Glu Phe Lys Lys Lys Thr Ile Thr Arg 65 70 75 80 Pro Val Val Phe Ile Thr His Gly Phe Thr Ser Ser Ala Ser Glu Thr 85 90 95 Asn Phe Ile Asn Leu Ala Lys Ala Leu Val Asp Lys Asp Asn Tyr Met 100 105 110 Val Ile Ser Ile Asp Trp Gln Thr Ala Ala Cys Thr Asn Glu Ala Ala 115 120 125 Gly Leu Lys Tyr Leu Tyr Tyr Pro Thr Ala Ala Arg Asn Thr Arg Leu 130 135 140 Val Gly Gln Tyr Ile Ala Thr Ile Thr Gln Lys Leu Val Lys His Tyr 145 150 155 160 Lys Ile Ser Met Ala Asn Ile Arg Leu Ile Gly His Ser Leu Gly Ala 165 170 175 His Ala Ser Gly Phe Ala Gly Lys Lys Val Gln Glu Leu Lys Leu Gly 180 185 190 Lys Tyr Ser Glu Ile Ile Gly Leu Asp Pro Ala Arg Pro Ser Phe Asp 195 200 205 Ser Asn His Cys Ser Glu Arg Leu Cys Glu Thr Asp Ala Glu Tyr Val 210 215 220 Gln Ile Ile His Thr Ser Asn Tyr Leu Gly Thr Glu Lys Thr Leu Gly 225 230 235 240 Thr Val Asp Phe Tyr Met Asn Asn Gly Lys Asn Gln Pro Gly Cys Gly 245 250 255 Arg Phe Phe Ser Glu Val Cys Ser His Ser Arg Ala Val Ile Tyr Met 260 265 270 Ala Glu Cys Ile Lys His Glu Cys Cys Leu Ile Gly Ile Pro Lys Ser 275 280 285 Lys Ser Ser Gln Pro Ile Ser Ser Cys Thr Lys Gln Glu Cys Val Cys 290 295 300 Val Gly Leu Asn Ala Lys Lys Tyr Pro Ser Arg Gly Ser Phe Tyr Val 305 310 315 320 Pro Val Glu Ser Thr Ala Pro Phe Cys Asn Asn Lys Gly Lys Ile Ile 325 330 335 85 331 PRT Vespula vulgaris 85 Ser Glu Arg Pro Lys Arg Val Phe Asn Ile Tyr Trp Asn Val Pro Thr 1 5 10 15 Phe Met Cys His Gln Tyr Asp Leu Tyr Phe Asp Glu Val Thr Asn Phe 20 25 30 Asn Ile Lys Arg Asn Ser Lys Asp Asp Phe Gln Gly Asp Lys Ile Ala 35 40 45 Ile Phe Tyr Asp Pro Gly Glu Phe Pro Ala Leu Leu Ser Leu Lys Asp 50 55 60 Gly Lys Tyr Lys Lys Arg Asn Gly Gly Val Pro Gln Glu Gly Asn Ile 65 70 75 80 Thr Ile His Leu Gln Lys Phe Ile Glu Asn Leu Asp Lys Ile Tyr Pro 85 90 95 Asn Arg Asn Phe Ser Gly Ile Gly Val Ile Asp Phe Glu Arg Trp Arg 100 105 110 Pro Ile Phe Arg Gln Asn Trp Gly Asn Met Lys Ile His Lys Asn Phe 115 120 125 Ser Ile Asp Leu Val Arg Asn Glu His Pro Thr Trp Asn Lys Lys Met 130 135 140 Ile Glu Leu Glu Ala Ser Lys Arg Phe Glu Lys Tyr Ala Arg Phe Phe 145 150 155 160 Met Glu Glu Thr Leu Lys Leu Ala Lys Lys Thr Arg Lys Gln Ala Asp 165 170 175 Trp Gly Tyr Tyr Gly Tyr Pro Tyr Cys Phe Asn Met Ser Pro Asn Asn 180 185 190 Leu Val Pro Glu Cys Asp Val Thr Ala Met His Glu Asn Asp Lys Met 195 200 205 Ser Trp Leu Phe Asn Asn Gln Asn Val Leu Leu Pro Ser Val Tyr Val 210 215 220 Arg Gln Glu Leu Thr Pro Asp Gln Arg Ile Gly Leu Val Gln Gly Arg 225 230 235 240 Val Lys Glu Ala Val Arg Ile Ser Asn Asn Leu Lys His Ser Pro Lys 245 250 255 Val Leu Ser Tyr Trp Trp Tyr Val Tyr Gln Asp Glu Thr Asn Thr Phe 260 265 270 Leu Thr Glu Thr Asp Val Lys Lys Thr Phe Gln Glu Ile Val Ile Asn 275 280 285 Gly Gly Asp Gly Ile Ile Ile Trp Gly Ser Ser Ser Asp Val Asn Ser 290 295 300 Leu Ser Lys Cys Lys Arg Leu Gln Asp Tyr Leu Leu Thr Val Leu Gly 305 310 315 320 Pro Ile Ala Ile Asn Val Thr Glu Ala Val Asn 325 330 86 206 PRT Vespula vidua 86 Lys Val Asn Tyr Cys Lys Ile Lys Cys Leu Lys Gly Gly Val His Thr 1 5 10 15 Ala Cys Lys Tyr Gly Thr Ser Thr Lys Pro Asn Cys Gly Lys Met Val 20 25 30 Val Lys Ala Tyr Gly Leu Thr Glu Ala Glu Lys Gln Glu Ile Leu Lys 35 40 45 Val His Asn Asp Phe Arg Gln Lys Val Ala Lys Gly Leu Glu Thr Arg 50 55 60 Gly Asn Pro Gly Pro Gln Pro Pro Ala Lys Asn Met Asn Asn Leu Val 65 70 75 80 Trp Asn Asp Glu Leu Ala Asn Ile Ala Gln Val Trp Ala Ser Gln Cys 85 90 95 Asn Tyr Gly His Asp Thr Cys Lys Asp Thr Glu Lys Tyr Pro Val Gly 100 105 110 Gln Asn Ile Ala Lys Arg Ser Thr Thr Ala Ala Leu Phe Asp Ser Pro 115 120 125 Gly Lys Leu Val Lys Met Trp Glu Asn Glu Val Lys Asp Phe Asn Pro 130 135 140 Asn Ile Glu Trp Ser Lys Asn Asn Leu Lys Lys Thr Gly His Tyr Thr 145 150 155 160 Gln Met Val Trp Ala Lys Thr Lys Glu Ile Gly Cys Gly Ser Val Lys 165 170 175 Tyr Val Lys Asp Glu Trp Tyr Thr His Tyr Leu Val Cys Asn Tyr Gly 180 185 190 Pro Ser Gly Asn Phe Arg Asn Glu Lys Leu Tyr Glu Lys Lys 195 200 205 87 160 PRT Betula pendula 87 Met Gly Val Phe Asn Tyr Glu Thr Glu Thr Thr Ser Val Ile Pro Ala 1 5 10 15 Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly Asp Asn Leu Phe Pro 20 25 30 Lys Val Ala Pro Gln Ala Ile Ser Ser Val Glu Asn Ile Glu Gly Asn 35 40 45 Gly Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Pro Glu Gly Phe Pro 50 55 60 Phe Lys Tyr Val Lys Asp Arg Val Asp Glu Val Asp His Thr Asn Phe 65 70 75 80 Lys Tyr Asn Tyr Ser Val Ile Glu Gly Gly Pro Ile Gly Asp Thr Leu 85 90 95 Glu Lys Ile Ser Asn Glu Ile Lys Ile Val Ala Thr Pro Asp Gly Gly 100 105 110 Ser Ile Leu Lys Ile Ser Asn Lys Tyr His Thr Lys Gly Asp His Glu 115 120 125 Val Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu 130 135 140 Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn 145 150 155 160 88 133 PRT Betula pendula 88 Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp 1 5 10 15 Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly 20 25 30 Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu 35 40 45 Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro 50 55 60 Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu 65 70 75 80 Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile 85 90 95 Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val 100 105 110 Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu 115 120 125 Ile Asp Gln Gly Leu 130 89 205 PRT Betula pendula 89 Met Pro Cys Ser Thr Glu Ala Met Glu Lys Ala Gly His Gly His Ala 1 5 10 15 Ser Thr Pro Arg Lys Arg Ser Leu Ser Asn Ser Ser Phe Arg Leu Arg 20 25 30 Ser Glu Ser Leu Asn Thr Leu Arg Leu Arg Arg Ile Phe Asp Leu Phe 35 40 45 Asp Lys Asn Ser Asp Gly Ile Ile Thr Val Asp Glu Leu Ser Arg Ala 50 55 60 Leu Asn Leu Leu Gly Leu Glu Thr Asp Leu Ser Glu Leu Glu Ser Thr 65 70 75 80 Val Lys Ser Phe Thr Arg Glu Gly Asn Ile Gly Leu Gln Phe Glu Asp 85 90 95 Phe Ile Ser Leu His Gln Ser Leu Asn Asp Ser Tyr Phe Ala Tyr Gly 100 105 110 Gly Glu Asp Glu Asp Asp Asn Glu Glu Asp Met Arg Lys Ser Ile Leu 115 120 125 Ser Gln Glu Glu Ala Asp Ser Phe Gly Gly Phe Lys Val Phe Asp Glu 130 135 140 Asp Gly Asp Gly Tyr Ile Ser Ala Arg Glu Leu Gln Met Val Leu Gly 145 150 155 160 Lys Leu Gly Phe Ser Glu Gly Ser Glu Ile Asp Arg Val Glu Lys Met 165 170 175 Ile Val Ser Val Asp Ser Asn Arg Asp Gly Arg Val Asp Phe Phe Glu 180 185 190 Phe Lys Asp Met Met Arg Ser Val Leu Val Arg Ser Ser 195 200 205 90 85 PRT Betula pendula 90 Met Ala Asp Asp His Pro Gln Asp Lys Ala Glu Arg Glu Arg Ile Phe 1 5 10 15 Lys Arg Phe Asp Ala Asn Gly Asp Gly Lys Ile Ser Ala Ala Glu Leu 20 25 30 Gly Glu Ala Leu Lys Thr Leu Gly Ser Ile Thr Pro Asp Glu Val Lys 35 40 45 His Met Met Ala Glu Ile Asp Thr Asp Gly Asp Gly Phe Ile Ser Phe 50 55 60 Gln Glu Phe Thr Asp Phe Gly Arg Ala Asn Arg Gly Leu Leu Lys Asp 65 70 75 80 Val Ala Lys Ile Phe 85 91 24 PRT Quercus alba misc_feature X is unknown amino acid 91 Gly Val Phe Thr Xaa Glu Ser Gln Glu Thr Ser Val Ile Ala Pro Ala 1 5 10 15 Xaa Leu Phe Lys Ala Leu Phe Leu 20 92 40 PRT Carpinus betulus misc_feature X is unknown amino acid 92 Gly Val Phe Asn Tyr Glu Ala Glu Thr Pro Ser Val Ile Pro Ala Ala 1 5 10 15 Arg Leu Phe Lys Ser Tyr Val Leu Asp Gly Asp Lys Leu Ile Pro Lys 20 25 30 Val Ala Pro Gln Ala Ile Xaa Lys 35 40 93 44 PRT Alnus glutinosa 93 Gly Val Phe Asn Tyr Glu Ala Glu Thr Pro Ser Val Ile Pro Ala Ala 1 5 10 15 Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly Asp Lys Leu Leu Pro Lys 20 25 30 Val Ala Pro Glu Ala Val Ser Ser Val Glu Asn Ile 35 40 94 110 PRT Betula pendula 94 Val Gln Cys Met Gln Val Trp Pro Pro Leu Gly Leu Lys Lys Phe Glu 1 5 10 15 Thr Leu Ser Tyr Leu Pro Pro Leu Ser Ser Glu Gln Leu Ala Lys Glu 20 25 30 Val Asp Tyr Leu Leu Arg Lys Asn Leu Ile Pro Cys Leu Glu Phe Glu 35 40 45 Leu Glu His Gly Phe Val Tyr Arg Glu His Asn Arg Ser Pro Gly Tyr 50 55 60 Tyr Asp Gly Arg Tyr Trp Thr Met Trp Lys Leu Pro Met Phe Gly Cys 65 70 75 80 Asn Asp Ser Ser Gln Val Leu Lys Glu Leu Glu Glu Cys Lys Lys Ala 85 90 95 Tyr Pro Ser Ala Phe Ile Arg Ile Ile Gly Phe Asp Asp Lys 100 105 110 95 626 PRT Arachis hypogaea 95 Met Arg Gly Arg Val Ser Pro Leu Met Leu Leu Leu Gly Ile Leu Val 1 5 10 15 Leu Ala Ser Val Ser Ala Thr His Ala Lys Ser Ser Pro Tyr Gln Lys 20 25 30 Lys Thr Glu Asn Pro Cys Ala Gln Arg Cys Leu Gln Ser Cys Gln Gln 35 40 45 Glu Pro Asp Asp Leu Lys Gln Lys Ala Cys Glu Ser Arg Cys Thr Lys 50 55 60 Leu Glu Tyr Asp Pro Arg Cys Val Tyr Asp Pro Arg Gly His Thr Gly 65 70 75 80 Thr Thr Asn Gln Arg Ser Pro Pro Gly Glu Arg Thr Arg Gly Arg Gln 85 90 95 Pro Gly Asp Tyr Asp Asp Asp Arg Arg Gln Pro Arg Arg Glu Glu Gly 100 105 110 Gly Arg Trp Gly Pro Ala Gly Pro Arg Glu Arg Glu Arg Glu Glu Asp 115 120 125 Trp Arg Gln Pro Arg Glu Asp Trp Arg Arg Pro Ser His Gln Gln Pro 130 135 140 Arg Lys Ile Arg Pro Glu Gly Arg Glu Gly Glu Gln Glu Trp Gly Thr 145 150 155 160 Pro Gly Ser His Val Arg Glu Glu Thr Ser Arg Asn Asn Pro Phe Tyr 165 170 175 Phe Pro Ser Arg Arg Phe Ser Thr Arg Tyr Gly Asn Gln Asn Gly Arg 180 185 190 Ile Arg Val Leu Gln Arg Phe Asp Gln Arg Ser Arg Gln Phe Gln Asn 195 200 205 Leu Gln Asn His Arg Ile Val Gln Ile Glu Ala Lys Pro Asn Thr Leu 210 215 220 Val Leu Pro Lys His Ala Asp Ala Asp Asn Ile Leu Val Ile Gln Gln 225 230 235 240 Gly Gln Ala Thr Val Thr Val Ala Asn Gly Asn Asn Arg Lys Ser Phe 245 250 255 Asn Leu Asp Glu Gly His Ala Leu Arg Ile Pro Ser Gly Phe Ile Ser 260 265 270 Tyr Ile Leu Asn Arg His Asp Asn Gln Asn Leu Arg Val Ala Lys Ile 275 280 285 Ser Met Pro Val Asn Thr Pro Gly Gln Phe Glu Asp Phe Phe Pro Ala 290 295 300 Ser Ser Arg Asp Gln Ser Ser Tyr Leu Gln Gly Phe Ser Arg Asn Thr 305 310 315 320 Leu Glu Ala Ala Phe Asn Ala Glu Phe Asn Glu Ile Arg Arg Val Leu 325 330 335 Leu Glu Glu Asn Ala Gly Gly Glu Gln Glu Glu Arg Gly Gln Arg Arg 340 345 350 Trp Ser Thr Arg Ser Ser Glu Asn Asn Glu Gly Val Ile Val Lys Val 355 360 365 Ser Lys Glu His Val Glu Glu Leu Thr Lys His Ala Lys Ser Val Ser 370 375 380 Lys Lys Gly Ser Glu Glu Glu Gly Asp Ile Thr Asn Pro Ile Asn Leu 385 390 395 400 Arg Glu Gly Glu Pro Asp Leu Ser Asn Asn Phe Gly Lys Leu Phe Glu 405 410 415 Val Lys Pro Asp Lys Lys Asn Pro Gln Leu Gln Asp Leu Asp Met Met 420 425 430 Leu Thr Cys Val Glu Ile Lys Glu Gly Ala Leu Met Leu Pro His Phe 435 440 445 Asn Ser Lys Ala Met Val Ile Val Val Val Asn Lys Gly Thr Gly Asn 450 455 460 Leu Glu Leu Val Ala Val Arg Lys Glu Gln Gln Gln Arg Gly Arg Arg 465 470 475 480 Glu Glu Glu Glu Asp Glu Asp Glu Glu Glu Glu Gly Ser Asn Arg Glu 485 490 495 Val Arg Arg Tyr Thr Ala Arg Leu Lys Glu Gly Asp Val Phe Ile Met 500 505 510 Pro Ala Ala His Pro Val Ala Ile Asn Ala Ser Ser Glu Leu His Leu 515 520 525 Leu Gly Phe Gly Ile Asn Ala Glu Asn Asn His Arg Ile Phe Leu Ala 530 535 540 Gly Asp Lys Asp Asn Val Ile Asp Gln Ile Glu Lys Gln Ala Lys Asp 545 550 555 560 Leu Ala Phe Pro Gly Ser Gly Glu Gln Val Glu Lys Leu Ile Lys Asn 565 570 575 Gln Lys Glu Ser His Phe Val Ser Ala Arg Pro Gln Ser Gln Ser Gln 580 585 590 Ser Pro Ser Ser Pro Glu Lys Glu Ser Pro Glu Lys Glu Asp Gln Glu 595 600 605 Glu Glu Asn Gln Gly Gly Lys Gly Pro Leu Leu Ser Ile Leu Lys Ala 610 615 620 Phe Asn 625 96 392 PRT Ambrosia artemisiifolia 96 Met Gly Ile Lys His Cys Cys Tyr Ile Leu Tyr Phe Thr Leu Ala Leu 1 5 10 15 Val Thr Leu Leu Gln Pro Val Arg Ser Ala Glu Asp Leu Gln Gln Ile 20 25 30 Leu Pro Ser Ala Asn Glu Thr Arg Ser Leu Thr Thr Cys Gly Thr Tyr 35 40 45 Asn Ile Ile Asp Gly Cys Trp Arg Gly Lys Ala Asp Trp Ala Glu Asn 50 55 60 Arg Lys Ala Leu Ala Asp Cys Ala Gln Gly Phe Ala Lys Gly Thr Ile 65 70 75 80 Gly Gly Lys Asp Gly Asp Ile Tyr Thr Val Thr Ser Glu Leu Asp Asp 85 90 95 Asp Val Ala Asn Pro Lys Glu Gly Thr Leu Arg Phe Gly Ala Ala Gln 100 105 110 Asn Arg Pro Leu Trp Ile Ile Phe Ala Arg Asp Met Val Ile Arg Leu 115 120 125 Asp Arg Glu Leu Ala Ile Asn Asn Asp Lys Thr Ile Asp Gly Arg Gly 130 135 140 Ala Lys Val Glu Ile Ile Asn Ala Gly Phe Ala Ile Tyr Asn Val Lys 145 150 155 160 Asn Ile Ile Ile His Asn Ile Ile Met His Asp Ile Val Val Asn Pro 165 170 175 Gly Gly Leu Ile Lys Ser His Asp Gly Pro Pro Val Pro Arg Lys Gly 180 185 190 Ser Asp Gly Asp Ala Ile Gly Ile Ser Gly Gly Ser Gln Ile Trp Ile 195 200 205 Asp His Cys Ser Leu Ser Lys Ala Val Asp Gly Leu Ile Asp Ala Lys 210 215 220 His Gly Ser Thr His Phe Thr Val Ser Asn Cys Leu Phe Thr Gln His 225 230 235 240 Gln Tyr Leu Leu Leu Phe Trp Asp Phe Asp Glu Arg Gly Met Leu Cys 245 250 255 Thr Val Ala Phe Asn Lys Phe Thr Asp Asn Val Asp Gln Arg Met Pro 260 265 270 Asn Leu Arg His Gly Phe Val Gln Val Val Asn Asn Asn Tyr Glu Arg 275 280 285 Trp Gly Ser Tyr Ala Leu Gly Gly Ser Ala Gly Pro Thr Ile Leu Ser 290 295 300 Gln Gly Asn Arg Phe Leu Ala Ser Asp Ile Lys Lys Glu Val Val Gly 305 310 315 320 Arg Tyr Gly Glu Ser Ala Met Ser Glu Ser Ile Asn Trp Asn Trp Arg 325 330 335 Ser Tyr Met Asp Val Phe Glu Asn Gly Ala Ile Phe Val Pro Ser Gly 340 345 350 Val Asp Pro Val Leu Thr Pro Glu Gln Asn Ala Gly Met Ile Pro Ala 355 360 365 Glu Pro Gly Glu Ala Val Leu Arg Leu Thr Ser Ser Ala Gly Val Leu 370 375 380 Ser Cys Gln Pro Gly Ala Pro Cys 385 390 97 397 PRT Ambrosia artemisiifolia 97 Met Gly Ile Lys His Cys Cys Tyr Ile Leu Tyr Phe Thr Leu Ala Leu 1 5 10 15 Val Thr Leu Val Gln Ala Gly Arg Leu Gly Glu Glu Val Asp Ile Leu 20 25 30 Pro Ser Pro Asn Asp Thr Arg Arg Ser Leu Gln Gly Cys Glu Ala His 35 40 45 Asn Ile Ile Asp Lys Cys Trp Arg Cys Lys Pro Asp Trp Ala Glu Asn 50 55 60 Arg Gln Ala Leu Gly Asn Cys Ala Gln Gly Phe Gly Lys Ala Thr His 65 70 75 80 Gly Gly Lys Trp Gly Asp Ile Tyr Met Val Thr Ser Asp Gln Asp Asp 85 90 95 Asp Val Val Asn Pro Lys Glu Gly Thr Leu Arg Phe Gly Ala Thr Gln 100 105 110 Asp Arg Pro Leu Trp Ile Ile Phe Gln Arg Asp Met Ile Ile Tyr Leu 115 120 125 Gln Gln Glu Met Val Val Thr Ser Asp Lys Thr Ile Asp Gly Arg Gly 130 135 140 Ala Lys Val Glu Leu Val Tyr Gly Gly Ile Thr Leu Met Asn Val Lys 145 150 155 160 Asn Val Ile Ile His Asn Ile Asp Ile His Asp Val Arg Val Leu Pro 165 170 175 Gly Gly Arg Ile Lys Ser Asn Gly Gly Pro Ala Ile Pro Arg His Gln 180 185 190 Ser Asp Gly Asp Ala Ile His Val Thr Gly Ser Ser Asp Ile Trp Ile 195 200 205 Asp His Cys Thr Leu Ser Lys Ser Phe Asp Gly Leu Val Asp Val Asn 210 215 220 Trp Gly Ser Thr Gly Val Thr Ile Ser Asn Cys Lys Phe Thr His His 225 230 235 240 Glu Lys Ala Val Leu Leu Gly Ala Ser Asp Thr His Phe Gln Asp Leu 245 250 255 Lys Met His Val Thr Leu Ala Tyr Asn Ile Phe Thr Asn Thr Val His 260 265 270 Glu Arg Met Pro Arg Cys Arg Phe Gly Phe Phe Gln Ile Val Asn Asn 275 280 285 Phe Tyr Asp Arg Trp Asp Lys Tyr Ala Ile Gly Gly Ser Ser Asn Pro 290 295 300 Thr Ile Leu Ser Gln Gly Asn Lys Phe Val Ala Pro Asp Phe Ile Tyr 305 310 315 320 Lys Lys Asn Val Cys Leu Arg Thr Gly Ala Gln Glu Pro Glu Trp Met 325 330 335 Thr Trp Asn Trp Arg Thr Gln Asn Asp Val Leu Glu Asn Gly Ala Ile 340 345 350 Phe Val Ala Ser Gly Ser Asp Pro Val Leu Thr Ala Glu Gln Asn Ala 355 360 365 Gly Met Met Gln Ala Glu Pro Gly Asp Met Val Pro Gln Leu Thr Met 370 375 380 Asn Ala Gly Val Leu Thr Cys Ser Pro Gly Ala Pro Cys 385 390 395 98 397 PRT Ambrosia artemisiifolia 98 Met Gly Ile Lys Gln Cys Cys Tyr Ile Leu Tyr Phe Thr Leu Ala Leu 1 5 10 15 Val Ala Leu Leu Gln Pro Val Arg Ser Ala Glu Gly Val Gly Glu Ile 20 25 30 Leu Pro Ser Val Asn Glu Thr Arg Ser Leu Gln Ala Cys Glu Ala Leu 35 40 45 Asn Ile Ile Asp Lys Cys Trp Arg Gly Lys Ala Asp Trp Glu Asn Asn 50 55 60 Arg Gln Ala Leu Ala Asp Cys Ala Gln Gly Phe Ala Lys Gly Thr Tyr 65 70 75 80 Gly Gly Lys Trp Gly Asp Val Tyr Thr Val Thr Ser Asn Leu Asp Asp 85 90 95 Asp Val Ala Asn Pro Lys Glu Gly Thr Leu Arg Phe Ala Ala Ala Gln 100 105 110 Asn Arg Pro Leu Trp Ile Ile Phe Lys Asn Asp Met Val Ile Asn Leu 115 120 125 Asn Gln Glu Leu Val Val Asn Ser Asp Lys Thr Ile Asp Gly Arg Gly 130 135 140 Val Lys Val Glu Ile Ile Asn Gly Gly Leu Thr Leu Met Asn Val Lys 145 150 155 160 Asn Ile Ile Ile His Asn Ile Asn Ile His Asp Val Lys Val Leu Pro 165 170 175 Gly Gly Met Ile Lys Ser Asn Asp Gly Pro Pro Ile Leu Arg Gln Ala 180 185 190 Ser Asp Gly Asp Thr Ile Asn Val Ala Gly Ser Ser Gln Ile Trp Ile 195 200 205 Asp His Cys Ser Leu Ser Lys Ser Phe Asp Gly Leu Val Asp Val Thr 210 215 220 Leu Gly Ser Thr His Val Thr Ile Ser Asn Cys Lys Phe Thr Gln Gln 225 230 235 240 Ser Lys Ala Ile Leu Leu Gly Ala Asp Asp Thr His Val Gln Asp Lys 245 250 255 Gly Met Leu Ala Thr Val Ala Phe Asn Met Phe Thr Asp Asn Val Asp 260 265 270 Gln Arg Met Pro Arg Cys Arg Phe Gly Phe Phe Gln Val Val Asn Asn 275 280 285 Asn Tyr Asp Arg Trp Gly Thr Tyr Ala Ile Gly Gly Ser Ser Ala Pro 290 295 300 Thr Ile Leu Cys Gln Gly Asn Arg Phe Leu Ala Pro Asp Asp Gln Ile 305 310 315 320 Lys Lys Asn Val Leu Ala Arg Thr Gly Thr Gly Ala Ala Glu Ser Met 325 330 335 Ala Trp Asn Trp Arg Ser Asp Lys Asp Leu Leu Glu Asn Gly Ala Ile 340 345 350 Phe Val Thr Ser Gly Ser Asp Pro Val Leu Thr Pro Val Gln Ser Ala 355 360 365 Gly Met Ile Pro Ala Glu Pro Gly Glu Ala Ala Ile Lys Leu Thr Ser 370 375 380 Ser Ala Gly Val Phe Ser Cys His Pro Gly Ala Pro Cys 385 390 395 99 398 PRT Ambrosia artemisiifolia 99 Met Gly Ile Lys His Cys Cys Tyr Ile Leu Tyr Phe Thr Leu Ala Leu 1 5 10 15 Val Thr Leu Leu Gln Pro Val Arg Ser Ala Glu Asp Val Glu Glu Phe 20 25 30 Leu Pro Ser Ala Asn Glu Thr Arg Arg Ser Leu Lys Ala Cys Glu Ala 35 40 45 His Asn Ile Ile Asp Lys Cys Trp Arg Cys Lys Ala Asp Trp Ala Asn 50 55 60 Asn Arg Gln Ala Leu Ala Asp Cys Ala Gln Gly Phe Ala Lys Gly Thr 65 70 75 80 Tyr Gly Gly Lys His Gly Asp Val Tyr Thr Val Thr Ser Asp Lys Asp 85 90 95 Asp Asp Val Ala Asn Pro Lys Glu Gly Thr Leu Arg Phe Ala Ala Ala 100 105 110 Gln Asn Arg Pro Leu Trp Ile Ile Phe Lys Arg Asn Met Val Ile His 115 120 125 Leu Asn Gln Glu Leu Val Val Asn Ser Asp Lys Thr Ile Asp Gly Arg 130 135 140 Gly Val Lys Val Asn Ile Val Asn Ala Gly Leu Thr Leu Met Asn Val 145 150 155 160 Lys Asn Ile Ile Ile His Asn Ile Asn Ile His Asp Ile Lys Val Cys 165 170 175 Pro Gly Gly Met Ile Lys Ser Asn Asp Gly Pro Pro Ile Leu Arg Gln 180 185 190 Gln Ser Asp Gly Asp Ala Ile Asn Val Ala Gly Ser Ser Gln Ile Trp 195 200 205 Ile Asp His Cys Ser Leu Ser Lys Ala Ser Asp Gly Leu Leu Asp Ile 210 215 220 Thr Leu Gly Ser Ser His Val Thr Val Ser Asn Cys Lys Phe Thr Gln 225 230 235 240 His Gln Phe Val Leu Leu Leu Gly Ala Asp Asp Thr His Tyr Gln Asp 245 250 255 Lys Gly Met Leu Ala Thr Val Ala Phe Asn Met Phe Thr Asp His Val 260 265 270 Asp Gln Arg Met Pro Arg Cys Arg Phe Gly Phe Phe Gln Val Val Asn 275 280 285 Asn Asn Tyr Asp Arg Trp Gly Thr Tyr Ala Ile Gly Gly Ser Ser Ala 290 295 300 Pro Thr Ile Leu Ser Gln Gly Asn Arg Phe Phe Ala Pro Asp Asp Ile 305 310 315 320 Ile Lys Lys Asn Val Leu Ala Arg Thr Gly Thr Gly Asn Ala Glu Ser 325 330 335 Met Ser Trp Asn Trp Arg Thr Asp Arg Asp Leu Leu Glu Asn Gly Ala 340 345 350 Ile Phe Leu Pro Ser Gly Ser Asp Pro Val Leu Thr Pro Glu Gln Lys 355 360 365 Ala Gly Met Ile Pro Ala Glu Pro Gly Glu Ala Val Leu Arg Leu Thr 370 375 380 Ser Ser Ala Gly Val Leu Ser Cys His Gln Gly Ala Pro Cys 385 390 395 100 396 PRT Ambrosia artemisiifolia 100 Met Gly Ile Lys His Cys Cys Tyr Ile Leu Tyr Phe Thr Leu Ala Leu 1 5 10 15 Val Thr Leu Leu Gln Pro Val Arg Ser Ala Glu Asp Leu Gln Glu Ile 20 25 30 Leu Pro Val Asn Glu Thr Arg Arg Leu Thr Thr Ser Gly Ala Tyr Asn 35 40 45 Ile Ile Asp Gly Cys Trp Arg Gly Lys Ala Asp Trp Ala Glu Asn Arg 50 55 60 Lys Ala Leu Ala Asp Cys Ala Gln Gly Phe Gly Lys Gly Thr Val Gly 65 70 75 80 Gly Lys Asp Gly Asp Ile Tyr Thr Val Thr Ser Glu Leu Asp Asp Asp 85 90 95 Val Ala Asn Pro Lys Glu Gly Thr Leu Arg Phe Gly Ala Ala Gln Asn 100 105 110 Arg Pro Leu Trp Ile Ile Phe Glu Arg Asp Met Val Ile Arg Leu Asp 115 120 125 Lys Glu Met Val Val Asn Ser Asp Lys Thr Ile Asp Gly Arg Gly Ala 130 135 140 Lys Val Glu Ile Ile Asn Ala Gly Phe Thr Leu Asn Gly Val Lys Asn 145 150 155 160 Val Ile Ile His Asn Ile Asn Met His Asp Val Lys Val Asn Pro Gly 165 170 175 Gly Leu Ile Lys Ser Asn Asp Gly Pro Ala Ala Pro Arg Ala Gly Ser 180 185 190 Asp Gly Asp Ala Ile Ser Ile Ser Gly Ser Ser Gln Ile Trp Ile Asp 195 200 205 His Cys Ser Leu Ser Lys Ser Val Asp Gly Leu Val Asp Ala Lys Leu 210 215 220 Gly Thr Thr Arg Leu Thr Val Ser Asn Ser Leu Phe Thr Gln His Gln 225 230 235 240 Phe Val Leu Leu Phe Gly Ala Gly Asp Glu Asn Ile Glu Asp Arg Gly 245 250 255 Met Leu Ala Thr Val Ala Phe Asn Thr Phe Thr Asp Asn Val Asp Gln 260 265 270 Arg Met Pro Arg Cys Arg His Gly Phe Phe Gln Val Val Asn Asn Asn 275 280 285 Tyr Asp Lys Trp Gly Ser Tyr Ala Ile Gly Gly Ser Ala Ser Pro Thr 290 295 300 Ile Leu Ser Gln Gly Asn Arg Phe Cys Ala Pro Asp Glu Arg Ser Lys 305 310 315 320 Lys Asn Val Leu Gly Arg His Gly Glu Ala Ala Ala Glu Ser Met Lys 325 330 335 Trp Asn Trp Arg Thr Asn Lys Asp Val Leu Glu Asn Gly Ala Ile Phe 340 345 350 Val Ala Ser Gly Val Asp Pro Val Leu Thr Pro Glu Gln Ser Ala Gly 355 360 365 Met Ile Pro Ala Glu Pro Gly Glu Ser Ala Leu Ser Leu Thr Ser Ser 370 375 380 Ala Gly Val Leu Ser Cys Gln Pro Gly Ala Pro Cys 385 390 395 101 373 PRT Cryptomeria japonica 101 Met Asp Ser Pro Cys Leu Val Ala Leu Leu Val Phe Ser Phe Val Ile 1 5 10 15 Gly Ser Cys Phe Ser Asp Asn Pro Ile Asp Ser Cys Trp Arg Gly Asp 20 25 30 Ser Asn Trp Ala Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val Gly 35 40 45 Phe Gly Ser Ser Thr Met Gly Gly Lys Gly Gly Asp Leu Tyr Thr Val 50 55 60 Thr Asn Ser Asp Asp Asp Pro Val Asn Pro Pro Gly Thr Leu Arg Tyr 65 70 75 80 Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn Met 85 90 95 Asn Ile Lys Leu Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr Phe 100 105 110 Asp Gly Arg Gly Ala Gln Val Tyr Ile Gly Asn Gly Gly Pro Cys Val 115 120 125 Phe Ile Lys Arg Val Ser Asn Val Ile Ile His Gly Leu Tyr Leu Tyr 130 135 140 Gly Cys Ser Thr Ser Val Leu Gly Asn Val Leu Ile Asn Glu Ser Phe 145 150 155 160 Gly Val Glu Pro Val His Pro Gln Asp Gly Asp Ala Leu Thr Leu Arg 165 170 175 Thr Ala Thr Asn Ile Trp Ile Asp His Asn Ser Phe Ser Asn Ser Ser 180 185 190 Asp Gly Leu Val Asp Val Thr Leu Thr Ser Thr Gly Val Thr Ile Ser 195 200 205 Asn Asn Leu Phe Phe Asn His His Lys Val Met Ser Leu Gly His Asp 210 215 220 Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe Asn 225 230 235 240 Gln Phe Gly Pro Asn Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr Gly 245 250 255 Leu Val His Val Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr Ala 260 265 270 Ile Gly Gly Ser Ser Asn Pro Thr Ile Leu Ser Glu Gly Asn Ser Phe 275 280 285 Thr Ala Pro Asn Glu Ser Tyr Lys Lys Gln Val Thr Ile Arg Ile Gly 290 295 300 Cys Lys Thr Ser Ser Ser Cys Ser Asn Trp Val Trp Gln Ser Thr Gln 305 310 315 320 Asp Val Phe Tyr Asn Gly Ala Tyr Phe Val Ser Ser Gly Lys Tyr Glu 325 330 335 Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe Asn Val Glu Asn Gly 340 345 350 Asn Ala Thr Pro His Leu Thr Gln Asn Ala Gly Val Leu Thr Cys Ser 355 360 365 Leu Ser Lys Arg Cys 370 102 374 PRT Cryptomeria japonica 102 Met Asp Ser Pro Cys Leu Val Ala Leu Leu Val Leu Ser Phe Val Ile 1 5 10 15 Gly Ser Cys Phe Ser Asp Asn Pro Ile Asp Ser Cys Trp Arg Gly Asp 20 25 30 Ser Asn Trp Ala Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val Gly 35 40 45 Phe Gly Ser Ser Thr Met Gly Gly Lys Gly Gly Asp Leu Tyr Thr Val 50 55 60 Thr Asn Ser Asp Asp Asp Pro Val Asn Pro Ala Pro Gly Thr Leu Arg 65 70 75 80 Tyr Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn 85 90 95 Met Asn Ile Lys Leu Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr 100 105 110 Phe Asp Gly Arg Gly Ala Gln Val Tyr Ile Gly Asn Gly Gly Pro Cys 115 120 125 Val Phe Ile Lys Arg Val Ser Asn Val Ile Ile His Gly Leu His Leu 130 135 140 Tyr Gly Cys Ser Thr Ser Val Leu Gly Asn Val Leu Ile Asn Glu Ser 145 150 155 160 Phe Gly Val Glu Pro Val His Pro Gln Asp Gly Asp Ala Leu Thr Leu 165 170 175 Arg Thr Ala Thr Asn Ile Trp Ile Asp His Asn Ser Phe Ser Asn Ser 180 185 190 Ser Asp Gly Leu Val Asp Val Thr Leu Ser Ser Thr Gly Val Thr Ile 195 200 205 Ser Asn Asn Leu Phe Phe Asn His His Lys Val Met Leu Leu Gly His 210 215 220 Asp Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe 225 230 235 240 Asn Gln Phe Gly Pro Asn Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr 245 250 255 Gly Leu Val His Val Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr 260 265 270 Ala Ile Gly Gly Ser Ser Asn Pro Thr Ile Leu Ser Glu Gly Asn Ser 275 280 285 Phe Thr Ala Pro Asn Glu Ser Tyr Lys Lys Gln Val Thr Ile Arg Ile 290 295 300 Gly Cys Lys Thr Ser Ser Ser Cys Ser Asn Trp Val Trp Gln Ser Thr 305 310 315 320 Gln Asp Val Phe Tyr Asn Gly Ala Tyr Phe Val Ser Ser Gly Lys Tyr 325 330 335 Glu Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe Asn Val Glu Asn 340 345 350 Gly Asn Ala Thr Pro Gln Leu Thr Lys Asn Ala Gly Val Leu Thr Cys 355 360 365 Ser Leu Ser Lys Arg Cys 370 103 514 PRT Cryptomeria japonica 103 Met Ala Met Lys Leu Ile Ala Pro Met Ala Phe Leu Ala Met Gln Leu 1 5 10 15 Ile Ile Met Ala Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp 20 25 30 Ser Val Val Glu Lys Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val 35 40 45 Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr 50 55 60 Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr 65 70 75 80 Ala Trp Gln Ala Ala Cys Lys Asn Pro Ser Ala Met Leu Leu Val Pro 85 90 95 Gly Ser Lys Lys Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys 100 105 110 Gln Pro His Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln 115 120 125 Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys 130 135 140 Leu Thr Gly Phe Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly 145 150 155 160 Lys Gln Trp Trp Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile 165 170 175 Cys Asn Asp Arg Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr 180 185 190 Gly Leu Ile Ile Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe His 195 200 205 Leu Val Phe Gly Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile 210 215 220 Thr Ala Pro Arg Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala 225 230 235 240 Ser Lys Asn Phe His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp 245 250 255 Cys Val Ala Ile Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu 260 265 270 Ile Cys Gly Pro Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu 275 280 285 Asn Ser Arg Ala Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe 290 295 300 Ile Asp Thr Gln Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser 305 310 315 320 Gly Met Ala Ser His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser 325 330 335 Glu Asn Pro Ile Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala 340 345 350 Cys Gln Asn Gln Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys 355 360 365 Asn Ile Arg Gly Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys 370 375 380 Ser Asp Ser Met Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu 385 390 395 400 Lys Leu Thr Ser Gly Lys Ile Ala Ser Cys Leu Asn Asp Asn Ala Asn 405 410 415 Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro 420 425 430 Ser Ala Lys Arg Lys Glu Ser Lys Ser His Lys His Pro Lys Thr Val 435 440 445 Met Val Glu Asn Met Arg Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile 450 455 460 Leu Leu Gly Ser Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys 465 470 475 480 Ser Pro Cys Lys Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln 485 490 495 Glu Tyr Tyr Pro Gln Arg Trp Ile Cys Ser Cys His Gly Lys Ile Tyr 500 505 510 His Pro 104 514 PRT Cryptomeria japonica 104 Met Ala Met Lys Phe Ile Ala Pro Met Ala Phe Val Ala Met Gln Leu 1 5 10 15 Ile Ile Met Ala Ala Ala Glu Asp Gln Ser Ala Gln Ile Met Leu Asp 20 25 30 Ser Asp Ile Glu Gln Tyr Leu Arg Ser Asn Arg Ser Leu Arg Lys Val 35 40 45 Glu His Ser Arg His Asp Ala Ile Asn Ile Phe Asn Val Glu Lys Tyr 50 55 60 Gly Ala Val Gly Asp Gly Lys His Asp Cys Thr Glu Ala Phe Ser Thr 65 70 75 80 Ala Trp Gln Ala Ala Cys Lys Lys Pro Ser Ala Met Leu Leu Val Pro 85 90 95 Gly Asn Lys Lys Phe Val Val Asn Asn Leu Phe Phe Asn Gly Pro Cys 100 105 110 Gln Pro His Phe Thr Phe Lys Val Asp Gly Ile Ile Ala Ala Tyr Gln 115 120 125 Asn Pro Ala Ser Trp Lys Asn Asn Arg Ile Trp Leu Gln Phe Ala Lys 130 135 140 Leu Thr Gly Phe Thr Leu Met Gly Lys Gly Val Ile Asp Gly Gln Gly 145 150 155 160 Lys Gln Trp Trp Ala Gly Gln Cys Lys Trp Val Asn Gly Arg Glu Ile 165 170 175 Cys Asn Asp Arg Asp Arg Pro Thr Ala Ile Lys Phe Asp Phe Ser Thr 180 185 190 Gly Leu Ile Ile Gln Gly Leu Lys Leu Met Asn Ser Pro Glu Phe His 195 200 205 Leu Val Phe Gly Asn Cys Glu Gly Val Lys Ile Ile Gly Ile Ser Ile 210 215 220 Thr Ala Pro Arg Asp Ser Pro Asn Thr Asp Gly Ile Asp Ile Phe Ala 225 230 235 240 Ser Lys Asn Phe His Leu Gln Lys Asn Thr Ile Gly Thr Gly Asp Asp 245 250 255 Cys Val Ala Ile Gly Thr Gly Ser Ser Asn Ile Val Ile Glu Asp Leu 260 265 270 Ile Cys Gly Pro Gly His Gly Ile Ser Ile Gly Ser Leu Gly Arg Glu 275 280 285 Asn Ser Arg Ala Glu Val Ser Tyr Val His Val Asn Gly Ala Lys Phe 290 295 300 Ile Asp Thr Gln Asn Gly Leu Arg Ile Lys Thr Trp Gln Gly Gly Ser 305 310 315 320 Gly Met Ala Ser His Ile Ile Tyr Glu Asn Val Glu Met Ile Asn Ser 325 330 335 Glu Asn Pro Ile Leu Ile Asn Gln Phe Tyr Cys Thr Ser Ala Ser Ala 340 345 350 Cys Gln Asn Gln Arg Ser Ala Val Gln Ile Gln Asp Val Thr Tyr Lys 355 360 365 Asn Ile Arg Gly Thr Ser Ala Thr Ala Ala Ala Ile Gln Leu Lys Cys 370 375 380 Ser Asp Ser Met Pro Cys Lys Asp Ile Lys Leu Ser Asp Ile Ser Leu 385 390 395 400 Lys Leu Thr Ser Gly Lys Ile Ala Ser Cys Leu Asn Asp Asn Ala Asn 405 410 415 Gly Tyr Phe Ser Gly His Val Ile Pro Ala Cys Lys Asn Leu Ser Pro 420 425 430 Ser Ala Lys Arg Lys Glu Ser Lys Ser His Lys His Pro Lys Thr Val 435 440 445 Met Val Lys Asn Met Gly Ala Tyr Asp Lys Gly Asn Arg Thr Arg Ile 450 455 460 Leu Leu Gly Ser Arg Pro Pro Asn Cys Thr Asn Lys Cys His Gly Cys 465 470 475 480 Ser Pro Cys Lys Ala Lys Leu Val Ile Val His Arg Ile Met Pro Gln 485 490 495 Glu Tyr Tyr Pro Gln Arg Trp Met Cys Ser Arg His Gly Lys Ile Tyr 500 505 510 His Pro 105 373 PRT Cryptomeria japonica 105 Met Asp Ser Pro Cys Leu Val Ala Leu Leu Val Leu Ser Phe Val Ile 1 5 10 15 Gly Ser Cys Phe Ser Asp Asn Pro Ile Asp Ser Cys Trp Arg Gly Asp 20 25 30 Ser Asn Trp Ala Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val Gly 35 40 45 Phe Gly Ser Ser Thr Met Gly Gly Lys Gly Gly Asp Leu Tyr Thr Val 50 55 60 Thr Asn Ser Asp Asp Asp Pro Val Asn Pro Pro Gly Thr Leu Arg Tyr 65 70 75 80 Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn Met 85 90 95 Asn Ile Lys Leu Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr Phe 100 105 110 Asp Gly Arg Gly Ala Gln Val Tyr Ile Gly Asn Gly Gly Pro Cys Val 115 120 125 Phe Ile Lys Arg Val Ser Asn Val Ile Ile His Gly Leu His Leu Tyr 130 135 140 Gly Cys Ser Thr Ser Val Leu Gly Asn Val Leu Ile Asn Glu Ser Phe 145 150 155 160 Gly Val Glu Pro Val His Pro Gln Asp Gly Asp Ala Leu Thr Leu Arg 165 170 175 Thr Ala Thr Asn Ile Trp Ile Asp His Asn Ser Phe Ser Asn Ser Ser 180 185 190 Asp Gly Leu Val Asp Val Thr Leu Ser Ser Thr Gly Val Thr Ile Ser 195 200 205 Asn Asn Leu Phe Phe Asn His His Lys Val Met Leu Leu Gly His Asp 210 215 220 Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe Asn 225 230 235 240 Gln Phe Gly Pro Asn Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr Gly 245 250 255 Leu Val His Val Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr Ala 260 265 270 Ile Gly Gly Ser Ser Asn Pro Thr Ile Leu Ser Glu Gly Asn Ser Phe 275 280 285 Thr Ala Pro Asn Glu Ser Tyr Lys Lys Gln Val Thr Ile Arg Ile Gly 290 295 300 Cys Lys Thr Ser Ser Ser Cys Ser Asn Trp Val Trp Gln Ser Thr Gln 305 310 315 320 Asp Val Phe Tyr Asn Gly Ala Tyr Phe Val Ser Ser Gly Lys Tyr Glu 325 330 335 Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe Asn Val Glu Asn Gly 340 345 350 Asn Ala Thr Pro Gln Leu Thr Lys Asn Ala Gly Val Leu Thr Cys Ser 355 360 365 Leu Ser Lys Arg Cys 370 106 374 PRT Cryptomeria japonica 106 Met Asp Ser Pro Cys Leu Val Ala Leu Leu Val Phe Ser Phe Val Ile 1 5 10 15 Gly Ser Cys Phe Ser Asp Asn Pro Ile Asp Ser Cys Trp Arg Gly Asp 20 25 30 Ser Asn Trp Ala Gln Asn Arg Met Lys Leu Ala Asp Cys Ala Val Gly 35 40 45 Phe Gly Ser Ser Thr Met Gly Gly Lys Gly Gly Asp Leu Tyr Thr Val 50 55 60 Thr Asn Ser Asp Asp Asp Pro Val Asn Pro Ala Pro Gly Thr Leu Arg 65 70 75 80 Tyr Gly Ala Thr Arg Asp Arg Pro Leu Trp Ile Ile Phe Ser Gly Asn 85 90 95 Met Asn Ile Lys Leu Lys Met Pro Met Tyr Ile Ala Gly Tyr Lys Thr 100 105 110 Phe Asp Gly Arg Gly Ala Gln Val Tyr Ile Gly Asn Gly Gly Pro Cys 115 120 125 Val Phe Ile Lys Arg Val Ser Asn Val Ile Ile His Gly Leu Tyr Leu 130 135 140 Tyr Gly Cys Ser Thr Ser Val Leu Gly Asn Val Leu Ile Asn Glu Ser 145 150 155 160 Phe Gly Val Glu Pro Val His Pro Gln Asp Gly Asp Ala Leu Thr Leu 165 170 175 Arg Thr Ala Thr Asn Ile Trp Ile Asp His Asn Ser Phe Ser Asn Ser 180 185 190 Ser Asp Gly Leu Val Asp Val Thr Leu Thr Ser Thr Gly Val Thr Ile 195 200 205 Ser Asn Asn Leu Phe Phe Asn His His Lys Val Met Ser Leu Gly His 210 215 220 Asp Asp Ala Tyr Ser Asp Asp Lys Ser Met Lys Val Thr Val Ala Phe 225 230 235 240 Asn Gln Phe Gly Pro Asn Cys Gly Gln Arg Met Pro Arg Ala Arg Tyr 245 250 255 Gly Leu Val His Val Ala Asn Asn Asn Tyr Asp Pro Trp Thr Ile Tyr 260 265 270 Ala Ile Gly Gly Ser Ser Asn Pro Thr Ile Leu Ser Glu Gly Asn Ser 275 280 285 Phe Thr Ala Pro Asn Glu Ser Tyr Lys Lys Gln Val Thr Ile Arg Ile 290 295 300 Gly Cys Lys Thr Ser Ser Ser Cys Ser Asn Trp Val Trp Gln Ser Thr 305 310 315 320 Gln Asp Val Phe Tyr Asn Gly Ala Tyr Phe Val Ser Ser Gly Lys Tyr 325 330 335 Glu Gly Gly Asn Ile Tyr Thr Lys Lys Glu Ala Phe Asn Val Glu Asn 340 345 350 Gly Asn Ala Thr Pro His Leu Thr Gln Asn Ala Gly Val Leu Thr Cys 355 360 365 Ser Leu Ser Lys Arg Cys 370 107 174 PRT Canis familiaris 107 Met Lys Thr Leu Leu Leu Thr Ile Gly Phe Ser Leu Ile Ala Ile Leu 1 5 10 15 Gln Ala Gln Asp Thr Pro Ala Leu Gly Lys Asp Thr Val Ala Val Ser 20 25 30 Gly Lys Trp Tyr Leu Lys Ala Met Thr Ala Asp Gln Glu Val Pro Glu 35 40 45 Lys Pro Asp Ser Val Thr Pro Met Ile Leu Lys Ala Gln Lys Gly Gly 50 55 60 Asn Leu Glu Ala Lys Ile Thr Met Leu Thr Asn Gly Gln Cys Gln Asn 65 70 75 80 Ile Thr Val Val Leu His Lys Thr Ser Glu Pro Gly Lys Tyr Thr Ala 85 90 95 Tyr Glu Gly Gln Arg Val Val Phe Ile Gln Pro Ser Pro Val Arg Asp 100 105 110 His Tyr Ile Leu Tyr Cys Glu Gly Glu Leu His Gly Arg Gln Ile Arg 115 120 125 Met Ala Lys Leu Leu Gly Arg Asp Pro Glu Gln Ser Gln Glu Ala Leu 130 135 140 Glu Asp Phe Arg Glu Phe Ser Arg Ala Lys Gly Leu Asn Gln Glu Ile 145 150 155 160 Leu Glu Leu Ala Gln Ser Glu Thr Cys Ser Pro Gly Gly Gln 165 170 108 24 PRT Canis familiaris 108 Glu Ala Tyr Lys Ser Glu Ile Ala His Arg Tyr Asn Asp Leu Gly Glu 1 5 10 15 Glu His Phe Arg Gly Leu Val Leu 20 109 265 PRT Canis familiaris 109 Leu Ser Ser Ala Lys Glu Arg Phe Lys Cys Ala Ser Leu Gln Lys Phe 1 5 10 15 Gly Asp Arg Ala Phe Lys Ala Trp Ser Val Ala Arg Leu Ser Gln Arg 20 25 30 Phe Pro Lys Ala Asp Phe Ala Glu Ile Ser Lys Val Val Thr Asp Leu 35 40 45 Thr Lys Val His Lys Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala 50 55 60 Asp Asp Arg Ala Asp Leu Ala Lys Tyr Met Cys Glu Asn Gln Asp Ser 65 70 75 80 Ile Ser Thr Lys Leu Lys Glu Cys Cys Asp Lys Pro Val Leu Glu Lys 85 90 95 Ser Gln Cys Leu Ala Glu Val Glu Arg Asp Glu Leu Pro Gly Asp Leu 100 105 110 Pro Ser Leu Ala Ala Asp Phe Val Glu Asp Lys Glu Val Cys Lys Asn 115 120 125 Tyr Gln Glu Ala Lys Asp Val Phe Leu Gly Thr Phe Leu Tyr Glu Tyr 130 135 140 Ser Arg Arg His Pro Glu Tyr Ser Val Ser Leu Leu Leu Arg Leu Ala 145 150 155 160 Lys Glu Tyr Glu Ala Thr Leu Glu Lys Cys Cys Ala Thr Asp Asp Pro 165 170 175 Pro Thr Cys Tyr Ala Lys Val Leu Asp Glu Phe Lys Pro Leu Val Asp 180 185 190 Glu Pro Gln Asn Leu Val Lys Thr Asn Cys Glu Leu Phe Glu Lys Leu 195 200 205 Gly Glu Tyr Gly Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys 210 215 220 Ala Pro Gln Val Ser Thr Pro Thr Leu Val Val Glu Val Ser Arg Lys 225 230 235 240 Leu Gly Lys Val Gly Thr Lys Cys Cys Lys Lys Pro Glu Ser Glu Arg 245 250 255 Met Ser Cys Ala Asp Asp Phe Leu Ser 260 265 110 180 PRT Canis familiaris 110 Met Gln Leu Leu Leu Leu Thr Val Gly Leu Ala Leu Ile Cys Gly Leu 1 5 10 15 Gln Ala Gln Glu Gly Asn His Glu Glu Pro Gln Gly Gly Leu Glu Glu 20 25 30 Leu Ser Gly Arg Trp His Ser Val Ala Leu Ala Ser Asn Lys Ser Asp 35 40 45 Leu Ile Lys Pro Trp Gly His Phe Arg Val Phe Ile His Ser Met Ser 50 55 60 Ala Lys Asp Gly Asn Leu His Gly Asp Ile Leu Ile Pro Gln Asp Gly 65 70 75 80 Gln Cys Glu Lys Val Ser Leu Thr Ala Phe Lys Thr Ala Thr Ser Asn 85 90 95 Lys Phe Asp Leu Glu Tyr Trp Gly His Asn Asp Leu Tyr Leu Ala Glu 100 105 110 Val Asp Pro Lys Ser Tyr Leu Ile Leu Tyr Met Ile Asn Gln Tyr Asn 115 120 125 Asp Asp Thr Ser Leu Val Ala His Leu Met Val Arg Asp Leu Ser Arg 130 135 140 Gln Gln Asp Phe Leu Pro Ala Phe Glu Ser Val Cys Glu Asp Ile Gly 145 150 155 160 Leu His Lys Asp Gln Ile Val Val Leu Ser Asp Asp Asp Arg Cys Gln 165 170 175 Gly Ser Arg Asp 180 111 187 PRT Equus caballus 111 Met Lys Leu Leu Leu Leu Cys Leu Gly Leu Ile Leu Val Cys Ala Gln 1 5 10 15 Gln Glu Glu Asn Ser Asp Val Ala Ile Arg Asn Phe Asp Ile Ser Lys 20 25 30 Ile Ser Gly Glu Trp Tyr Ser Ile Phe Leu Ala Ser Asp Val Lys Glu 35 40 45 Lys Ile Glu Glu Asn Gly Ser Met Arg Val Phe Val Asp Val Ile Arg 50 55 60 Ala Leu Asp Asn Ser Ser Leu Tyr Ala Glu Tyr Gln Thr Lys Val Asn 65 70 75 80 Gly Glu Cys Thr Glu Phe Pro Met Val Phe Asp Lys Thr Glu Glu Asp 85 90 95 Gly Val Tyr Ser Leu Asn Tyr Asp Gly Tyr Asn Val Phe Arg Ile Ser 100 105 110 Glu Phe Glu Asn Asp Glu His Ile Ile Leu Tyr Leu Val Asn Phe Asp 115 120 125 Lys Asp Arg Pro Phe Gln Leu Phe Glu Phe Tyr Ala Arg Glu Pro Asp 130 135 140 Val Ser Pro Glu Ile Lys Glu Glu Phe Val Lys Ile Val Gln Lys Arg 145 150 155 160 Gly Ile Val Lys Glu Asn Ile Ile Asp Leu Thr Lys Ile Asp Arg Cys 165 170 175 Phe Gln Leu Arg Gly Asn Gly Val Ala Gln Ala 180 185 112 29 PRT Equus caballus misc_feature X is unknown amino acid 112 Ser Gln Xaa Pro Gln Ser Glu Thr Asp Tyr Ser Gln Leu Ser Gly Glu 1 5 10 15 Trp Asn Thr Ile Tyr Gly Ala Ala Ser Asn Ile Xaa Lys 20 25 113 211 PRT Euroglyphus maynei 113 Thr Tyr Ala Cys Ser Ile Asn Ser Val Ser Leu Pro Ser Glu Leu Asp 1 5 10 15 Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys 20 25 30 Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ser Thr Glu Ser Ala Tyr 35 40 45 Leu Ala Tyr Arg Asn Met Ser Leu Asp Leu Ala Glu Gln Glu Leu Val 50 55 60 Asp Cys Ala Ser Gln Asn Gly Cys His Gly Asp Thr Ile Pro Arg Gly 65 70 75 80 Ile Glu Tyr Ile Gln Gln Asn Gly Val Val Gln Glu His Tyr Tyr Pro 85 90 95 Tyr Val Ala Arg Glu Gln Ser Cys His Arg Pro Asn Ala Gln Arg Tyr 100 105 110 Gly Leu Lys Asn Tyr Cys Gln Ile Ser Pro Pro Asp Ser Asn Lys Ile 115 120 125 Arg Gln Ala Leu Thr Gln Thr His Thr Ala Val Ala Val Ile Ile Gly 130 135 140 Ile Lys Asp Leu Asn Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Met 145 150 155 160 Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 165 170 175 Gly Tyr Gly Asn Thr Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser 180 185 190 Trp Asp Thr Thr Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn 195 200 205 Ile Asn Leu 210 114 211 PRT Euroglyphus maynei 114 Thr Tyr Ala Cys Ser Ile Asn Ser Val Ser Leu Pro Ser Glu Leu Asp 1 5 10 15 Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys 20 25 30 Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ser Thr Glu Ser Ala Tyr 35 40 45 Leu Ala Tyr Arg Asn Met Ser Leu Asp Leu Ala Glu Gln Glu Leu Val 50 55 60 Asp Cys Ala Ser Gln Asn Gly Cys His Gly Asp Thr Ile Pro Arg Gly 65 70 75 80 Ile Glu Tyr Ile Gln Gln Asn Gly Val Val Gln Glu His Tyr Tyr Pro 85 90 95 Tyr Val Ala Arg Glu Gln Ser Cys His Arg Pro Asn Ala Gln Arg Tyr 100 105 110 Gly Leu Lys Asn Tyr Cys Gln Ile Ser Pro Pro Asp Ser Asn Lys Ile 115 120 125 Arg Gln Ala Leu Thr Gln Thr His Thr Ala Val Ala Val Ile Ile Gly 130 135 140 Ile Lys Asp Leu Asn Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Met 145 150 155 160 Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 165 170 175 Gly Tyr Gly Asn Thr Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser 180 185 190 Trp Asp Thr Thr Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn 195 200 205 Ile Asn Leu 210 115 211 PRT Euroglyphus maynei 115 Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp 1 5 10 15 Leu Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys 20 25 30 Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr 35 40 45 Leu Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val 50 55 60 Asp Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly 65 70 75 80 Ile Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg 85 90 95 Tyr Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe 100 105 110 Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile 115 120 125 Arg Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly 130 135 140 Ile Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile 145 150 155 160 Gln Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 165 170 175 Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser 180 185 190 Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn 195 200 205 Ile Asp Leu 210 116 212 PRT Euroglyphus maynei 116 Glu Thr Ser Ala Cys Arg Ile Asn Ser Val Asn Val Pro Ser Glu Leu 1 5 10 15 Asp Leu Arg Ser Leu Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly 20 25 30 Cys Gly Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala 35 40 45 Tyr Leu Ala Tyr Arg Asn Thr Ser Leu Asp Leu Ser Glu Gln Glu Leu 50 55 60 Val Asp Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg 65 70 75 80 Gly Ile Glu Tyr Ile Gln Gln Asn Gly Val Val Glu Glu Arg Ser Tyr 85 90 95 Pro Tyr Val Ala Arg Glu Gln Gln Cys Arg Arg Pro Asn Ser Gln His 100 105 110 Tyr Gly Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asp Val Lys Gln 115 120 125 Ile Arg Glu Ala Leu Thr Gln Thr His Thr Ala Ile Ala Val Ile Ile 130 135 140 Gly Ile Lys Asp Leu Arg Ala Phe Gln His Tyr Asp Gly Arg Thr Ile 145 150 155 160 Ile Gln His Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile 165 170 175 Val Gly Tyr Gly Ser Thr Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 180 185 190 Ser Trp Asp Thr Thr Trp Gly Asp Ser Gly Tyr Gly Tyr Phe Gln Ala 195 200 205 Gly Asn Asn Leu 210 117 307 PRT Poa pratensis 117 Met Ala Val Gln Lys Tyr Thr Val Ala Leu Phe Leu Val Ala Leu Val 1 5 10 15 Val Gly Pro Ala Ala Ser Tyr Ala Ala Asp Leu Ser Tyr Gly Ala Pro 20 25 30 Ala Thr Pro Ala Ala Pro Ala Ala Gly Tyr Thr Pro Ala Ala Pro Ala 35 40 45 Gly Ala Ala Pro Lys Ala Thr Thr Asp Glu Gln Lys Met Ile Glu Lys 50 55 60 Ile Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Gly Gly Val Pro 65 70 75 80 Ala Ala Asn Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala Ala Ser 85 90 95 Asn Lys Ala Phe Ala Glu Ala Leu Ser Thr Glu Pro Lys Gly Ala Ala 100 105 110 Val Asp Ser Ser Lys Ala Ala Leu Thr Ser Lys Leu Asp Ala Ala Tyr 115 120 125 Lys Leu Ala Tyr Lys Ser Ala Glu Gly Ala Thr Pro Glu Ala Lys Tyr 130 135 140 Asp Asp Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile Ala Gly 145 150 155 160 Thr Leu Glu Val His Gly Val Lys Pro Ala Ala Glu Glu Val Lys Ala 165 170 175 Thr Pro Ala Gly Glu Leu Gln Val Ile Asp Lys Val Asp Ala Ala Phe 180 185 190 Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp Lys Phe 195 200 205 Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile Lys Ala Ser Thr Gly 210 215 220 Gly Ala Tyr Gln Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala Ala Val 225 230 235 240 Lys Gln Ser Tyr Ala Ala Thr Val Ala Thr Ala Pro Ala Val Lys Tyr 245 250 255 Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met Ser Gln 260 265 270 Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Ala Thr Gly Thr Ala Thr 275 280 285 Ala Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Ala Gly Gly 290 295 300 Tyr Lys Val 305 118 333 PRT Poa pratensis 118 Met Ala Val His Gln Tyr Thr Val Ala Leu Phe Leu Ala Val Ala Leu 1 5 10 15 Val Ala Gly Pro Ala Ala Ser Tyr Ala Ala Asp Val Gly Tyr Gly Ala 20 25 30 Pro Ala Thr Leu Ala Thr Pro Ala Thr Pro Ala Ala Pro Ala Ala Gly 35 40 45 Tyr Thr Pro Ala Ala Pro Ala Gly Ala Ala Pro Lys Ala Thr Thr Asp 50 55 60 Glu Gln Lys Leu Ile Glu Lys Ile Asn Ala Gly Phe Lys Ala Ala Val 65 70 75 80 Ala Ala Ala Ala Gly Val Pro Ala Val Asp Lys Tyr Lys Thr Phe Val 85 90 95 Ala Thr Phe Gly Thr Ala Ser Asn Lys Ala Phe Ala Glu Ala Leu Ser 100 105 110 Thr Glu Pro Lys Gly Ala Ala Ala Ala Ser Ser Asn Ala Val Leu Thr 115 120 125 Ser Lys Leu Asp Ala Ala Tyr Lys Leu Ala Tyr Lys Ser Ala Glu Gly 130 135 140 Ala Thr Pro Glu Ala Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu 145 150 155 160 Ala Leu Arg Ile Ile Ala Gly Thr Leu Glu Val His Ala Val Lys Pro 165 170 175 Ala Gly Glu Glu Val Lys Ala Ile Pro Ala Gly Glu Leu Gln Val Ile 180 185 190 Asp Lys Val Asp Ala Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala 195 200 205 Ala Pro Ala Asn Asp Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp 210 215 220 Ala Ile Lys Ala Ser Thr Gly Gly Ala Tyr Gln Ser Tyr Lys Phe Ile 225 230 235 240 Pro Ala Leu Glu Ala Ala Val Lys Gln Ser Tyr Ala Ala Thr Val Ala 245 250 255 Thr Ala Pro Ala Val Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys 260 265 270 Ala Ile Thr Ala Met Ser Gln Ala Gln Lys Ala Ala Lys Pro Ala Ala 275 280 285 Ala Val Thr Ala Thr Ala Thr Gly Ala Val Gly Ala Ala Thr Gly Ala 290 295 300 Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Ala Gly Gly Tyr Lys 305 310 315 320 Thr Gly Ala Ala Thr Pro Thr Ala Gly Gly Tyr Lys Val 325 330 119 373 PRT Poa pratensis 119 Met Asp Lys Ala Asn Gly Ala Tyr Lys Thr Ala Leu Lys Ala Ala Ser 1 5 10 15 Ala Val Ala Pro Ala Glu Lys Phe Pro Val Phe Gln Ala Thr Phe Asp 20 25 30 Lys Asn Leu Lys Glu Gly Leu Ser Gly Pro Asp Ala Val Gly Phe Ala 35 40 45 Lys Lys Leu Asp Ala Phe Ile Gln Thr Ser Tyr Leu Ser Thr Lys Ala 50 55 60 Ala Glu Pro Lys Glu Lys Phe Asp Leu Phe Val Leu Ser Leu Thr Glu 65 70 75 80 Val Leu Arg Phe Met Ala Gly Ala Val Lys Ala Pro Pro Ala Ser Lys 85 90 95 Phe Pro Ala Lys Pro Ala Pro Lys Val Ala Ala Tyr Thr Pro Ala Ala 100 105 110 Pro Ala Gly Ala Ala Pro Lys Ala Thr Thr Asp Glu Gln Lys Leu Ile 115 120 125 Glu Lys Ile Asn Val Gly Phe Lys Ala Ala Val Ala Ala Ala Ala Gly 130 135 140 Val Pro Ala Ala Ser Lys Tyr Lys Thr Phe Val Ala Thr Phe Gly Ala 145 150 155 160 Ala Ser Asn Lys Ala Phe Ala Glu Ala Leu Ser Thr Glu Pro Lys Gly 165 170 175 Ala Ala Val Ala Ser Ser Lys Ala Val Leu Thr Ser Lys Leu Asp Ala 180 185 190 Ala Tyr Lys Leu Ala Tyr Lys Ser Ala Glu Gly Ala Thr Pro Glu Ala 195 200 205 Lys Tyr Asp Ala Tyr Val Ala Thr Leu Ser Glu Ala Leu Arg Ile Ile 210 215 220 Ala Gly Thr Leu Glu Val His Gly Val Lys Pro Ala Ala Glu Glu Val 225 230 235 240 Lys Ala Ile Pro Ala Gly Glu Leu Gln Val Ile Asp Lys Val Asp Ala 245 250 255 Ala Phe Lys Val Ala Ala Thr Ala Ala Asn Ala Ala Pro Ala Asn Asp 260 265 270 Lys Phe Thr Val Phe Glu Ala Ala Phe Asn Asp Ala Ile Lys Ala Ser 275 280 285 Thr Gly Gly Ala Tyr Gln Ser Tyr Lys Phe Ile Pro Ala Leu Glu Ala 290 295 300 Ala Val Lys Gln Ser Tyr Ala Ala Thr Val Ala Thr Ala Pro Ala Val 305 310 315 320 Lys Tyr Thr Val Phe Glu Thr Ala Leu Lys Lys Ala Ile Thr Ala Met 325 330 335 Ser Gln Ala Gln Lys Ala Ala Lys Pro Ala Ala Ala Val Thr Gly Thr 340 345 350 Ala Thr Ser Ala Val Gly Ala Ala Thr Gly Ala Ala Thr Ala Ala Ala 355 360 365 Gly Gly Tyr Lys Val 370 120 685 PRT Periplaneta americana 120 Met Lys Thr Ala Leu Val Phe Ala Ala Val Val Ala Phe Val Ala Ala 1 5 10 15 Arg Phe Pro Asp His Lys Asp Tyr Lys Gln Leu Ala Asp Lys Gln Phe 20 25 30 Leu Ala Lys Gln Arg Asp Val Leu Arg Leu Phe His Arg Val His Gln 35 40 45 His Asn Ile Leu Asn Asp Gln Val Glu Val Gly Ile Pro Met Thr Ser 50 55 60 Lys Gln Thr Ser Ala Thr Thr Val Pro Pro Ser Gly Glu Ala Val His 65 70 75 80 Gly Val Leu Gln Glu Gly His Ala Arg Pro Arg Gly Glu Pro Phe Ser 85 90 95 Val Asn Tyr Glu Lys His Arg Glu Gln Ala Ile Met Leu Tyr Asp Leu 100 105 110 Leu Tyr Phe Ala Asn Asp Tyr Asp Thr Phe Tyr Lys Thr Ala Cys Trp 115 120 125 Ala Arg Asp Arg Val Asn Glu Gly Met Phe Met Tyr Ser Phe Ser Ile 130 135 140 Ala Val Phe His Arg Asp Asp Met Gln Gly Val Met Leu Pro Pro Pro 145 150 155 160 Tyr Glu Val Tyr Pro Tyr Leu Phe Val Asp His Asp Val Ile His Met 165 170 175 Ala Gln Lys Tyr Trp Met Lys Asn Ala Gly Ser Gly Glu His His Ser 180 185 190 His Val Ile Pro Val Asn Phe Thr Leu Arg Thr Gln Asp His Leu Leu 195 200 205 Ala Tyr Phe Thr Ser Asp Val Asn Leu Asn Ala Phe Asn Thr Tyr Tyr 210 215 220 Arg Tyr Tyr Tyr Pro Ser Trp Tyr Asn Thr Thr Leu Tyr Gly His Asn 225 230 235 240 Ile Asp Arg Arg Gly Glu Gln Phe Tyr Tyr Thr Tyr Lys Gln Ile Tyr 245 250 255 Ala Arg Tyr Phe Leu Glu Arg Leu Ser Asn Asp Leu Pro Asp Val Tyr 260 265 270 Pro Phe Tyr Tyr Ser Lys Pro Val Lys Ser Ala Tyr Asn Pro Asn Leu 275 280 285 Arg Tyr His Asn Gly Glu Glu Met Pro Val Arg Pro Ser Asn Met Tyr 290 295 300 Val Thr Asn Phe Asp Leu Tyr Tyr Ile Ala Asp Ile Lys Asn Tyr Glu 305 310 315 320 Lys Arg Val Glu Asp Ala Ile Asp Phe Gly Tyr Ala Phe Asp Glu His 325 330 335 Met Lys Pro His Ser Leu Tyr His Asp Val His Gly Met Glu Tyr Leu 340 345 350 Ala Asp Met Ile Glu Gly Asn Met Asp Ser Pro Asn Phe Tyr Phe Tyr 355 360 365 Gly Ser Ile Tyr His Met Tyr His Ser Met Ile Gly His Ile Val Asp 370 375 380 Pro Tyr His Lys Met Gly Leu Ala Pro Ser Leu Glu His Pro Glu Thr 385 390 395 400 Val Leu Arg Asp Pro Val Phe Tyr Gln Leu Trp Lys Arg Val Asp His 405 410 415 Leu Phe Gln Lys Tyr Lys Asn Arg Leu Pro Arg Tyr Thr His Asp Glu 420 425 430 Leu Ala Phe Glu Gly Val Lys Val Glu Asn Val Asp Val Gly Lys Leu 435 440 445 Tyr Thr Tyr Phe Glu Gln Tyr Asp Met Ser Leu Asp Met Ala Val Tyr 450 455 460 Val Asn Asn Val Asp Gln Ile Ser Asn Val Asp Val Gln Leu Ala Val 465 470 475 480 Arg Leu Asn His Lys Pro Phe Thr Tyr Asn Ile Glu Val Ser Ser Asp 485 490 495 Lys Ala Gln Asp Val Tyr Val Ala Val Phe Leu Gly Pro Lys Tyr Asp 500 505 510 Tyr Leu Gly Arg Glu Tyr Asp Leu Asn Asp Arg Arg His Tyr Phe Val 515 520 525 Glu Met Asp Arg Phe Pro Tyr His Val Gly Ala Gly Lys Thr Val Ile 530 535 540 Glu Arg Asn Ser His Asp Ser Asn Ile Ile Ala Pro Glu Arg Asp Ser 545 550 555 560 Tyr Arg Thr Phe Tyr Lys Lys Val Gln Glu Ala Tyr Glu Gly Lys Ser 565 570 575 Gln Tyr Tyr Val Asp Lys Gly His Asn Tyr Cys Gly Tyr Pro Glu Asn 580 585 590 Leu Leu Ile Pro Lys Gly Lys Lys Gly Gly Gln Ala Tyr Thr Phe Tyr 595 600 605 Val Ile Val Thr Pro Tyr Val Lys Gln Asp Glu His Asp Phe Glu Pro 610 615 620 Tyr Asn Tyr Lys Ala Phe Ser Tyr Cys Gly Val Gly Ser Glu Arg Lys 625 630 635 640 Tyr Pro Asp Asn Lys Pro Leu Gly Tyr Pro Phe Asp Arg Lys Ile Tyr 645 650 655 Ser Asn Asp Phe Tyr Thr Pro Asn Met Tyr Phe Lys Asp Val Ile Ile 660 665 670 Phe His Lys Lys Tyr Asp Glu Val Gly Val Gln Gly His 675 680 685 121 446 PRT Periplaneta americana 121 Ile Asn Glu Ile His Ser Ile Ile Gly Leu Pro Pro Phe Val Pro Pro 1 5 10 15 Ser Arg Arg His Ala Arg Arg Gly Val Gly Ile Asn Gly Leu Ile Asp 20 25 30 Asp Val Ile Ala Ile Leu Pro Val Asp Glu Leu Lys Ala Leu Phe Gln 35 40 45 Glu Lys Leu Glu Thr Ser Pro Asp Phe Lys Ala Leu Tyr Asp Ala Ile 50 55 60 Arg Ser Pro Glu Phe Gln Ser Ile Ile Ser Thr Leu Asn Ala Met Gln 65 70 75 80 Arg Ser Glu His His Gln Asn Leu Arg Asp Lys Gly Val Asp Val Asp 85 90 95 His Phe Ile Gln Leu Ile Arg Ala Leu Phe Gly Leu Ser Arg Ala Ala 100 105 110 Arg Asn Leu Gln Asp Asp Leu Asn Asp Phe Leu His Ser Leu Glu Pro 115 120 125 Ile Ser Pro Arg His Arg His Gly Leu Pro Arg Gln Arg Arg Arg Ser 130 135 140 Ala Arg Val Ser Ala Tyr Leu His Ala Asp Asp Phe His Lys Ile Ile 145 150 155 160 Thr Thr Ile Glu Ala Leu Pro Glu Phe Ala Asn Phe Tyr Asn Phe Leu 165 170 175 Lys Glu His Gly Leu Asp Val Val Asp Tyr Ile Asn Glu Ile His Ser 180 185 190 Ile Ile Gly Leu Pro Pro Phe Val Pro Pro Ser Arg Arg His Ala Arg 195 200 205 Arg Gly Val Gly Ile Asn Gly Leu Ile Asp Asp Val Ile Ala Ile Leu 210 215 220 Pro Val Asp Glu Leu Lys Ala Leu Phe Gln Glu Lys Leu Glu Thr Ser 225 230 235 240 Pro Asp Phe Lys Ala Leu Tyr Asp Ala Ile Arg Ser Pro Glu Phe Gln 245 250 255 Ser Ile Ile Ser Thr Leu Asn Ala Met Pro Glu Tyr Gln Glu Leu Leu 260 265 270 Gln Asn Leu Arg Asp Lys Gly Val Asp Val Asp His Phe Ile Arg Val 275 280 285 Asp Gln Gly Thr Leu Arg Thr Leu Ser Ser Gly Gln Arg Asn Leu Gln 290 295 300 Asp Asp Leu Asn Asp Phe Leu Ala Leu Ile Pro Thr Asp Gln Ile Leu 305 310 315 320 Ala Ile Ala Met Asp Tyr Leu Ala Asn Asp Ala Glu Val Gln Glu Leu 325 330 335 Val Ala Tyr Leu Gln Ser Asp Asp Phe His Lys Ile Ile Thr Thr Ile 340 345 350 Glu Ala Leu Pro Glu Phe Ala Asn Phe Tyr Asn Phe Leu Lys Glu His 355 360 365 Gly Leu Asp Val Val Asp Tyr Ile Asn Glu Ile His Ser Ile Ile Gly 370 375 380 Leu Pro Pro Phe Val Pro Pro Ser Gln Arg His Ala Arg Arg Gly Val 385 390 395 400 Gly Ile Asn Gly Leu Ile Asp Asp Val Ile Ala Ile Leu Pro Val Asp 405 410 415 Glu Leu Lys Ala Leu Phe Gln Glu Lys Leu Glu Thr Ser Pro Asp Phe 420 425 430 Lys Ala Leu Tyr Asp Ala Ile Asp Leu Arg Ser Ser Arg Ala 435 440 445 122 352 PRT Blattella germanica 122 Met Ile Gly Leu Lys Leu Val Thr Val Leu Phe Ala Val Ala Thr Ile 1 5 10 15 Thr His Ala Ala Glu Leu Gln Arg Val Pro Leu Tyr Lys Leu Val His 20 25 30 Val Phe Ile Asn Thr Gln Tyr Ala Gly Ile Thr Lys Ile Gly Asn Gln 35 40 45 Asn Phe Leu Thr Val Phe Asp Ser Thr Ser Cys Asn Val Val Val Ala 50 55 60 Ser Gln Glu Cys Val Gly Gly Ala Cys Val Cys Pro Asn Leu Gln Lys 65 70 75 80 Tyr Glu Lys Leu Lys Pro Lys Tyr Ile Ser Asp Gly Asn Val Gln Val 85 90 95 Lys Phe Phe Asp Thr Gly Ser Ala Val Gly Arg Gly Ile Glu Asp Ser 100 105 110 Leu Thr Ile Ser Asn Leu Thr Thr Ser Gln Gln Asp Ile Val Leu Ala 115 120 125 Asp Glu Leu Ser Gln Glu Val Cys Ile Leu Ser Ala Asp Val Val Val 130 135 140 Gly Ile Ala Ala Pro Gly Cys Pro Asn Ala Leu Lys Gly Lys Thr Val 145 150 155 160 Leu Glu Asn Phe Val Glu Glu Asn Leu Ile Ala Pro Val Phe Ser Ile 165 170 175 His His Ala Arg Phe Gln Asp Gly Glu His Phe Gly Glu Ile Ile Phe 180 185 190 Gly Gly Ser Asp Trp Lys Tyr Val Asp Gly Glu Phe Thr Tyr Val Pro 195 200 205 Leu Val Gly Asp Asp Ser Trp Lys Phe Arg Leu Asp Gly Val Lys Ile 210 215 220 Gly Asp Thr Thr Val Ala Pro Ala Gly Thr Gln Ala Ile Ile Asp Thr 225 230 235 240 Ser Lys Ala Ile Ile Val Gly Pro Lys Ala Tyr Val Asn Pro Ile Asn 245 250 255 Glu Ala Ile Gly Cys Val Val Glu Lys Thr Thr Thr Arg Arg Ile Cys 260 265 270 Lys Leu Asp Cys Ser Lys Ile Pro Ser Leu Pro Asp Val Thr Phe Val 275 280 285 Ile Asn Gly Arg Asn Phe Asn Ile Ser Ser Gln Tyr Tyr Ile Gln Gln 290 295 300 Asn Gly Asn Leu Cys Tyr Ser Gly Phe Gln Pro Cys Gly His Ser Asp 305 310 315 320 His Phe Phe Ile Gly Asp Phe Phe Val Asp His Tyr Tyr Ser Glu Phe 325 330 335 Asn Trp Glu Asn Lys Thr Met Gly Phe Gly Arg Ser Val Glu Ser Val 340 345 350 123 182 PRT Blattella germanica 123 Ala Val Leu Ala Leu Cys Ala Thr Asp Thr Leu Ala Asn Glu Asp Cys 1 5 10 15 Phe Arg His Glu Ser Leu Val Pro Asn Leu Asp Tyr Glu Arg Phe Arg 20 25 30 Gly Ser Trp Ile Ile Ala Ala Gly Thr Ser Glu Ala Leu Thr Gln Tyr 35 40 45 Lys Cys Trp Ile Asp Arg Phe Ser Tyr Asp Asp Ala Leu Val Ser Lys 50 55 60 Tyr Thr Asp Ser Gln Gly Lys Asn Arg Thr Thr Ile Arg Gly Arg Thr 65 70 75 80 Lys Phe Glu Gly Asn Lys Phe Thr Ile Asp Tyr Asn Asp Lys Gly Lys 85 90 95 Ala Phe Ser Ala Pro Tyr Ser Val Leu Ala Thr Asp Tyr Glu Asn Tyr 100 105 110 Ala Ile Val Glu Gly Cys Pro Ala Ala Ala Asn Gly His Val Ile Tyr 115 120 125 Val Gln Ile Arg Phe Ser Val Arg Arg Phe His Pro Lys Leu Gly Asp 130 135 140 Lys Glu Met Ile Gln His Tyr Thr Leu Asp Gln Val Asn Gln His Lys 145 150 155 160 Lys Ala Ile Glu Glu Asp Leu Lys His Phe Asn Leu Lys Tyr Glu Asp 165 170 175 Leu His Ser Thr Cys His 180 124 200 PRT Blattella germanica 124 Tyr Lys Leu Thr Tyr Cys Pro Val Lys Ala Leu Gly Glu Pro Ile Arg 1 5 10 15 Phe Leu Leu Ser Tyr Gly Glu Lys Asp Phe Glu Asp Tyr Arg Phe Gln 20 25 30 Glu Gly Asp Trp Pro Asn Leu Lys Pro Ser Met Pro Phe Gly Lys Thr 35 40 45 Pro Val Leu Glu Ile Asp Gly Lys Gln Thr His Gln Ser Val Ala Ile 50 55 60 Ser Arg Tyr Leu Gly Lys Gln Phe Gly Leu Ser Gly Lys Asp Asp Trp 65 70 75 80 Glu Asn Leu Glu Ile Asp Met Ile Val Asp Thr Ile Ser Asp Phe Arg 85 90 95 Ala Ala Ile Ala Asn Tyr His Tyr Asp Ala Asp Glu Asn Ser Lys Gln 100 105 110 Lys Lys Trp Asp Pro Leu Lys Lys Glu Thr Ile Pro Tyr Tyr Thr Lys 115 120 125 Lys Phe Asp Glu Val Val Lys Ala Asn Gly Gly Tyr Leu Ala Ala Gly 130 135 140 Lys Leu Thr Trp Ala Asp Phe Tyr Phe Val Ala Ile Leu Asp Tyr Leu 145 150 155 160 Asn His Met Ala Lys Glu Asp Leu Val Ala Asn Gln Pro Asn Leu Lys 165 170 175 Ala Leu Arg Glu Lys Val Leu Gly Leu Pro Ala Ile Lys Ala Trp Val 180 185 190 Ala Lys Arg Pro Pro Thr Asp Leu 195 200 

1. A method of desensitising a patient to a polypeptide allergen the method comprising administering to the patient a peptide derived from the allergen wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule.
 2. A method according to claim 1 wherein the peptide is included in a composition containing a plurality of peptides derived from the said allergen.
 3. A method according to claim 2 wherein the plurality of peptides derived from said allergen includes peptides for which restriction to Class II DR molecules DR2, DR3, DR4 and DR7 can be demonstrated, provided that such peptides can be derived from the allergen.
 4. A method according to claim 1 wherein the patient possesses any one of the MHC Class II DR molecules DR2, DR3, DR4 or DR7.
 5. A method according to claim 1 wherein the patient possesses the MHC Class II molecule DR4:
 6. A method according to claim 2 wherein the composition contains the Fel d I-derived peptides as given in SEQ ID Nos. 1, 2 and
 3. 7. A method according to claim 2 wherein the composition contains the soluble MHC Class II-restricted peptides of the Fel d I-derived peptides described in FIG.
 9. 8. A composition comprising a plurality of peptides derived from a polypeptide allergen wherein for at least one of the peptides in the composition restriction to a MHC Class II molecule can be demonstrated and the composition is able to induce a late phase response in an individual possessing the given MHC Class II molecule.
 9. A composition according to claim 8 wherein at least one peptide is present in the composition for which restriction to each of MHC Class II DR molecules DR2, DR3, DR4 and DR7 can be demonstrated, provided that such peptides can be derived from the allergen.
 10. A composition according to any one of claims 8 or 9 for use in medicine.
 11. A pharmaceutical formulation comprising a composition according to any one of claims 8 or 9 and a pharmaceutically acceptable carrier.
 12. A method according to claim 1 wherein a composition according to any one of claims 8 or 9 is administered to the patient.
 13. A method according to claim 1, or a composition according to any one of claims 8 or 9, or a pharmaceutical preparation according to claim 11 wherein the polypeptide allergen is any one of Fel d 1, Der p I, Der p II, Der fI or Der fII and allergens present in any of the following: grass, tree and weed (including ragweed) pollens; fungi and moulds; foods, stinging insects, the chirnomidae (non-biting midges); spiders and mites, housefly, fruit fly, sheep blow fly, screw worm fly, grain weevil, silkworm, honeybee, non-biting midge larvae, bee moth larvae, mealworm, cockroach, larvae of Tenibriomolitor beetle, mammals such as cat, dog, horse, cow, pig, sheep, rabbit, rat, guinea pig, mice and gerbil.
 14. A composition according to claims 8 or 9, or a pharmaceutical preparation according to claim 11 wherein the polypeptide allergen is Fel d I and as given in SEQ ID Nos. 1, 2 and 3, or the composition contains the soluble MHC Class II-restricted peptides of the Fel d I-derived peptides described in FIG.
 9. 15. A method of selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to a polypeptide allergen capable of eliciting an allergic response in the patient, which patient possesses a particular MHC Class II molecule, the method comprising the steps of (1) selecting a candidate peptide derived from the polypeptide allergen, (2) determining whether the candidate peptide demonstrates restriction to the said MHC Class II molecule, and (3) determining whether the candidate peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule.
 16. A method according to claim 15 wherein step (2) is carried out prior to step (3) and only candidate peptides which demonstrate restriction to the particular MHC Class II molecule are selected for testing in step (3).
 17. A method according to claim 16 wherein candidate peptides capable of inducing a late phase response and which demonstrate restriction to the particular MHC Class II molecule are selected as an immunotherapeutic agent.
 18. A method according to claim 15 wherein determination of whether the candidate peptide demonstrates restriction to the said MHC Class II molecule is by using a T cell proliferation assay.
 19. A method according to claim 15 wherein the allergen is selected from the group as defined in claim
 13. 20. A method according to claim 15 wherein in step (2) determination of whether the candidate peptide demonstrates restriction to the said MHC Class II molecule is by using the patient's cells in a T cell proliferation assay, and in step (3) determining whether the candidate peptide is able to induce a late phase response in the patient.
 21. A method according to claim 15 wherein the MHC molecule is any one of HLA-DR, HLA-DP, HLA-DQ, or subclasses thereof.
 22. A peptide when selected by claim
 15. 23. A database of peptides characterised according to their ability to bind an MHC Class II molecule and induce a late phase response in an individual possessing the said MHC Class II molecule.
 24. A peptide listed in a database according to claim 23, for use in therapy.
 25. A method for selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to an allergen comprising the steps of: a) tissue-typing the patient to determine MHC Class II type; and b) selecting, from a database of peptides which are known to bind to particular MHC Class II molecules and induce a late phase response in an individual possessing such MHC Class II molecules, one or more peptides capable of binding to the MHC Class II molecules possessed by the patient.
 26. A method of determining an initial dose of an immunotherapeutic peptide for desensitising a patient to a polypeptide allergen, which peptide is derived from the allergen and wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated for the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC molecule, the method comprising (1) determining the dose which is able to generate an observable late phase response in a given proportion of individuals who possess the said MHC molecule and in whom the peptide is able to induce a late phase response and (2) selecting a lower dose which is incapable of inducing an observable late phase response in substantially all individuals who possess the said MHC molecule and in whom the peptide is able to induce a late phase response.
 27. A method according to claim 26 wherein in step (1) the given proportion is 50%.
 28. A method according to claim 26 wherein the lower dose is 0.01% of the dose which is able to generate an observable late phase response in the given proportion of individuals.
 29. A method according to claim 26 wherein in steps (1) and (2) the peptide is included in a plurality of peptides derived from the said allergen. 